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ABSTRACT 
Background 
Para-aminosalicylic acid (PAS) is a bacteriostatic anti-tuberculosis (anti-TB) drug, 
used in the treatment of multi-drug resistant (MDR) and extensively drug-resistant 
(XDR) tuberculosis (TB). While PAS has shown great efficacy, it is notorious for its 
association with gastrointestinal (GI) intolerance. The intolerance was considered to be 
due to the dosing strategy, which therefore caused clinicians to opt for divided doses as 
opposed to a single large dose daily, but no evidence of improvement has been reported. 
It has thus been proposed that the rate of absorption and/or metabolism of PAS could 
possibly be responsible for poor tolerability of the drug.  
Aims 
The aim of the study was to investigate the potential association between the plasma 
concentrations of the main metabolites, acetyl-PAS (APAS) and glycine-PAS (GPAS), 
and the occurrence of GI intolerance, after the administration of a granular slow release 
PAS (GSR-PAS) formulation.  
Study design and methodology 
A two-period study of PAS and its metabolites was conducted in 29 adult patients (≥ 
18 years old) MDR- and XDR-TB, at the Brooklyn Chest Hospital, Cape Town, South 
Africa. These patients were assigned to a 4g twice-daily GSR-PAS regimen for 1 week 
followed by another week given 8g once-daily GSR-PAS. Whole blood was collected 
in EDTA-containing tubes at 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose, at the end of 
each week.  
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PAS plasma concentrations were determined using an ultra high performance liquid 
chromatography system coupled to a tandem mass spectrometer, (UHPLC-MS/MS) of 
which the assay was developed and partially validated according to the Food 
and Drug Administration (FDA) criteria. Thereafter, pharmacokinetic analysis was 
performed for the metabolites and parent drug of which pharmacokinetic parameters 
Cmax, AUC0-24 and Tmax were determined by non-compartmental analysis, using 
Winnonlin software version 8.0.  
The tolerability of PAS was evaluated using a 10-point visual analogue scale (VAS) 
rating the severity of the adverse effects (AE’s) experienced, with the most left 
indicating no symptoms and the most right indicating severe symptoms. The patients 
completed the evaluation on a daily basis after dosing. The AE’s evaluated included 
nausea, bloating, diarrhoea, vomiting, and abdominal pain and cramps.  
A correlation analysis using STATA software version 15.1 was used to measure the 
association between each AE and the median Cmax of PAS, APAS and GPAS using the 
Spearman’s rank correlation. Statistical significant was set at a P value less than 0.05.  
Results: 
The developed method proved successful in the assay of APAS, GPAS and PAS in a 
single run of 4 minutes. A large inter-individual variability was observed in the Cmax 
ranging from 40.42 to 102.41 mg/L for PAS, and 10.00 to 22.36 mg/L and 3.90 to 9.45 
mg/L for APAS and GPAS, respectively. The VAS data reported that 26 patients had 
evidence of GI intolerance, but the majority of these scores were clustered around zero. 
Abdominal pain and cramps were found to be statistically more frequent in the 4g 
twice-daily than 8g once-daily regime [0.14(0 – 0.59) versus 0(0 – 0.08); median (IQR); 
p= 0.018]. Statistically significant inverse associations were observed between APAS 
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concentrations and bloating (rho= -0.448; p= 0.025) and diarrhoea (rho= -0.407; p= 
0.044), respectively, for the twice-daily dose. The same inverse association was found 
for GPAS concentrations and diarrhoea (rho= -0.412; p= 0.041). 
Conclusions: 
Plasma concentrations of metabolites APAS and GPAS did not correlate with the 
occurrence of AE’s. On the contrary, the data showed that higher plasma concentrations 
of APAS and GPAS were associated with lower scores of AE’s, which were statistically 
significant relationships but considered clinically negligible. Further work with a larger 
population size may be needed to determine the true effect of metabolite formation on 
the presence of GI discomfort when treated with PAS.  
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OPSOMMING 
Agtergrond 
Para-aminosalisielsuur (PAS) is ŉ bakteriostatiese anti-tuberkulosemedisyne wat in 
die behandeling van middelweerstandige (MDR) en uiters middelweerstandige (XDR) 
tuberkulose (TB) gebruik word. Alhoewel PAS aanmerklike doeltreffendheid toon, is 
dit bekend vir ŉ verband met gastro-intestinale (GI) intoleransie. Die intoleransie word 
aan die doseringstrategie verbind, wat dus meebring dat klinikusse verdeelde dosisse 
verkies teenoor ŉ enkele groot daaglikse dosis, maar geen bewyse van verbetering is 
egter gerapporteer nie. Daar is dus voorgestel dat die tempo van absorpsie en/of 
metabolisme van PAS moontlik vir swak toleransie van die medisyne verantwoordelik 
is.  
Doelwitte 
Die doel van die studie was om ondersoek in te stel na die moontlike verband tussen 
die plasmakonsentrasies van die hoofmetaboliete, asetiel-PAS (APAS) en glisien-PAS 
(GPAS), en die voorkoms van GI-intoleransie ná toediening van ŉ formulering van ŉ 
granulêre stadigvrystellende PAS (GSR-PAS).  
Studie-ontwerp en -metodologie 
ŉ Tweetydperk-studie van PAS en sy metaboliete is uitgevoer onder 29 volwasse 
MDR- en XDR-TB-pasiënte (≥ 18 jaar oud) by die Brooklyn Chest Hospitaal in 
Kaapstad, Suid-Afrika. Hierdie pasiënte is ingedeel vir ŉ GSR-PAS-regimen van 4 g 
twee keer per dag vir een week, gevolg deur nog ŉ week waarin hulle een keer per dag 
8 g GSR-PAS ontvang het. Heelbloed is in EDTA-bevattende buise teen 1, 2, 3, 4, 6, 
8, 12 en 24 ure ná toediening van die dosis aan die einde van elke week geneem.  
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PAS-plasmakonsentrasies is bepaal met behulp van ŉ ultrahoëverrigting-vloeistof-
chromatografiestelsel gekoppel aan ŉ tandem-massaspektrometer, waarvan die toets 
volgens kriteria van die Amerikaanse Voedsel- en Medisyne-administrasie ontwikkel 
en bekragtig is. Daarna is farmakokinetiese ontleding vir die metaboliete en 
moedermedikasie uitgevoer, waarvan farmakokinetiese parameters Cmax, AUC0-24 en 
Tmax deur niekompartementele ontleding bepaal is met gebruik van Winnonlin-
sagteware weergawe 8.0.  
Toleransie van PAS is met behulp van ŉ tienpunt- visuele analoë skaal (VAS) 
geëvalueer, wat die erns van die negatiewe gevolge (NG’s) wat ervaar is, gerangeer het, 
met heel links wat geen simptome aantoon en heel regs wat ernstige simptome aantoon. 
Die pasiënte het die evaluering daagliks ná dosering voltooi. Die NG’s wat geëvalueer 
is, het naarheid, opgeblaasdheid, diarree, vomering en maagpyn en -krampe ingesluit. 
ŉ Korrelasie-ontleding met behulp van STATA-sagteware weergawe 15.1 is gebruik 
om die verband tussen elke NG en die mediaan Cmax van PAS, APAS en GPAS aan die 
hand van die Spearman-rangkorrelasie te meet. Statisties betekenisvol is gestel as ŉ P-
waarde onder 0.05.  
Resultate: 
Die ontwikkelde metode het sukses getoon in die toets van APAS, GPAS en PAS in ŉ 
enkellopie van 4 minute. ŉ Groter interindividuele veranderlikheid is waargeneem in 
die Cmax, wat gewissel het van 40.42 tot 102.41 mg/L vir PAS, en 10.00 tot 22.36 mg/L 
en 3.90 tot 9.45 mg/L vir onderskeidelik APAS en GPAS. Die VAS-data het getoon dat 
26 pasiënte bewyse van GI-intoleransie getoon het, maar die meerderheid van hierdie 
tellings het trosvorming om nul getoon. Maagpyn en -krampe is gevind om statisties 
meer gereeld voor te kom by die regimen van 4 g twee keer per dag as dié van 8 g een 
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keer per dag [0.14(0 – 0.59) teenoor 0(0 – 0.08); mediaan (IQR); p = 0.018]. Statisties 
betekenisvolle inverse verbande is waargeneem tussen onderskeidelik APAS-
konsentrasies en opgeblaasdheid (rho = -0.448; p = 0.025) en diarree (rho = -0.407; p 
= 0.044) vir die dosis wat twee keer per dag toegedien is. Dieselfde inverse verband is 
gevind vir GPAS-konsentrasies en diarree (rho = -0.412; p = 0.041). 
Gevolgtrekkings: 
Plasmakonsentrasies van metaboliete APAS en GPAS het nie ŉ verband getoon met 
die voorkoms van NG’s nie. In teendeel, die data het getoon dat hoër 
plasmakonsentrasies van APAS en GPAS verband gehou het met laer tellings NG’s, 
wat statisties betekenisvolle verhoudings was, maar as klinies onbeduidend geag is. 
Verdere studie met ŉ groot populasiegrootte is moontlik nodig om die ware uitwerking 
van metabolietvorming op die teenwoordigheid van GI-ongemak tydens behandeling 
met PAS te bepaal.  
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Tuberculosis (TB), despite its decline in incidence rates, remains the leading cause of death 
worldwide from a single infectious disease.(1) This global epidemic remains a public health 
concern in sub-Saharan Africa, due to the prevalent co-infection with the human 
immunodeficiency virus (HIV) and the occurrence of drug resistant TB (DR-TB).(1–4)  
Compared to drug susceptible TB (DS-TB), multi-drug resistant (MDR) and extensively 
drug-resistant (XDR) TB is difficult to treat as it requires longer course duration and the use 
of chemotherapeutics with a higher toxicity profile.(5,6) Studies have found that relatively 
little advancement has been made in XDR-TB treatment since one of its first reports in South 
Africa, 10 years ago.(7,8)  
Among the drugs used to treat DR-TB is para-aminosalicylic acid (PAS), one of the first 
anti-bacterial drugs discovered.(9) At the time of its inception, PAS was used as a core anti-
TB drug, until drugs with increased efficacy and improved intolerance became available.(10,11) 
Due to the lack of use of PAS for many decades, it has acquired low resistance.(11) Presently, 
the WHO(1,12) has recommended use of PAS as a group C medicine, in the management of 
MDR- and XDR-TB regimens, to strengthen the regimen or as an alternative when priority 
drugs cannot be used.(12) The primary barrier of PAS use is its widely documented toxic 
profile. Occurrence of severe adverse effects related to PAS is reported to be one of the 
highest amongst drugs used in DR regimens.(8) Mostly reported are gastrointestinal distress, 
such as nausea, vomiting and diarrhoea.(13–15) Identifying the probable causes of these adverse 
reactions associated with PAS, would assist in managing its toxicity and improving its use. 
This presented study explored pharmacokinetic parameters of PAS and its main metabolites 
to identify co-variates that may play a role in gastrointestinal toxicity, such as the 
concentrations at which metabolites and parent drug are present in the plasma.  
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While newer drugs bedaquiline and delaminid are apparently better tolerated, treatment 
failures have already been reported as a result of newly emerged drug resistance.(16) 
Consequently, XDR-TB treatment failures are pooling in patients who remain therapeutically 
destitute. Under these circumstances, it is worthy to consider revision and repurposing of 
older drugs, such as PAS. 
Discussed below is a general outline of the work presented in each chapter; 
In Chapter One, a general introduction and rational is presented in order to state the purpose 
and value of the proposed study. The chapter discusses the epidemiology, current available 
treatment strategies of uncomplicated TB and DR-TB. The discussion continues regarding 
with the basic pharmacokinetics (PK) and pharmacodynamics (PD) characteristics of anti-TB 
drugs. Thereafter, a literature review of the anti-TB agent, para-aminosalicylic (PAS) and its 
metabolites Acetyl-PAS and Glycine-PAS is presented, highlighting its pharmacokinetics, 
mode of action, current dosing regimen and toxicological adverse effects.  
Chapter Two is an outline of the analytical techniques employed. A large component of the 
study was the development and validation of a method to assay PAS and its metabolites using 
the currently available technology, namely liquid chromatography (LC) coupled to a mass 
spectrometry (MS) detector. An overview of the appropriate LCMS instrumentation used and 
the fundamentals of method development is discussed. The chapter also presents a literature 
review of the analytical methods previously reported for the determination of PAS and its 
metabolites since its introduction.  
The study aims and objectives are described shortly in Chapter Three. 
The study research question is addressed in Chapter Four. The experimental techniques that 
have been used are described which includes LCMS method development and validation, 
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non-compartmental analysis (NCA) for the PK evaluation of each compound in question, and 
the various statistical software used to summarise collected data and determine the 
relationship between concentration of each compound and the experienced adverse effect. 
Characteristics of the population in this study are described, as well as results, discussion and 
conclusions.  
In Chapter Five, a discussion of the results generated is presented, and followed by 
conclusions, limitations and future work.  
This thesis also includes the method development and validation of esomeprazole and its 
three major metabolites, which is described in Addendum A. Although this chapter’s work is 
unrelated to the core study, it has been included to show the skill sets developed throughout 
this degree. The chapter presents a novel sample extraction method used to assay 
esomeprazole and its three major metabolites for the purpose of a pharmacokinetic study, 
which has been published and of which I am a co-author. It has been included as Addendum 
B: Cluver CA, Hannan NJ, van Papendorp E, Hiscock R, Beard S, Mol BW, Theron GB, Hall 
DR, Decloedt EH, Stander M, Adams KT, Rensburg M, Schubert P, Walker SP, Tong S. 
Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled 
trial. Am J Obstet Gynecol. 2018 Jul 25. Pii: S0002-9378(18)30606-9. doi: 
10.1016/j.ajog.2018.07.019. [Epub ahead of print] PubMed PMID: 30055127.  
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Chapter One 
Literature review – Antituberculosis agent, para-
aminosalicylic acid (PAS) 
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1.1. Epidemiology of tuberculosis 
Tuberculosis (TB) is a chronic infectious disease caused by the acid-fast bacillus 
Mycobacterium tuberculosis (M. tuberculosis).(1) It typically affects the lungs (pulmonary 
TB), but can also affect other sites (extrapulmonary TB). In 2016, there were an estimated 
10.4 million (range 8.8 million – 12.2 million) incident cases of TB globally, with 1.30 
million deaths (range, 1.20 million – 1.40 million) among individuals not infected with the 
human immunodeficiency virus (HIV) and an additional 0.37 million deaths (0.35 million – 
0.43 million) among HIV-infected individuals (Figure 1.1). While the global TB incidence is 
falling by 2% per annum, it remains the ninth leading cause of mortality worldwide, and the 
leading cause from a single infectious agent.(2) It is estimated that Nigeria and South Africa 
each accounted for 4% of the total global number of cases as of 2016. 
Figure 1.1: Global estimated TB incidence rate in 2016, for incidence per 100 000 population per year. (2) 
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With the use of modern molecular genetic techniques, Gutierrez and colleagues estimate an 
early progenitor present in East Africa as early as 3 million years ago. It is believed that early 
hominids were infected at this time.(3) Robert Koch, a German physician, announced his 
discovery and identification of the tubercle bacillus in 1882.(4) During this time, the only 
available treatment consisted of rest, a rich diet with some alcohol and carefully supervised 
exercise and resulted in the opening of sanatoria, which were facilities devoted to this anti-
TB regimen. This approach proved more successful in healing patients than any previous 
treatment regimens.(5)
The discovery of streptomycin in 1944 was the first advancement of treating TB 
pharmacologically. This was followed by the introduction of isoniazid in the 1950’s, which 
shaped the primary basis of anti-TB chemotherapy until the 1960’s. During this time, the 
general anti-TB drug regimen consisted of streptomycin, isoniazid and para-aminosalicylic 
acid (PAS) in the initial months of treatment. The subsequent months included isoniazid and 
PAS, requiring a total treatment duration of 18 months. The discovery of rifampicin in 1965 
prompted the launch of a short course treatment for TB in 1970. The directly observed 
treatment, short course (DOTS) strategy, when properly implemented with the necessary 
infrastructure, produces high TB cure rates and curtails the development of acquired drug-
resistant TB.(6) 
According to the South African National Tuberculosis Management Guidelines 2014 (Table 
1.1), the current standard first-line treatment constitutes an intensive (initial) phase of two 
months consisting of rifampicin, isoniazid, pyrazinamide, and ethambutol, to rapidly kill the 
9
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mycobacteria. To prevent subsequent relapse, a continuation phase consisting of rifampicin 
and isoniazid is followed for a period of four months.(7,8)  
 
Table 1.1: Standard treatment regimen of core first line drugs for known drug susceptible 
TB. (8) 
Pre-treatment body 
weight (kg) 
Intensive Phase (7 
days a week for 2 
months) 
Continuation Phase (7 days a week for 4 
months) 
RHZE  
(150; 75; 400; 275) 
mg 
RH  
(150; 75) mg 
RH  
(300; 150) mg 
30-37  2 tablets 2 tablets  
38-54  3 tablets 3 tablets 
55-70  4 tablets  2 tablets 
>70 kg 5 tablets 2 tablets 
R = rifampicin; H = isoniazid; Z = pyrazinamide; E = ethambutol; pyridoxine (Vitamin B6) 25 mg daily 
recommended for patients to prevent neuropathy commonly caused by isoniazid.  
 
1.2. Multidrug- and Extensively drug-resistant tuberculosis  
 
Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), is defined 
as strains of M. tuberculosis that are resistant to at least isoniazid and rifampicin, two of the 
most effective first line drugs used in the treatment of drug susceptible TB.(1) In the case of 
XDR-TB, the strains have an additional resistance to one of the fluoroquinolones, as well as 
one of the second line injectable drugs such as amikacin, kanamycin or capreomycin.(9) The 
surfacing of drug resistance in conjunction to co-infection with HIV, threatens global TB care 
and prevention, and remains a major public health concern in several countries.  
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It is estimated that globally 600 000 (range, 540 000 - 660 000) incident cases were attributed 
to MDR-TB, which constitutes 22% of the global TB burden. Furthermore, South Africa 
contributes approximately 1-2% to this MDR-TB occurrence.(2) A review by Andrews et al.(9) 
described the discovery of large numbers of cases of MDR-TB and XDR-TB in South Africa, 
as an evolving epidemic rather than sporadic localized outbreaks. It was noted that the 
prevalence of MDR-TB remained low in the mid-1990s but soared in the latter half of the 
decade.(10–12) Between 1993 and 1997 twenty-one individuals in Cape Town acquired TB 
resistance to four core drugs – isoniazid, rifampicin, ethambutol, and streptomycin – and 
were found to be HIV negative. These findings indicated that TB drug resistance was not 
necessarily associated with HIV co-infection.(13,14) In 2006 primary drug resistance was found 
associated with recent transmission and due to nosocomial transmission in an outbreak of 
MDR-TB and XDR-TB at the Church of Scotland Hospital in rural Tugela Ferry, KwaZulu-
Natal. Systemic surveillance conducted at the hospital between January 2005 and March 
2006 discovered that amongst 542 patients with positive sputum TB cultures, 221 (41%) had 
MDR-TB and 53 (9.7%) had XDR-TB, respectively.(15) The mortality of XDR-TB patients, 
which included several health care workers, was as high as 98%. The majority of patients 
with XDR-TB had no prior TB or HIV infections, thus indicating the cause of this outbreak 
to be inadequate infection control.(9,15,16) 
 
Standard treatment regimens have proven inadequate for patients with drug resistance TB. 
Patients with XDR-TB are especially difficult to treat, and have a significantly worse 
treatment outcome than MDR-TB cases. As described in drug susceptible TB, a combination 
treatment plan is imperative to prevent additional resistance. Treatment possibilities include 
an individualised regimen based on results achieved from drug-susceptibility testing (DST), 
which is usually used in MDR-TB patients with a history of using second-line drugs.(8) 
11
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Typically, in patients with resistance to the standard regimen (rifampicin, isoniazid, 
pyrazinamide, ethambutol) a treatment plan including aminoglycosides (amikacin, 
kanamycin, capreomycin), a fluoroquinolone (levofloxacin, moxifloxacin), and an oral 
bacteriostatic agent (para-aminosalicylic acid, cycloserine, ethionamide, prothionamide) is 
used among other drugs.(17) It is crucial that individualised treatment is designed for patients 
with XDR-TB, in order to establish a suitable regimen.(8) 
The recommended duration of treatment is guided by culture conversion and is determined by 
adding 18 months to the culture conversion dates. A minimum of five drugs should be 
included in the intensive phase, and four drugs in continuation phase as per the standard 
regimen (Table 1.2). 
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Table 1.2: Standardised MDR-TB regimen for adults (including children 8 years and 
older).(8)  
Intensive Phase: 6 months or minimum of 4 months 
Drug 
Body weight (kg) 
< 33 kg  33 – 50 kg 51 – 70 kg > 70 kg 
Kanamycin 15 – 20 mg/kg  500 – 750 mg 1000 mg 1000 mg 
Moxifloxacin 400 mg 
(children: 7.5 – 
10 mg/kg) 
400 mg 400 mg 400 mg 
Ethionamide 15 – 20 mg/kg 500 mg 750 mg 750 – 1000 mg 
Terizidone 5 – 20 mg/kg 750 mg 750 mg 750 – 1000 mg 
Pyrazinamide 30 – 40 mg/kg 1000 – 1750 mg 1750 – 2000 mg 2000 – 2500 mg  
Or, in children < 8 years  
Amikacin  15 – 22.5 mg      
Levofloxacin  10 – 15 mg     
Or, if known inhA mutation  
Ethambutol  20 – 25 mg     
High dose 
Isoniazid 
15 – 20 mg     
Continuation Phase: Minimum of 18 months after TB culture conversion 
Drug 
Body weight (kg) 
< 33 kg  33 – 50 kg 51 – 70 kg > 70 kg 
Moxifloxacin 400 mg 400 mg 400 mg 400 mg 
Ethionamide 15 -20 mg 500 mg 750 mg 750 – 1000 mg 
Terizidone 15 – 20 mg 750 mg  750 mg 750 – 1000 mg 
Pyrazinamide 30 - 40 mg 1000 – 1750 mg 1750 – 2000 mg 2000 – 2500 mg 
Or, intolerance to moxifloxacin  
Levofloxacin  750 mg (below 
51 kg) 
1000 mg (equal 
or above 51 kg)  
  
InhA mutation = low level resistance to isoniazid. Pyridoxine (Vitamin B6) 150 mg to be given daily to patients 
on terizidone or cycloserine.  
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Recently, the WHO reviewed new evidence received individually from clinical trials, 
cohort/observational studies and programmatic implementation of both longer and shorter 
MDR-TB regimens. A rapid communication was published which highlights the new 
standard of care for MDR-TB treatment, based on evidence for effectiveness and safety.(18) 
The regimen consists of a revised grouping of TB drugs recommended for use in longer 
MDR-TB regimens (18 – 20 months), and is designed to include at least five drugs 
considered to be efficacious (Table 1.3). The use of injectables, capreomycin and kanamycin, 
is no longer recommended given their increased risk for adverse reactions and treatment 
failure when they are used in longer MDR-TB regimens.  
 
Table 1.3: Revised grouping of drugs recommended for use in longer MDR-TB regimens.(18) 
Group   Drug 
Group A: 
Drugs to be prioritised  
(Include all three drugs, unless they cannot 
be used) 
 
Levofloxacin/Moxifloxacin, Bedaquiline, 
Linezolid 
Group B: 
Drugs to be added next  
(Add both drugs, unless they cannot be used) 
 
Clofazamine, Cycloserine/Terizidone 
Group C: 
Drugs to be included to complete regimens  
(Add when agents from group A and group 
B cannot be used) 
 
Ethambutol, Delamanid, Pyrazinamide, 
Imipenem-cilastatin/Meropenem, 
Amikacin/Streptomycin, 
Ethionamide/Prothionamide/p-
aminosalicylic acid 
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1.3. Anti-tuberculosis agents 
 
The main desired properties of an anti-TB agent is to rapidly eliminate actively metabolizing 
bacilli, sterilize TB lesions and prevent resistance to companion drugs.(19,20) These three 
activities are determined by the dynamic combination of host, microbe and drug factors.(20) In 
pharmacology, this relationship is described by the principles of pharmacokinetics and 
pharmacodynamics.  
 
1.4. Pharmacokinetics  
 
Pharmacokinetics (PK) describes the time course of absorption, distribution, metabolism and 
excretion (ADME) of a drug in bodily fluids.(19,21) Essentially, the process of ADME 
characterizes the rise and fall of drug concentrations over time, known as the drug’s 
pharmacokinetic profile.(22) Using this profile, mathematical models can be applied to 
determine the pharmacokinetic parameters of the drug. Parameters such as maximum 
concentration (Cmax), minimum concentration (Cmin), time to reach the maximum 
concentration (Tmax), area under the curve (AUC) bioavailability (F), clearance (CL), half-life 
(t1/2) and volume of distribution (Vd) can be quantified and used to determine optimal drug 
dosage regimens.(23) 
 
1.5. Pharmacodynamics  
 
Pharmacodynamics (PD) is defined as the drug’s effect in relation to its concentration in the 
body.(19) Generally, PD refers to what the drug does to the body, however, antimicrobial PD 
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describes the relationship between the drug concentration and its effect on the pathogen 
residing within the host organism.(19,21) Based on the antimicrobial pharmacodynamic action 
of a drug, it can be classified as bacteriostatic or bactericidal.(24)  
Bacteriostatic agents inhibit the growth of bacilli, keeping them in the stationary phase of 
growth and relying on the host’s defence mechanism to remove bacilli from the tissues.(24,25) 
Should the host defences fail to do so, the bacilli will resume growth after discontinuation of 
the bacteriostatic agent. Currently TB is treated with combination regimens consisting of 
bacteriostatic and bactericidal agents.(26) The latter group, rapidly reduces the size of the 
bacillary population in the sputum of TB patients after starting the treatment, and prevents the 
emergence of resistance to companion drugs.(27)  
 
PD parameters quantify the activity of an antimicrobial agent pertaining to growth inhibition 
and eradication of the pathogen(22) and this activity can be determined in vitro or in vivo. The 
minimum inhibitory concentration (MIC) or minimum bactericidal concentration (MBC) are 
the major parameters, which quantify the potency of the antimicrobial agent in vitro. The 
MIC represents the lowest drug concentration that inhibits microbial growth after incubation 
for 16-20 hours with a standard inoculum of 1-5 x 105 colony forming units (CFU/mL).(19,28) 
The MBC refers to the drug concentration that kills 99.99% of the initial inoculum. By 
contrast, in vivo activity is described by the early bactericidal activity (EBA) of a drug, which 
measures the decreasing rate of CFU/mL in the sputum of patients during the first two days 
of drug treatment and is expressed as log10 (CFU/mL)/day.(19) 
 
In order to actively inhibit the infectious pathogen, the concentration of the bacteriostatic 
agent must remain above the MIC of the pathogen. Bactericidal activity can follow two 
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patterns, either time-dependent activity or concentration-dependent activity. In time-
dependent activity, killing of the bacteria depends on the duration of drug exposure, whereas 
concentration-dependent killing requires the maximum concentration possible at the site of 
infection.(27,29) The Cmax to MIC or AUC to MIC ratios correlate best with the eradication 
rates, as demonstrated in Figure 1.2.  
 
 
Figure 1.2: AUC/MIC and Cmax/MIC ratios, correlation of serum pharmacokinetics (Cmax, AUC) with MIC 
(susceptibility) of an organism, which best describes eradication rate. The MIC at which the magnitudes of these 
ratios that are required for clinical success are achieved becomes the pharmacokinetic/pharmacodynamic profile 
of the drug. Adapted from Jacobs(29)  
 
1.6. Factors influencing PK/PD profile of anti-TB agents  
 
Inter subject variability in drug response has been a major problem in drug development and 
clinical practice as a whole. As a consequence, it can lead to the risk of developing an 
adverse drug reaction or therapeutic failure. Potential factors responsible for subject 
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variability in drug response include the patient’s age, disease state (particularly liver and 
renal function), concomitant drug therapy, genetic variability and lifestyle behaviour such as 
smoking and alcohol consumption.(30) Of even greater importance in the therapeutic and toxic 
profile of a drug is the biotransformation process, which is responsible for detoxification, 
excretion and/or activation, by drug metabolizing enzymes.(31) Generally biotransformation 
pathways include the oxidation, hydrolysis or reduction of the parent drug (phase I enzyme), 
followed by conjugation of the oxidised moiety with highly polar molecules such as sulphate 
and glucuronic acid (phase II enzyme). Biotransformation of a drug can be mediated by phase 
I, phase II or a combination of both pathways.(31,32) Phase I consist primarily of the 
cytochrome P450 (CYP) superfamily of enzymes, which are abundant in the liver, 
gastrointestinal tract, the lungs and kidneys.(33) Among the phase II conjugating enzymes are 
N-acetyltransferases (NAT), which are present in various isoforms that are substrate specific. 
Typically, conjugation reactions enhance the excretion of a drug by increasing its 
hydrophilicity, and thereby exerting a detoxification effect. However, under certain 
conditions, conjugation reactions may result in activated metabolites and increased toxicity 
by xenobiotics.(32) As mentioned above, subject variability largely contributes to altered drug 
metabolism, as a result of factors including genetic variation of drug metabolizing enzymes, 
the presence or absence of diseases such as TB and HIV and the use of concomitant 
medications.(30)  
 
1.7. Intolerance of anti-TB agents  
 
Studies have shown that the occurrence of adverse drug reactions contributes significantly to 
morbidity and patient hospitalization.(34,35) The frequency, severity and nature of anti-TB 
drug induced adverse reactions have always been a matter of concern. Therefore, the clinical 
18
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monitoring of all TB patients during treatment is of importance, as serious adverse reactions 
induced by anti-TB therapy may lead to non-compliance of patients and consequently, 
treatment failure or emergence of drug resistant M. tuberculosis. First line anti-TB agents 
may cause gastrointestinal disturbance and hepatotoxicity.(8,36) Anti-TB agents used in MDR- 
and XDR-TB regimens are associated with more and worse adverse effects, and therefore 
create a big challenge in the management and treatment of patients with drug resistant TB.(37)  
 
1.8. Para-aminosalicylic acid 
 
Para-aminosalicylic acid (PAS, p-aminosalicylic acid, 4-aminosalicylic acid, 4-ASA) was one 
of the first chemotherapeutic agents found to be effective in the treatment of M. 
tuberculosis.(38) Before more potent drugs became available, PAS was used in combination 
therapy and showed its substantial efficacy and ability to prevent resistance in its companion 
drugs, allowing it to be part of standard TB treatment.(39) However, shortly after its discovery, 
PAS was noticed to cause severe gastrointestinal (GI) intolerance, resulting in its replacement 
with better tolerated and equally efficacious drugs, such as ethambutol and isoniazid.(40) Amid 
the widespread HIV epidemic and rates of resistance to first-line and second-line drugs, PAS 
usage has gained a new life.(41)  
 
The manufacturing of a new granular slow release PAS (GSR-PAS) formulation with fewer 
GI adverse effects (AEs)(42–44) has supported its reintroduction. Another benefit is the low 
drug resistance to PAS since its use was uncommon for several decades.(42) It is now 
primarily used as a second-line drug to strengthen regimens for patients who have XDR-TB, 
or have not responded to standard MDR-TB regimens.(41) It has been implemented in the 
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current WHO Guidelines for the programmed management of DR-TB.(17,26) Presently, the 
GSR-PAS formulation is used in the USA, Europe and many other countries.(41,44,45)  
 
1.8.1. Mechanism of action of PAS 
 
PAS is classified as a highly specific bacteriostatic agent, inhibiting the growth of M. 
tuberculosis at a concentration of 1 µg/mL in vitro.(19) Even though PAS is widely researched 
and used in clinical practice, its exact mechanism of action remains elusive, but three 
mechanisms have been considered. 
Firstly, it is speculated that PAS inhibits folic acid synthesis, by acting as a competitive 
inhibitor of para-amino benzoic acid (PABA).(46) Structural similarities between PAS and 
sulphonamides, which are well studied analogues of PABA, led to the suggestion that PAS 
might compete with PABA for dihydropteroate synthase (DHPS), a key enzyme in the folate 
biosynthesis pathway of bacteria (Figure 1.3).(42) 
Secondly, in contrast to sulphonamides, PAS appears to be a poor inhibitor of DHPS in vitro, 
suggesting the possibility for an alternative target.(47) Rengarajan et al.(42) identified clinical 
PAS-resistant isolates of M. tuberculosis that had mutations in the thymidylate synthase 
(thyA) gene, which resulted in decreased enzyme activity. As thyA modulates the enzyme 
needed to determine intracellular folate levels, it is suggested that PAS acts as a folate 
antagonist, which inhibits folic acid synthesis (Figure 1.3).  
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Figure 1.3: Postulated mechanism of action of PAS in the folic acid biosynthesis pathway. PABA, para-
aminobenzoic acid; DHPS, dihydropteroate synthase; DHP, dihydropteroate; DHF, dihydropfolate; THF, 
tetrahydrofolate; dUMP, deoxyuridine 5’-monophosphate; dTMP, deoxythymidine 5’-monophosphate. Adapted 
from Rengarajan.(42)   
 
Thirdly, another suggested the mechanism of action, is the ability of PAS to inhibit the 
synthesis of mycobactins, a cell wall component that is crucial for the iron transport in M. 
tuberculosis, thereby preventing the bacilli from acquiring iron from the host and reducing 
the activity of bacterial enzymes that require iron.(48–50) 
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1.8.2. Pharmacokinetics of PAS 
After PAS was introduced, many formulations were manufactured, including various salts, 
enteric coated granules, a PAS-resin complex and later encapsulated gastro-resistant granules, 
to prevent early breakdown in the stomach.(41) The drug’s bioavailability largely relies on the 
chemical species and the dosage form administered (Table 1.4).(26,51) 
Table 1.4: Summary of pharmacokinetic characteristics of different formulations of PAS, 
administered orally in healthy subjects. Adapted from Berning(52) and Momekov(26).  
PAS 
preparation 
Dose (g) Cmax (µg/mL) Tmax (h) AUC0-∞ 
(µg/h/mL) 
Free PAS 4.0 49.98 3.54 209.07 
Sodium PAS 2.8 155.44 0.83 313.22 
Calcium PAS 2.6 139.51 1.02 326.22 
Potassium PAS 2.6 121.09 1.10 313.22 
PAS resin 
complex 
4.0 78.0 2.1 - 
GSR-PAS 4.0 20.23 7.95 107.92 
GSR-PAS = granular slow release formulation.(44) 
PAS is completely absorbed from the gastrointestinal tract (GIT) after oral administration, 
with peak plasma concentrations occurring within 2 hours after ingestion. Typically, in the 
slow release formulation, mean plasma maximum concentrations (Cmax) of 20 – 60 µg/mL are 
achieved in 4 – 6 hours after a single 4g dose.(19,26,40) In contrast, among individuals with 
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MDR/XDR-TB, a mean Cmax of 51.3 µg/mL was reached at a Tmax (time to maximum 
concentration) of 5.2 hours.(43)  
 
PAS is 50 – 60% bound to plasma proteins, and well distributed throughout the total body 
water. The highest concentrations are detected in the kidney, lungs, liver and to some degree 
in the cerebrospinal fluid (CSF), if the meninges are inflamed.(19,26) Following a conventional 
oral dose, PAS has a half-life of approximately1 hour, and minimal plasma concentrations 
reached within 4 – 5 hours.(51)  
 
After 24 hours approximately 80% of the dose is excreted in the urine, by glomerular 
filtration and tubular secretion, with more than 50% in the metabolised form.(52,53) 
Elimination is affected by severe renal and/or hepatic dysfunction, and the use of PAS is 
therefore not recommended in such individuals.(26)  
 
1.8.2.1. Metabolism of PAS 
 
The metabolic breakdown of PAS occurs rapidly starting in the intestinal mucosa and 
continuing in the liver. The primary biotransformation is via acetylation of the free amino 
group.(54) This reaction forms N-acetyl-para-aminosalicylic acid (APAS, acetyl-PAS) and is 
mediated by N-acetyltransferase 1 (NAT1).(19,51) In addition to acetylation there is also glycine 
conjugation of the carboxyl group to form p-aminosalicyluric acid (GPAS, glycine-PAS).(51) 
Due to a limited number of drugs being conjugated with glycine, the pathway has not been 
characterised.(55) Although APAS and GPAS are the main products, other minor metabolites 
have been identified in the urine, including ether glucuronides of PAS (Figure 1.4).(56)  
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Figure 1.4: Conjugations reactions of PAS by acetylating enzymes producing Acetyl-PAS (Ac-PAS, APAS), by 
glucoronate and sulphate conjugating enzymes, and by glycin conjugating enzymes producing Glycyl-PAS 
(Glycine-PAS, Gly-PAS, GPAS). Adapted from Lehmann.(56) 
 
When exploring the metabolic profile of PAS, it was noted that APAS is devoid of 
bacteriostatic activity against M. tuberculosis, with the exception of very high plasma 
concentrations, in the urine.(56) By contrast, GPAS exerts some anti-TB activity proportional 
to the dose of PAS.(56) The dose of PAS has also shown to have a significant effect on the 
acetylation and glycine-conjugation pathways as these processes are known to be 
saturable.(57) At a low dose (4g daily), PAS absorption is succumbed to rapid first-pass 
acetylation, thus causing APAS to be detected in the blood before unchanged PAS.(58) When 
a higher dose (8g daily) is administered, acetyl conjugation is saturated, resulting in 
significantly higher GPAS and free PAS plasma concentrations, which is believed to be due 
to the competition for a common substrate, coenzyme A, by the conjugating enzyme 
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systems.(56,57) Therefore, first pass effect greatly affects metabolism, and in turn the resulting 
plasma concentrations.(56) 
1.8.2.2. Pharmacokinetic studies of PAS 
Despite the many years that PAS has been used there is a paucity of pharmacokinetic data in 
the literature. A small number of studies have evaluated the pharmacokinetic characteristics 
of the metabolite APAS, and even fewer that of GPAS. Nevertheless, reports are available for 
studies conducted in healthy subjects and patients with drug susceptible and other patients 
with drug resistant TB, including adults and children with TB.(43,58–61) 
In these studies, the recommended GSR-PAS formulation is evaluated, at different dosing 
strategies. Especially marked is the difference in release characteristics of the granules when 
compared to previous preparations. In adults receiving a single 4 g GSR-PAS, the mean Cmax 
was around 20 µg/mL (SD; standard deviation = 8.80 µg/mL), 2 – 4 times less than the 
typical PAS tablets, and the Tmax was 7.95 hours (SD = 6.12 hours) compared to 0.5 – 2 hours 
in the tablet. This allows PAS to be present longer and remain above the required MIC, in 
systemic circulation.(58,62,63) Serum concentrations of APAS was also reported, as mean Cmax 
of 17.50 µg/mL (SD = 3.48 µg/mL) and Tmax of 9.27 hours (SD = 5.24 hours). The majority 
of subjects had APAS detected in serum before PAS itself. These findings were consistent 
with previous reports of first pass metabolism.(56–58)  
Inter-individual variation was significant in the pharmacokinetics of patients treated for 
MDR- and XDR-TB.(43,59) One study conducted in an adult South African population, 
25
Stellenbosch University  https://scholar.sun.ac.za
reported a mean Cmax, Tmax and AUC0-∞ of 51.3 µg/mL (SD = 20.0 µg/mL), 5.2 hours (SD = 
2.04 hours) and 368.0 µg/h/mL (SD = 194.0 µg/h/mL) respectively, receiving a 4 g GSR-
PAS dose. These findings were within the same range using the slow release formulation in a 
previously reported American population.(58) The latter study found that the coefficient of 
variation for Cmax varied by 43.5% and Tmax by 76.9%. The most probable reason for this may 
be individual capacity to absorb the PAS granules, which may result in overlapping 
absorption, distribution and elimination phases.(58)  
 
In the evaluation of the effects of feeding on GSR-PAS absorption, changes in gastric pH 
produced by orange juice or antacids were not significant. However, absorption was 
improved by co-administration of a high-fat meal, which showed an increased Cmax and delay 
in Tmax, in turn increasing the time that concentrations remain above the target MIC.(60) 
Additionally, the potential effect of drug interactions among HIV-infected subjects 
concomitantly administered PAS and efavirenz (EFV), has been reported. Concurrent use of 
EFV showed approximately 52% increase in PAS clearance, and an overall reduction of 30% 
in the mean AUC.(61)  
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1.8.3. Dosing regimens of PAS 
While it has been reported that up to 65% of patients with XDR-TB can be successfully 
treated, studies in South Africa found that within 2 years of diagnosis, as many as 50% and 
80% of patients with MDR- and XDR-TB had died, respectively.(64–66) Despite its drawbacks, 
PAS is an essential drug in the treatment of patients with MDR-TB and especially patients 
with XDR-TB. A study conducted in South Africa identified three (6%) of 48 M. tuberculosis 
isolates from XDR-TB patients, demonstrating resistance to PAS.(65) Therefore, these 
circumstances call for a revision of the recommended use and dosing regimen of PAS. 
The GSR-PAS preparation is locally available, and prescribed as 8 – 12 g in three divided 
doses.(7) In order to maintain plasma concentrations above the MIC of 1 µg/mL, a multiple 
dosing regimen is recommended, as with other typical bacteriostatic agents.(67) This regimen 
was derived from TB studies using earlier formulations, as the divided doses were thought to 
reduce the intolerance to PAS. (45,59) However, a number of earlier studies reported that once-
daily dosing of PAS was better tolerated than multiple daily dosing.(56,68) 
In the study by Marsden, which looked at different dosages and rhythm of administration of 
PAS it was reported that 119 (30%) of patients receiving divided sodium PAS doses 
experienced GI disturbances, compared to only 44 (12%) on a once-daily regimen.(69) Yue 
and Cohen(70) reported similar findings using the sodium salt preparation when 12 g PAS was 
given as 4 g three times daily (14.8%), 6 g twice-daily (15.5%), and 12 g once-daily (10.1%), 
respectively.(41) A Swedish study reported that PAS as a “single massive dose” was preferred 
by “about two thirds of the patients on PAS medication”.(71) 
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With the GSR-PAS formulation, significantly less intolerance has been observed with only a 
minority of patients experiencing vomiting, nausea, bloating, or diarrhoea. In a study by 
Peloquin(58) a single 4 g once-daily compared with 4 g twice-daily GSR-PAS dose was found 
to be equally well tolerated. In a similar investigation comparing a 4 g twice-daily and 8 g 
once-daily GSR-PAS dose, findings suggested that twice-daily dosing was associated with 
more intolerance than the once-daily dosing.(72) In addition, it was noted that abdominal pain 
and discomfort and diarrhoea occurred when minimum plasma concentrations of PAS were 
present. These findings led Sy and colleges(72) to the hypothesis that rapid absorption and 
biotransformation of PAS may potentiate GI intolerance, probably as a result of its metabolic 
entities being produced. However, their hypothesis could not be evaluated, as their study did 
not determine the metabolite concentrations.  
1.8.4. Adverse effects of PAS 
After the first use of PAS, its adverse effect profile was well characterized. Several 
formulations were manufactured to overcome the GI intolerance. These effects were reduced 
with the GSR-PAS, which allowed less production of meta-aminophenol, a potentially toxic 
degradation-product of PAS.(73) The slower release in the small intestines avoided gastric 
irritation, compared to the previously used salt preparations.(45) 
The most commonly occurring AEs associated with PAS are hypothyroidism and GI 
intolerance, including nausea, bloating, vomiting, diarrhoea, abdominal pain and anorexia.(74) 
While mild GI effects were evident in up to 70% of patients using the older formulation, 
these are rarely severe enough to warrant discontinuation of the drug.(26)  
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Hypersensitivity reactions are seen in 5 – 10% of patients, manifesting as fever, joint pains, 
sore throat, and skin eruptions, which can occur independently or are accompanied by the 
fever. In a retrospective study of 7492 patients treated for TB, hepatitis developed in 38 
(0.5%), from which 28 (0.3%) cases were attributed to the use of rapidly absorbed PAS 
preparations (i.e. salt and/or granules).(74) Symptoms such as jaundice appeared within 4 
weeks after start of therapy. A high mortality rate for hepatotoxicity (21%) has been seen 
with continued use after symptoms are observed.(52) 
Other rarely reported AEs include haematological aberrations, such as leukopenia, 
agranulocytosis, thrombocytopenia and acute haemolytic anaemia.(75) Hypokalemia, acidosis 
and crystalluria have occurred occasionally.(75,76)  
A recent review of drug associated adverse effects with the use of PAS, reported that seven 
(7%) of 101 patients with XDR-TB had to stop taking PAS.(37) This figure is consistent with 
earlier studies, which reported intolerance in approximately 10% of patients.(77) GI adverse 
reactions were predominantly reported, including nausea, vomiting, diarrhoea and other 
gastrointestinal symptoms. The frequency of adverse effects were high (approximately 60%) 
in the studied XDR-TB treatment regimens, that included ethionamide, pyrazinamide, 
ethambutol and capreomycin.(37)  
Due to the predominant use of PAS in DR-TB, the strategy of combined therapy is a concern, 
as the intolerance cannot be ascertained to PAS alone.(26) For this reason, the influence of 
drug interactions with PAS needs to be considered when determining the causative of the 
frequently observed GI adverse reactions.  
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1.8.5. Drug interactions with PAS 
PAS is known to have interactions with other drugs, the most notable being the inhibiting 
effect on isoniazid acetylation during PAS therapy, causing isoniazid concentrations to be 
significantly higher when co-administered with PAS.(19,78) It has been reported that EFV 
increases the elimination of PAS, thereby potentially compromising therapeutic efficacy 
when administered together.(61) At present it is unclear whether significant interactions occur 
between PAS and other antiretroviral (ARV) drugs.  
The identified pharmacokinetic and pharmacodynamic drug-drug interactions between PAS 
and other medicines are presented in Table 1.5.  
Table 1.5: Reported pharmacokinetic/pharmacodynamic drug-drug interactions between PAS 
and other medicines.  
Concomitant drug Effect 
Pharmacokinetic 
Digoxin Decreases the absorption of PAS   
Isoniazid  Inhibition of isoniazid acetylation leading to increased concentrations 
Rifampicin  Absorption is reduced by PAS  
Vitamin B12 PAS reduces serum concentrations of vitamin B12  
Folate Absorption is reduced by PAS  
Probenecid Increases serum concentrations of PAS  
Adapted from Arbex(48), McIlleron(76), and Momekov(26). 
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Table 1.5: Reported pharmacokinetic/pharmacodynamic drug-drug interactions between PAS 
and other medicines (continued).  
Concomitant drug Effect 
Pharmacodynamic 
Angiotensin converting enzyme inhibitors PAS reduces the antihypertensive effects 
Calcium channel blockers Increases anticoagulant effect of PAS 
Carbonic anhydrase inhibitors Potentiate adverse effects of both drugs 
Corticosteroids Increases severity of corticosteroid adverse effects 
Loop diuretics PAS can reduce effects of loop diuretics, and the loop 
diuretics can increase serum concentrations of PAS
Non-selective NSAIDS (except diclofenac) May increase adverse effects of PAS  
Sulfonylurea PAS increases hypoglycemic effects  
Oral anticoagulants, thrombolytics, salicylates Risk of bleeding is increased by PAS  
Ethionamide  Potential increase in risk of hepatotoxicity and 
hypothyroidism 
Methotrexate PAS may increase toxicity of methotrexate 
Azathioprine Toxicity is increase by PAS 
Tiaprofenic acid Increases risk of gastrointestinal bleeding  
Trandolapril Efficacy may be reduced by PAS 
Thioguanine PAS may enhance toxicity   
Warfarin Antiplatelet effects of PAS may increase bleeding risk of 
warfarin
Tolmetin Increases risk of gastrointestinal bleeding  
Sulindac PAS may decrease serum concentrations, and sulindac 
enhances risk of toxity such as bleeding
Azathioprine Toxicity is increased by PAS 
Treprostinil Risk of bleeding is increased  
Mercaptopurine Toxic effects are increased by PAS  
Adapted from Arbex(48), McIlleron(76), and Momekov(26). 
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1.8.6. Pharmacogenomics of PAS 
 
Arylamine N-acetyltransferases are divided into two classes, polymorphic (NAT2) and 
traditionally designated monomorphic (NAT1).(79,80) Differences in the acetylating activity in 
isoniazid was the earliest identified genetic variation in drug metabolism. Substrates of NAT2 
include isoniazid, hydralazine and sulphamethazine, therefore inter-individual variation in N-
acetylation is observed in these drugs. In contrast, monomorphic substrates such as PAS and 
PABA are metabolized by NAT1.(81,82)  
Allelic variation of NAT1 have been identified, which associate with decreased enzyme 
activity, although very rarely occurring.(83) As NAT1 is chiefly responsible for metabolism 
of PAS, it has been used as a probe for NAT1 function. Among the described polymorphisms 
the most common are NAT1*10, NAT1*3 and NAT1*11, with reference to wild-type 
NAT1*4.(83,84) 
A reduction in enzyme activity associated with the NAT1*14 allele was found in a southern 
African population, consisting of African and mixed ancestry. No evidence was found to 
support increased activity associated with NAT1*10.(72,85) An interesting finding was 
particularly high PAS exposure in a patient with a NAT1*10/1*3 genotype and two others 
carrying NAT1*14 allele, implying reduced enzyme function.  
The influence of NAT2 genes on PAS metabolism is noted by Sy et al.(72) These findings 
reflect interactions between NAT1 and NAT2 genes, similarly to that reported in oncology 
studies,(86) which noted that NAT1 and NAT2 polymorphisms can interact with one another 
and increase or decrease the risk of cancer developments.(86)  
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Chapter Two 
Literature Review -Analytical Techniques 
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2.1. Introduction 
Separation of analytes from potential interferences is fundamentally important in bio 
analytical investigations. Additionally, there is a need to determine trace quantities, where the 
analyte concentration relative to the sample matrix components may be exceptionally small. 
At current, ultra-high performance liquid chromatography (UHPLC) used as separation 
method coupled to a mass spectrometer (MS) as the quantification method is widely used in 
biological and clinical research settings. Together these two systems form a UHPLC-MS/MS 
technique, which enhances the properties of selectivity, sensitivity and rapid analysis when 
monitoring therapeutic agents.  
This chapter outlines the analytical techniques related to the study presented. Firstly, an 
overview of basic chromatography is discussed, followed by an elaborate focus on liquid 
chromatography separation methods, as well as appropriate mass spectrometry detectors. 
Thirdly, we cover the fundamentals of method development and validation as stipulated by 
the Food and Drug Administrations (FDA). Fourthly, we discuss the importance of sample 
preparation and use of internal standards. Lastly, we give a literature overview of LC-MS 
methodology applied to anti-TB chemotherapeutic PAS and its metabolites APAS and GPAS. 
2.2. Description of chromatography 
Chromatography is defined as a separation method, which involves two phases – one 
stationary and one mobile. Separation occurs by transporting the sample or analyte, in the 
mobile phase through or over a non-miscible stationary phase, which is fixed on a solid 
43
Stellenbosch University  https://scholar.sun.ac.za
surface or in a column. The sample is dissolved in the mobile phase, which may be a gas (gas 
chromatography), a liquid (liquid chromatography) or a supercritical fluid (supercritical fluid 
chromatography). 
 
Components of the sample separate between the two phases, resulting in different migration 
rates through the system. With the flow of the mobile phase, those components that are 
retained weakly by the stationary phase elute from the system before strongly retained 
components. Due to the differences in mobility, components may be divided into discrete 
bands and be distinctly quantified.(1–3)  
 
Separation modes are distinguished by the physical means in which the analyte and the 
stationary and mobile phase interacts with each other. More importantly, the classification is 
based on the types of mobile and stationary phases and the state of equilibrium in the transfer 
of components between the two phases. The most frequently applied column chromatography 
has a stationary phase, which is held in a tube, commonly known as a column, through which 
the mobile phase is applied, by pressure or gravity. The separation method employed relies 
on the molecular characteristics related to partition (liquid-liquid), adsorption (liquid-solid), 
affinity (shape) or differences among the molecular weight, as described in Table 2.1.(3) 
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Table 2.1: Summary of common column chromatographic separation methods.  
Molecular characteristic Physical property Separation method 
Polarity Volatility Gas-liquid chromatography 
Solubility Liquid-liquid chromatography 
Adsorptivity Liquid-solid chromatography 
Ionic Charge Ion-exchange chromatography 
 Electrophoresis 
Size (mass) Diffusion Gel permeation chromatography 
 Dialysis 
Shape  Sedimentation Ultracentrifugation 
Liquid binding Affinity chromatography 
Adapted from Skoog et al.(4) 
 
2.3. Chromatographic separation factors 
 
The essential objectives of a chromatographic separation are to obtain optimal resolution 
within a minimum expenditure of time. Resolution (Rs), of a column provides a quantitative 
measure of the columns ability to resolve two solutes (analytes), in a mixture. Insufficient Rs, 
could cause co-elution of analyte, which ultimately decreases the reproducibility of the 
separation method. Below we discuss the factors related to Rs, namely retention factor (k), 
selectivity (α), and column efficiency, as displayed in Figure 2.1.(4–7) 
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 Figure 2.1: Schematic representation of the contributing parameters in chromatographic separations. Adapted 
from Chromacademy Science.(6)  
 
2.3.1. Retention factor 
 
The retention factor (k), previously known as capacity factor, is the ratio of the time the 
analyte resides in the column relative to the time it resides in the mobile phase, while the 
retention time refers to the total time the solute spends in the column. This factor relies on 
variables such as the flow rate of the mobile phase, and the dimensions of the column.(5,6) The 
fast elution of an analyte causes the retention time to vary, creating a greater probability of 
co-elution of the analyte with other components of the sample mixture. Consequently, 
isobaric interferences occur which are either completely or partially masking the peak of 
interest, ultimately reducing the analyte response. Alternatively, peak broadening and lengthy 
run times occurs as a result of too much retention. Under these circumstances, the precision 
and accuracy in integrating peaks is compromised.(5,8) Optimization of the retention factor can 
be achieved by altering the mobile phase, stationary phase or phase ratio.  
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2.3.2. Selectivity  
 
The selectivity factor, also known as separation factor (α) is the ability of the 
chromatographic system to chemically differentiate the components of the sample mixture. 
This factor is measured as a ratio of the retention (capacity) factors (k) of the two peaks in 
question, and is visualized as the distance between the apices of the two peaks.  
 
The selectivity factor should always be larger than 1, as α being 1 is indicative of co-eluting 
peaks. Therefore, large selectivity values represent good separation between the apex of each 
peak, and therefore good separation power of the method.(6) Due to dependency on the 
chemistry of the analyte, the optimization of the selectivity of a separation can also be 
achieved by modifying the stationary and mobile phase constituents.  
 
2.3.3. Column efficiency  
 
The efficiency of a chromatographic peak is defined by the measure of the peak width and 
sharpness, as the analyte band travels through the system and column. Ideally, 
chromatographic peaks would be as sharp as a pencil thin line, but due to dispersion effects, 
the narrow peaks broaden during their movement through the column. A quantitative measure 
of chromatographic efficiency is described by, plate number (N).(6) 
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2.4. Liquid chromatography 
 
This study focused on the use of liquid chromatography (LC), a separation technique ideally 
suited for molecules of biomedical research, which are usually limited by sample volatility 
and thermal stability.(7) LC refers to any chromatographic technique in which the mobile 
phase is liquid, as opposed to gas chromatography (GC), where the mobile phase is a gas.(7) 
In classical LC, the liquid mobile phase containing the analyte (protein, metabolite, drug) 
moves through a column, by applying a gravitational force, which causes fractions to be 
collected over a several hours. The column is discarded after a single separation, and thus 
needs to be repacked for each separation.(7,9) 
 
Modern LC, also called high performance liquid chromatography (HPLC) has proven to be 
the predominant technology used in laboratories globally, for decades.(9) HPLC provides the 
advantage of rapid and superior separations, using high pressure pumps as well as special 
columns and column packing.(7) The high pressured pumps allowed for a desired flow rate of 
the solvent, through the column. The selectivity was enhanced by the interaction of both 
mobile and stationary phase (unique column packing) with the sample.(9)  
 
2.4.1. HPLC instrumentation 
 
A typical UHPLC system performs separation by pumping the mobile phase from a reservoir, 
by high pressure tubing and fittings, through the column, and out to the detector (Figure 2.2). 
The injector is able to introduce the dissolved sample into the flowing mobile phase stream, 
which carries the sample to the column. Here, the separation of the molecules occurs 
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according to the column packing material of the stationary phase and its interaction with the 
mobile phase. A signal is detected for the separated molecule bands as they elute from the 
column. A suitable data acquisition system is then used to illustrate a chromatogram, which is 
generated by plotting the signal intensity as a function of time. High-pressure tubing and 
fittings are used throughout the system, to interconnect the pump, injector, column and 
detector components to form the channel for the mobile phase, sample, and separated 
compound bands.(10) The most critical instrumentation consists of the column and detector.  
 
 
Figure 2.2: A schematic of a typical HPLC system. Adapted from Waters Corporation.(10) 
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2.4.2. Modes of column separation in LC  
 
The separation principles applied to LC, is dependent of the physico-chemical properties of 
the analytes of interest. Three primary properties determined prior to separations, include the 
polarity, electrical charge and molecular size of the analytes. A number of separation 
mechanisms used, include adsorption chromatography, partition chromatography, and ion 
exchange. Only the two primary separation mechanisms used, when considering the polarity 
of the compounds of interest, is discussed below.(10)  
 
2.4.2.1. Normal phase chromatography  
 
Normal phase LC, is a close parallel to adsorption and partition chromatography, which uses 
a polar stationary phase with a relatively non-polar mobile phase.(1) This technique is 
commonly referred to as ‘liquid-solid’ chromatography. In NP-LC, the polar stationary 
phases such as bare silica or support bonded phases that have a diol, cyano, diethylamino, 
amino or diamino functional groups are used. Together with these stationary phases, non-
polar or weakly polar organic solvents such as hexane, isopropanol, dichloromethane or ethyl 
acetate are utilized.(7) NP-LC performs separation based on the polar absorption of the 
molecules in question, or the solvent molecules onto the column surface. The stationary 
phase is thus very selective for polar (hydrophillic) molecules, which are retained longer 
while the least polar (hydrophobic) molecules are eluted first.(6,11) Consequently, the highly 
polar nature of the stationary phase used in NP-LC, may lead to strong binding of polar 
components present in the mobile phase, ultimately resulting in long column equilibration 
times and poor reproducibility.(12)  
  
50
Stellenbosch University  https://scholar.sun.ac.za
2.4.2.2. Reversed phase chromatography 
 
Reversed phase LC, is a form of partition chromatography, carried out on columns with a 
non-polar or weakly polar stationary phase. Frequently used stationary phases possess 
modified silica bearing an n-alkyl hydrophobic ligand such as octadecyl (C18), octyl (C8), n-
butyl (C4), phenyl, or cyano-propyl functional groups chemically bonded to microporous 
silica particles on the column. The type of n-alkyl ligand significantly influences the retention 
of analyte molecules and thus manipulates the selectivity of the separation.(13) Along with 
these stationary phases, is the use of a relatively polar mobile phase, usually composed of 
methanol, acetonitrile, and tetrahydrofuran organic solvents used in different combinations 
with water.(7) The separation mechanism of RP-LC occurs by partitioning of the solute 
molecule between the mobile phase and the immobilised non-polar (hydrophobic) stationary 
phase, in turn causing non-polar molecules to be retained longer than polar molecules. The 
solutes are therefore eluted in order of increasing molecular hydrophobicity.(13)  
 
However, the elution order on RP-LC varies in respect to factors such as polarity, organic 
solvent composition, operating temperature, the ionic modifier and gradient elution.(14) 
Elution can proceed either by isocratic conditions, where the concentration of organic solvent 
is constant, or by gradient elution whereby the amount of organic solvent is increased over a 
period of time. For these reasons, RP-LC consists of many factors that can be adjusted in 
order to affect how an analyte molecule will interact with both the stationary and mobile 
phase. The hydrocarbon-like makeup of the stationary phase has shown to equilibrate rapidly 
with these modifications.(13) Other benefits of RP-LC includes a wide range of 
chromatographic conditions for closely related molecules while also structurally distinct, 
generally high recoveries, and superior reproducibility of repeated separations carried out 
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over a long period of time as a result of the stability of the column packing material under a 
wide range of mobile phase conditions.(15,16)  
 
Both normal and reversed phase chromatography are used for the separation, identification 
and quantification of anti-TB agents, and their metabolites. Due to its versatility, robustness 
and high resolving power, RP-LC is mostly utilized in assays developed for anti-retroviral 
and anti-TB studies. The standard care in TB treatment is combination therapy, and therefore 
a single separation method is needed to accurately determine a number of compounds of 
interest. Silica based RP columns which contain di-functionally bonded C8 and C18 ligands 
has shown favourable results in peak shape. The first choice for method development and 
analysis of small molecules (molecular weight < 2000 Da) are C18 RP columns (Figure 2.3). 
 
 
 
Figure 2.3: Reversed phase HPLC columns. Adapted from Agilent Technologies.(17)  
  
52
Stellenbosch University  https://scholar.sun.ac.za
2.4.3. Optimization of chromatographic separation  
 
Varying experimental conditions until the components of a mixture are separated efficiently 
with a minimum expenditure of time optimizes a chromatographic separation. In seeking 
optimum conditions for achieving a desired separation, the critical parameters pertaining to 
retention (k’), selectivity (α), and efficiency (N), may be adjusted. Optimization is thus 
aimed at altering the relative migration rates of solutes and at reducing peak broadening(18). 
Parameters that are optimized include the column temperature, the column chemistry and 
dimensions, flow rate, pH of the solvent, organic modifier (i.e. methanol or acetonitrile), 
buffer strength, the mobile phase gradient, wash solutions and injection solvent.(19,20) 
 
2.5. Ultra-high performance liquid chromatography  
 
Ultra-high performance liquid chromatography (UHPLC) is a modified method of HPLC, as 
it follows the same principles but brings enhanced performance of separation. The UHPLC 
method comprises high pressure pumps and small porous particle sizes, which improve run 
times and separation power.(21)  
 
Researchers have found that a decrease in particle size (sub 2 micron) of the analytical 
column shows significant increase in the separation efficiency in packed columns. This is a 
result of small particles providing a more uniform solvent flow rate through the column. In 
turn, this method allows the mobile phase consumption to be reduced by at least 80% 
compared to the HPLC, thus shortening the run times up to 7 fold.(22,23)  
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However, the reduction in particle size leads to a rapid increase in back pressure, due to small 
particles having a high resistance to solvent flow. Therefore, UHPLC sized particles require a 
high pressure of up to 6000 psi, to maintain retention and capacity similar to HPLC.(24,25)  
 
2.6. Detection 
 
Several detection systems have been developed for the screening, identification and 
quantification of drug residues in biological matrices. Most common detectors in LC are 
concentration-sensitive, in that the output signal is a function of the concentrations of eluate 
(sample) passing from the column to the detector cell. Largely, a detector should be non-
destructive, insensitive to mobile phase composition and fluctuating temperatures while also 
providing a linear response and sensitivity to low concentrations.(1) Most notably are UV, 
fluorescence, electrochemical and refractive index detectors. In the current study we have 
used mass spectrometry as detector, and briefly describe the system.  
 
2.6.1. Mass spectrometric detector 
 
Mass spectrometry (MS) detection is currently the most powerful mode in today’s market for 
quantification and identification of complex sample mixtures. MS essentially involves the 
production, separation and detection of charged species. Due to the fact that only charged 
species are detectable, the analyte molecules firstly need to be ionized. Thereafter, ions are 
filtered based on their mass-to-charge (m/z) ratios in the mass analyser.(1,26,27) The relative 
abundance of the molecule can then be extrapolated from a mass spectrum, which is a 2D 
plot of m/z ratio of the molecules respective ions versus the ion intensity or ion abundance. 
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When comparing MS to other analytical techniques, the advantages in MS are increased 
sensitivity and specificity. These characteristics result from a combination of the analyser as a 
(m/z) ratio filter and the ability to determine fragmentation patterns of analyte molecules.(28) 
For these reasons, MS has become the most ideal detector for interfacing with liquid 
chromatography systems.  
 
2.7. Hyphenated LC-MS technique  
 
The combination of liquid chromatography (LC) and mass spectrometry (MS), hyphenated 
LC-MS, combines the separating power of LC, with the strong detection power of MS. This 
superior technique is particularly valuable in trace level analysis. Depicted in Figure 2.4 are 
the basic components of an LC-MS system.  
 
Historically MS had been of limited use in clinical disciplines, due to the need for separation 
of the analyte molecule from the sample matrix (blood, urine, plasma). Additionally, was the 
need to produce stable volatile derivatives of the analyte molecule while also subjecting it to 
ionization. Another limitation of the coupling technique, is the enormous mismatch between 
the relatively large mass flows involved in LC and the vacuum requirements of the MS. To 
overcome this problem, several ionization interfaces have been developed for efficient 
sample introduction into the MS.  
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 Figure 2.4: Basic components of an UHPLC-MS system. Adapted from Alberts.(18)  
 
 
2.7.1. Ionization source  
 
MS techniques are distinguished based on the ionization source selected. The choice of 
source is dependent on its compatibility with the introduction separation method (LC, GC), as 
well as the resolution of the instrument with the targeted mass range of the analytes.(9) Within 
the context of this thesis, aspects of the source electrospray ionisation (ESI) are briefly 
described.  
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ESI is a form of atmospheric pressure ionization (API) interface, primarily used for the 
analysis of charged species. API allows ion formation at atmospheric pressure instead of in 
the vacuum chamber of the mass spectrometer. This enables the direct introduction of non-
volatile, charged and unstable analytes into the mass analyzer. It is required that analytes be 
in the ionized form prior to transfer into the ESI interface, by manipulation of LC eluent pH 
before or after separation in the column.(26,27) Essentially, three processes are involved in 
transferring sample ions from the eluent into the gas phase within the instrument. ESI does 
this as follows. Firstly, the LC eluate is transferred from the column into a metal capillary 
inlet, which is charged with a high voltage. The action of this high energy at the capillary, 
together with surrounding high speed gases in the API region, results in production of 
charged droplets. The droplets are then evaporated using a heated drying gas within the 
interface, which allows desolvation and increased charge density of the droplets. The 
repeated action of evaporation produces smaller highly charged droplets, which are capable 
of forming gas-phase ions that are then analysed in the mass spectrometer by their m/z 
ratios.(27) Therefore, ESI is considered a very low energy ionization process, which usually 
yields an intact parent ion with single or multiple charges. The charge on the droplet surface 
depends on the capillary voltage, where a positive capillary forms positive ions (protonated 
species), and a negative capillary forms negative ions (deprotonated species). Ions that are 
oppositely charged to the analyser will freely move through a narrow stream that is focused 
on the mass analyser.(18,26)  
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2.7.2. Mass analyser  
 
Many types of mass analysers are associated with routine LC-MS analysis, which differ in 
the fundamental way they separate species. The most commonly used designs include 
quadrupole, ion trap, orbitrap and time-of-flight analysers.  
 
The quadrupole mass analyser contains four parallel rods arranged in a symmetrical manner. 
The opposing rods are connected together by applying controlled voltages to the rods, which 
impart an electrostatic/magnetic field inside the analyser. The ions produced in the source, 
are focused into the analyser, and travel along the axis of the rods. For a specific range of 
voltages applied, only ions with a certain m/z ratio will pass through the quadrupole without 
touching the rods, therefore these ions are known to have stable trajectories. Ions with 
unstable trajectories will collide with a rod and become neutralized. Subsequently, these ions 
will not enter the detector. Hereby, separation is achieved by controlling the voltages applied 
to the mass analyser rod, so that ions with varying m/z ratios can be focused onto the detector 
for their MS spectrum to be generated.(4,27)  
 
The golden standard of quadrupole mass analysers is known as the triple-quadrupole mass 
analyser. This system contains three sets of quadrupole rods arranged in series, for the 
combination of two mass selective experiments. In the first quadruople (Q1), ions of a 
particle m/z ratio are filtered, known as the precursor ion. The second quadrupole (nowadays 
the quadrupole is replaced by a hexapole or other device) is a collision induced dissociation 
(CID) source, consisting of an inert gas such as argon or helium, used to fragment the 
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precursor ions from Q1. The third quadrupole (Q3) filters fragment ions from the CID source, 
known as the product ions. The result is known as tandem mass spectrometry (MS/MS).(26)  
 
2.8. Storage of biological samples 
 
In order to avoid degradation or other potential chemical changes in the analyte drug, the 
biological sample is usually frozen immediately upon collection and thawed before analysis. 
In most cases, pre-treatment of sample is necessary before running the assay. The appropriate 
method of preparation depends on factors such as texture, chemical composition of the 
sample and the degree of drug protein binding. Usually, the sample stability is tested prior to 
collection to determine a protocol for this procedure.  
 
2.9. Sample preparation  
 
The advantage of combining LC with MS has shown to provide an analytical technique with 
a high capability to distinguish between different molecules. However, despite the advances 
made in instrumentation for determining analytes in biological samples, there is still a need 
for pre-treatment of the sample. The purpose of sample preparation includes the following: 
removal of interfering endogenous biological substances that may lead to ion suppression, 
which causes these substances to co-elute with the analyte from the LC column. Secondly, is 
the need to convert the analyte into a more suitable form for injection, separation and 
detection. Thirdly, is to concentrate the target analyte to improve the sensitivity.(5,29)  
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Several preparation techniques have been developed, the most common liquid phase methods 
applied to LC-MS instruments include liquid-liquid extraction (LLE), solid phase extraction 
(SPE), and protein precipitation (PPT). For some analyte molecules, precipitation may be the 
first step, followed by purification and concentration by LLE or SPE.(29) An advantage in 
liquid samples, usually found in biological studies, is their ability to dissolve in any polar or 
non-polar organic solvent.(5) In this study, we have applied PPT as it is widely used for 
plasma and blood sample extraction.  
 
2.9.1. Protein precipitation (PPT)  
 
This simple, cost effective and rapid preparation method is used for the clean-up of analytes 
from a sample with a relatively high abundance of protein. It is therefore, suitable for 
extraction of biological samples (plasma, serum, urine and blood) in clinical, toxicological 
and therapeutic drug monitoring (TDM) studies. Its cost effectiveness, simplicity and rapidity 
has made PPT the most frequently employed technique for analysis of anti-TB agents, as they 
are hydrophobic in nature.(30)   
 
The technique is based on the interaction between the reagent applied and the moieties of the 
present proteins. Reagents such as water miscible organic solvents, interfere with the 
intramolecular hydrophobic interactions of proteins while also reducing the hydration state of 
the proteins. Consequently, the less hydrated proteins are, the less soluble they become.  
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A typical PPT protocol is as follows. An organic solvent, commonly acetonitrile, acetone or 
methanol, is added to the biological sample. Following the precipitation reaction, which may 
require vortexing (mixing), the sample mixture is centrifuged to draw the protein precipitate 
to the bottom of the sample tube. The analyte separated to the top liquid layer, is then 
removed or evaporated to dryness and reconstituted in a more suitable solvent for injection 
into the LC-MS. The instrumental response of the analyte in the unknown sample is then 
obtained from a sample in which the concentration is known.(5,30) This technique does not get 
rid of lipids and small polar molecules like anions, cations, amino acids and sugars and it 
should be kept in mind when the chromatographic methods are developed to separate the 
analytes from these molecules that might interfere in the analysis.  
 
2.10. Calibration and Internal standards 
 
In order to maintain reliable quantitative data, the LC-MS system compares the instrumental 
response obtained for the analyte in the unknown clinical sample with that from a sample 
with a known concentration, referred to as a calibration standard. In typical study setting, a 
set of calibration standards (usually at least 6 points) are prepared over the target 
concentration range of the analyte of interest. The instrumental response of each calibrator is 
measured and the relationship between response (y-axis) and known concentrations of 
calibrators (x-axis) is established. Typically, the relationship should be linear, as shown in 
Figure 2.5. This calibration curve is then used to transform measurements made on test 
samples into estimates of the amount of analyte present in a clinical sample.(5,31) The range of 
calibrators include the limit of detection (LOD), which is the lowest concentration at which 
the analyte is detectable but not necessarily quantifiable as an exact value. Also in the range 
is the lower limit of quantification (LLOQ), presenting the lowest concentration at which the 
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analyte can be quantified with acceptable precision (repeatability and reproducibility) and 
accuracy under the specified conditions of analysis.  
 
Routinely, LC-MS methods use calibrators processed in the same manner as the clinical 
samples. Calibrators are subjected to the same type of matrix, which is known to be free of 
the analyte, extracted with the same technique and at the same time.  
 
 
Figure 2.5: Typical calibration curve. Position of limit of detection (LOD) and lower limit of quantification 
(LLOQ) within the concentration range, are indicated. Adapted from Barwick.(31)  
 
Another way of ensuring reproducibility and reliability is the incorporation of a known 
amount of a non-analyte compound, named an internal standard (IS), to clinical samples, 
calibration standards and blank samples prior to extraction and analysis. Hereby, the 
calibration curve illustrated in Figure 2.5, presents the known concentrations of analyte (x-
axis) versus the ratio of analyte response to the internal standard response (y-axis). By adding 
an IS, the analyst is able to identify differences in extraction from sample to sample, and to 
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correct for effects such as instrument drift or variable sample injection volume. This is 
possible because the IS is added to each sample and therefore measured in the same solution 
and at the same time. It is however necessary to use an IS which has similar chromatographic 
behaviour as the analyte of interest, while still being distinguishable from the analyte in the 
mass spectrum.(5)  
 
Quality control samples (QC’s) are samples that have known concentrations of the analyte 
that are analysed in between the test samples to ensure that the system stays accurate through-
out the run.  Typically three QC’s are made by fortification of a plasma/matrix blank sample 
at three different levels, one just above the lower limit of quantification one at an 
intermediate concentration and one just below the higher limit of quantification, designated 
LOQ, MQC and HQC respectively. Acceptance of the data relies on QC’s being successfully 
quantified within predefined limits, determined by method validation criteria for bioanalytical 
research.(5)  
 
2.11. Method validation  
 
In LC, validation is the process of producing documented evidence that components such as 
the instrument and method perform as expected within specified design parameters and 
requirements. This is to ensure that the obtained results are reliable with respect to the 
equipment, including the instrument and computer controlling it, and the analytical method 
used to run on that equipment.  
 
63
Stellenbosch University  https://scholar.sun.ac.za
After development of an analytical method, the process of validation is established by 
laboratory studies and performance characteristics, as a tool of quality assurance.(32) This is to 
ensure that the method meets the requirements for the intended analytical application. Table 
2.2 describes the performance parameters, which have been evaluated in this study, according 
to guidelines stipulated by the Food and Drug Administration. 
 
During method development the stability of the analyte in the given matrix, which includes 
the effects of sample collection, handling and storage, is a prerequisite for reliable 
quantification.(33,34) This is to ensure that the concentration of the analyte at the time of 
sample collection corresponds with the concentration at the time of analysis.(35) Stability 
should be assessed in the same matrix as intended for the in study samples, and under 
typically expected sample conditions as described in Table 2.3. Comparing the experimental 
standard solution response relative to a freshly prepared standard tests the stability parameter. 
Acceptance criteria includes a consistent RSD of 2% and 20% at the standard stock solutions 
and the LLOQ, respectively.  
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Table 2.2: Acceptance criteria of various method validation parameters.(33) 
Parameter Experimental procedure Acceptance criteria 
Specificity  3 x injection of 3 blank samples from 
various matrices. 
 
Injection of a sample spiked with the 
analytes of interest.  
Chromatograms should present no 
interference from the blank sample. 
 
Chromatograms should present no 
co-eluting peaks at the same 
retention time as the analytes.  
Precision Repeated injections of calibration 
standards for analysis per batch 
samples.  
20% RSD of peak area at LLOQ 
should not be exceeded. At higher 
concentrations, 15% RSD is 
accepted.  
Accuracy  5 x injection of spiked QC samples at 3 
concentrations (LLOQ, LQC, MQC, 
HQC).  
Accuracy is reported as the % 
recovery of the difference between 
mean measured amount and the true 
value, which should not exceed 20% 
from the actual value, i.e. 80 – 120% 
recovery.  
Linearity  5 x injection of 6 calibration standards 
prepared at 25, 50, 75, 100, 150, and 
200% 
RSD and accuracy % must be 
reported for each standard. The peak 
area of each standard should be 
plotted on a calibration curve using 
Excel to calculate regression 
equation and correlation coefficient 
> 0.999.  
Lower limit of 
quantification 
(LLOQ)  
5 x injection of lowest standard on 
calibration curve.  
Concentration response of 5 x blank 
sample, with RSD and accuracy % 
no less than 20%.  
Limit of detection 
(LOD) 
5 x injection of standard.  Concentration response of 3 x SD of 
blank sample is acceptable.  
Robustness  Reported by changes in concentration as 
a response to changes in key variables.  
Discretion should be used to decide. 
Intra- and inter-day 
reproducibility 
Repeated injections of calibration 
standards for analysis, per batch on 
different days (inter-precision) and on 
the same day between different batches 
(intra-precision).  
20% RSD of peak area at LLOQ 
should not be exceeded. At higher 
concentrations, 15% RSD is 
accepted. 
RSD = relative standard deviation; QC’s = quality controls; LLOQ = lower limit of quantification; LQC = lower 
quality control; MQC = medium quality control; HQC = high quality control; SD = standard deviation  
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Table 2.3: Typical stability experiments evaluated during method development, for various 
stages of analysis.(33,34)  
Stability determinant Experimental procedure 
Freeze-thaw 3 x QCs prepared in triplicate and subjected to 3 x freeze/thaw 
cycles, to account for stability during reanalysis of samples. 
Long term QCs prepared in intended matrix at the intended storage temperature 
(i.e. - 80º C) and over the same period. 
Auto-sampler QCs prepared appropriately and subjected to auto-sampler conditions 
i.e. temperature and expected maximum time of analytical run. 
Temperate QCs prepared at conditions of analyte during sample extraction 
process (i.e. temperate and time needed for preparation) should be 
determined to prevent degradation of analyte during sample 
preparation 
Stock solution QCs prepared under intended storage conditions of sample prior to 
analysis, i.e. refrigerator (~ 4º C). 
 
 
2.12. Para-aminosalicylic acid  
 
Para-aminosalicylic acid (PAS, 4-amino-2-hydroxybenzoic acid) is an acid of about the same 
strength as benzoic acid.(36,37) PAS is approximately 0.2% soluble in water, but its salt 
formulations are soluble up to 96%.(38) It has a chemical structure comprised of carboxyl, 
hydroxyl and amine groups. The acetylation of the free amino group and conjugation at the 
carboxyl group are most prominent steps in the biotransformation process. In man, glycine-
PAS (GPAS) presents the main conjugation product, while acetyl-PAS (APAS) is the main 
acetylated product. The decarboxylation product excreted with the urine under normal 
conditions, known as m-aminophenol, is another by-product formed non-enzymatically.(39,40)  
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2.13. Analytical analysis of PAS and major metabolites 
Several methods have been developed for the determination of PAS, fewer methods for 
APAS and only two reported for GPAS in human biological fluids. Among the earlier 
methods is spectrophotometry and paper chromatography applied by Way et al.(41) and 
Unverricht et al.(42) for the analysis of PAS in blood and urine, respectively. For the 
quantification of free PAS GPAS and APAS in plasma, a simple method was established 
using a colourimetric route by Lauener et al.(43) A similar method (unpublished) was used by 
Lehmann(39) in whole blood and urine. These methods lacked specificity, as they were 
severely affected by various medications including antibiotics, sulphonamides and some food 
ingredients.(44) 
The earliest mention of the determination of PAS in plasma using HPLC was reported by 
Honigberg et al.(45) Therapeutic levels were quantified with a non-extractive sample 
preparation method and an ion-pairing reversed-phase (RP) HPLC technique coupled to a 
fluorescence detector. The reversed-phase system allowed the mobile phase to be miscibile 
with the sample matrix, and for the rapid elution of polar components in the matrix. Due to 
the acidic nature of PAS (pKa = 3.25), the ion-pairing mobile phase was used to increase the 
factor k, to additionally resolve the drug from components in the matrix. The use of HPLC 
proved to eliminate the interference from other components, which was a major limitation in 
the colorimetric assay.  
Although analysis by HPLC showed to be more specific, researchers evaluated alternative 
methods to overcome the complicated equipment and running costs. To directly determine 
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PAS and p-aminobenzoic acid (PABA) in various biological fluids, Pemberton et al.(46) and 
Liandiou and Ioannou(44) used a spectrofluorometric method. These fluorescence methods 
provided a cost effective alternative as well as less susceptible to exogenous interferences 
than the colorimetric method. However, the problem was not entirely solved. The lack of 
complete specificity still remained, due to several overlapping spectra from endogenous and 
extraneous compounds.  
Cummins et al.(47) quantified PAS and acetylated metabolite APAS, in human urine using 
capillary zone electrophoresis method. Direct injection of urine onto the capillary showed no 
significant inferences with the exception of aspirin (acetylsalicylic acid, ASA), which eluted 
very close to the APAS peak.  
For the purpose of pharmacokinetic studies, the literature reports many assays established to 
simultaneously assay second-line anti-tuberculosis (anti-TB) agents, which includes PAS and 
often its metabolite APAS.  These methods include HPLC systems coupled to fluorescence 
detection(48) and ultraviolet (UV) detection.(49,50) The UV detection methods included an ion 
interaction reagent and use of different mobile phases, making this technique suitable for 
simultaneous separation of xenobiotics with a broad range of polarities.  
Apart from its use as a second-line anti-TB drug, PAS is considered a promising therapeutic 
agent for treatment of manganese-induced neurodegenerative disorders. To determine how 
PAS exerts its therapeutic effectiveness and whether it or its metabolites can cross the blood-
brain barrier, Hong et al.(51) developed and validated an HPLC method coupled to 
fluorescence detector to assay PAS and APAS in plasma, cerebrospinal fluid (CSF) and 
tissues of rat models.  
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An HPLC method combined with MS detection using electrospray interface was developed 
by Pastorini et al.(52) for the determination of 5-aminosalicylic acid (5-ASA) and its 
metabolite N-acetyl-5-aminosalicylic acid (N-Ac-5-ASA) in human plasma. This study used 
PAS and APAS as internal standards, which is the first known mention of analysing PAS and 
its derivatives with a mass detector. Hereafter, PAS was assayed to determine its 
pharmacokinetics in plasma samples using a HPLC coupled to a MS/MS detector with an 
atmospheric turbulon ionization interface. The validated method used another anti-TB agent, 
Thiacetazone as internal standard.(53) Kim et al.(54) reported a similar LC-MS/MS method for 
the quantification of 20 anti-TB drugs including PAS, in human plasma.  
In more recent years, UHPLC-MS/MS has also been utilized in the quantification of first-line 
and second-line anti-TB agents, in human plasma.(55–57) These methods were uniquely 
designed for simultaneous analysis of drugs used in the standard treatment regimen of MDR- 
and XDR-TB patients therefore, making the technique advantageous for the therapeutic drug 
monitoring of most prescribed anti-TB medications. However, to the best of our knowledge, 
no method that is applicable simultaneously to PAS and both metabolites (APAS, GPAS) has 
been developed on a UHPLC-MS/MS system.  
A summary of the mentioned analytical techniques developed to quantify PAS alone, and/or 
simultaneously with other anti-TB agents, is presented in Table 2.4.  
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Table 2.4: Summary of internal standards, columns and solvents reported in the literature for 
analysis of anti-tuberculosis drug PAS in various matrices, using HPLC and UHPLC methods.  
Author Analyte Sample 
volume and 
matrices 
Internal 
standard 
Sample preparation  LC columns Mobile phase Range (µg/mL) 
(45) PAS 100 μL 
human 
plasma 
Anthranilic 
acid 
PPT with 100% 
Methanol 
LiChrosorb C18 
column (250 x 3.2 
mm; <10 μm)  
Methanol:water 
(20:80, v/v) containing 
0.005 M tetrabutyl-
ammonium hydroxide 
and 0.01 M disodium 
acid phosphate (pH 
5.5, adjusted with 
phosphoric acid) 
2.0 – 50.0  
(46) PAS,
PABA 
100 µL 
human urine  
Not 
available 
Alkaline hydrolysis 
with 0.5 mL of 4 M 
sodium hydroxide  
Polymer Laboratories 
100 A RP-S column 
(150 x 4.6 mm; 8μm)  
Acetonitrile (12%) in 
100 mM sodium 
dihydrogen phosphate 
buffer (pH 4.6)  
0.025 – 15.0 mM 
(48) PAS Human 
plasma and 
urine 
Not 
available 
Not available  Lichrospher 100 RP18 
column (250 x 4.6 
mm; 5 μm) 
Not available 1.0 – 100.0 μg  
(49) PAS Rat serum 
and plasma 
Not 
available 
Filtration through 0.20 
μm Millipore filter and 
1/20 dilution with 
ultrapure water 
Lichrospher 100 RP18 
column (250 x 4.6 
mm; 5 μm) 
Acetonitrile:water 
(50:50, v/v) in 100% 
acetonitrile 
Not available 
(50) PAS
MAP
Pellets Acetanilide  PPT and reconstitution 
with mobile phase  
RP 18e column and 
Chromolith 
SpeedROD RP-18e 
column 
20 mM phosphate 
buffer, 20 mM TBAS 
and 16% (v/v) 
methanol  
Not available 
(52) 5-ASA 
N-5-ASA 
Human 
plasma 
5-ASA: 
para-
aminosalicy
lic acid
N-5-ASA: 
N-acetyl-
para-
aminosalicy
lic acid
PPT, and reconstituted 
with 50 mmol/L acetic 
acid in 500 μL water 
Synergi-Hydro-RP 
(150 x 2.0 mm; 4 μm) 
17.5 mmol/L acetic 
acid in water (A), 
acetonitrile (B) 
0.05 – 4.0  
(51) PAS
APAS
200 μL rat 
plasma 
200 μL rat  
CSF 
200 μL rat 
brain tissue 
5-ASA PPT with methanol 
and reconstituted with 
mobile phase 
LLE with 6.0 M 
hydrochloric acid, 
followed by PPT as 
described in plasma 
PPT with methanol 
and 6.0 M 
hydrochloric acid, 
followed by 
reconstitution with 
mobile phase 
RP Econosphere C18 
column (250 x 4.6 
mm; 5 μm) 
17.5 mM potassium 
phosphate buffer at pH 
3.5 (A), methanol (B) 
0.005 – 500  
0.017 – 166.7 
μg/g 
0.017 – 166.7  
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Table 2.3: Summary of internal standards, columns and solvents reported in the literature for 
analysis of anti-tuberculosis drug PAS in various matrices, using HPLC and UHPLC methods 
(continued).  
Author Analyte Sample 
Volume and 
Matrices 
Internal Standard Sample Preparation  LC Columns Mobile Phase Range (µg/mL) 
(53) PAS 100 µL 
human 
plasma  
THIA PPT with methanol  Agilent Zorbax 
column (150 x 2.1 
mm; 3.5 μm) 
0.1% formic acid in 
water (A), 0.1% 
formic acid in 
methanol (B) 
1 – 100  
(56) STP
KMN
CLS
PAS
CTM 
PTM
MXF 
LEV
LNZ
50 µL human 
serum 
STP: 
Dihydrostreptomycin  
KMN: Gentamicin 
CLS: Muscimol 
PAS: 4-
aminobenzoic acid 
CTM: 
Roxithromycin 
PTM: Ethionamide 
MOX, LEV, LNZ: 
Lomefloxacin 
PPT with 3 M HCl in 
50% methanol, and 
reconstitution with 1M 
NaOH in 100% 
methanol  
Waters HSS T3 
column (50 x 2.1; 
1.8 µm) 
10 mM ammonium 
formate in 0.1% 
formic acid (A), 
0.1% formic acid in 
acetonitrile (B)  
STP, KAN, 
CLS, PAS: 5.0 – 
100.0  
CLM, PTM: 0.5 
– 10.0 
MXF, LEV, 
LNZ: 1.0 – 20.0 
(54) AKN
STP
KMN
PZA 
INH
RFM
ETM
CLS
PAS
LNZ
MXF 
LEV
CTM 
PTM
AMX
CPX 
CFM
RTM 
100 µL 
human 
plasma  
50 µL human 
plasma 
AKN, STP, KMN, 
PZA: Apramycin  
RFM: Rifampin-d3 
INH, ETM, CLS, 
PAS, LNZ, MXF, 
LEV, CTM, PTM, 
AMX, CPX, CFM 
RTM: Moxifloxacin-
d4 
PPT with methanol 
PPT with acetonitrile 
Atlantis HILIC 
column (150 x 2.1 
mm; 3 
µm)Atlantis dC18 
column (150 x 2.0 
mm; 3 µm) 
0.1% formic acid 
(A), 0.1% formic 
acid in acetonitrile 
(B) 
AKN, KAN, 
STP: 1.0 – 50.0  
PZA: 2.0 – 100.0  
AMX, LNZ: 0.4 
– 20.0 
CPX, LEV, 
MXF, PTM,  
RFM, RTM: 0.2 
– 10.0 
CTM, ETM, 
ETH, INH: 0.1 – 
5.0 
CFM: 0.04 – 2.0 
CLS: 0.8 – 40.0 
PAS: 1.0 – 50.0 
71
Stellenbosch University  https://scholar.sun.ac.za
Table 2.3: Summary of internal standards, columns and solvents reported in the literature for 
analysis of anti-tuberculosis drug PAS in various matrices, using HPLC and UHPLC methods 
(continued). 
Author Analyte Sample 
Volume and 
Matrices 
Internal Standard Sample 
Preparation  
LC 
Columns 
Mobile Phase Range (µg/mL) 
(57) CLS
PAS
PTM
LEV
STP
MXF 
KMN 
50 µL 
human 
serum 
CLS: Muscimol 
PAS: 4-
aminobenzoic acid 
CTM: 
Roxithromycin 
PTM: Ethionamide 
STP: 
Dihydrostreptomycin  
MOX, LEV: 
Lomefloxacin 
KMN: Gentamicin 
PPT with 3 M 
HCl in 50% 
methanol, and 
reconstitution 
with 1M NaOH 
in 100% 
methanol  
HSS T3 
column (50 
x 2.1 mm; 
1.8 μm)  
10 mM 
ammonium 
formate in 0.1% 
formic acid (A), 
0.1% formic acid 
in acetonitrile (B) 
STP, KMN, CLS, 
PAS: 5.0 – 100  
PTM: 0.5 – 10.0  
MXF, LEV: 1.0 – 
20.0  
(58 STP
KMN
CTM 
CLS
MXF 
LEV
LNZ
PAS
PTM
100 μL 
whole blood 
STP: 
Dihydrostreptomycin  
KMN: Gentamicin 
CTM: 
Roxithromycin 
CLS: Muscimol 
MOX, LEV, LNZ: 
Lomefloxacin 
PAS: 4-
aminobenzoic acid 
PTM: Ethionamide 
PPT with 3 M 
HCl in 50% 
methanol, and 
reconstitution 
with 1M NaOH 
in 100% 
methanol  
HSS T3 
column (50 
x 2.1 mm; 
1.8 μm)  
10 mM 
ammonium 
formate in 0.1% 
formic acid (A), 
0.1% formic acid 
in acetonitrile (B) 
STP, KMN, CLS, 
PAS: 5 – 100 
CTM, PTM: 0.5 
– 10 
MXF, LEV, 
LNZ: 1 – 20 ,  
PAS – Para-aminosalicylic acid; PABA – 4-aminobenzoice acid; INH – Isoniazid; ETH – Ethionamide; MOR – 
morphazinamdie; MAP – m-aminophenol; 5-ASA – 5-aminosalicylic acid; N-5-ASA – N-acetyl-5-aminosalicylic 
acid; APAS – N-acetyl-para-aminosalicylic acid; STP – streptomycin; KMN – kanamycin; CLS – Cycloserine; 
CTM – clarithromycin; PTM – Prothionamide; MXF – Moxifloxacin; LEV – Levofloxacin; LNZ – Linezolid; 
AKN – Amikacin; PZA – Pyrazinamide; RFM – Rifampicin; ETM – Ethambutol; AMX – Amoxicillin; CPX – 
Ciprofloxacin; CFM – Clofazimine; RTM – Roxithromycin  
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Chapter 3 
Aims and Objectives 
79
Stellenbosch University  https://scholar.sun.ac.za
The aim of this study was to assess the association between adverse gastrointestinal reactions 
and the concentrations at which, the metabolites of PAS, namely acetyl-PAS (APAS) and 
glycine-PAS (GPAS) are present in plasma. As part of an ongoing project, the population 
consisted of adult patients treated for MDR- or XDR-TB who had been dosed with 4g twice-
daily and 8g once-daily GSR-PAS on two separate occasions. In an approach to define 
contributors of toxicity the following objectives were performed: 
1. The first objective was to measure the levels of APAS, GPAS and PAS in the
population, using ultra high performance liquid chromatography (UHPLC) and mass
spectrometry (MS).
2. Once the concentrations were determined, the second objective was to describe the
pharmacokinetics (PK) of each compound. With this we were able to determine whether
differences exist in the PK of PAS under the two dosing strategies.
3. The third objective statistically evaluated the relationship between peak concentrations
of APAS and GPAS and the measure of intolerance, designated as a VAS score, using
a Spearman’s correlation test.
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Chapter Four 
Quantification of para-aminosalicylic acid (PAS) 
and metabolites (APAS, GPAS) in human plasma 
by UHPLC-MS/MS  
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The current project is a follow up of the original study conducted in 2013 at Clinical 
Pharmacology (Stellenbosch), whereby a HPLC-MS method was used to quantify the parent 
drug para-Aminosalicylic acid (PAS). The same population was studied in the current project, 
with the addition of determining the metabolite (Acetyl-PAS and Glycine-PAS) 
concentrations. In order to endorse the validation of the assay presented in this chapter, method 
characteristics such as the sample extraction procedure and post extraction stability of PAS was 
maintained, as previously described and validated in the original study.  
4.1. Introduction 
In recent years, several methods have been developed for the simultaneous analysis of second-
line anti-tuberculosis (anti-TB) drugs by HPLC and UHPLC, which included PAS.(1–3) The 
combination of these methods is regarded as the gold standard for identification and 
quantification analyses of drugs for pharmacokinetic studies in complicated matrices. To the 
best of our knowledge, assays for the simultaneous screening of PAS and its metabolites in 
human plasma have not previously been developed. This chapter discusses the application of 
UHPLC combined with tandem mass spectrometry (MS/MS) using electrospray ionization 
(ESI) as a tool for the analysis of PAS and its metabolic derivatives acetyl-PAS (APAS) and 
glycine-PAS (GPAS). We report the method validation according to internationally accepted 
criteria for bio-analytical drug analysis.  
Limited data exist in the literature regarding the pharmacokinetic profile of PAS, APAS and 
GPAS, when PAS is administered as the granular slow release formulation in patients with 
MDR or/and XDR-TB. The influence of single and divided dosing, as well as various dosing 
conditions (i.e. the intake of food, fruit juice, antacids) has been reported for PAS in TB patients 
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and in healthy volunteers.(4,5) A more recent study by Sy et al.(6) investigated the 
pharmacokinetics of a granular slow release (GSR) formulation of PAS in patients with multi-
drug resistant (MDR) or extensively drug resistant (XDR) TB. The pharmacokinetics of PAS 
was determined in patients receiving two regimens (8g once-daily followed by 4g twice-daily) 
and the influence of N-acetyltransferase 1 (NAT1) and NAT2 genes on PAS concentrations. The 
influence of NAT1 and NAT2 on tolerability was also investigated. Sy and colleagues suggested 
that the metabolite of PAS, namely APAS and GPAS, are worth investigating to determine the 
influence of their concentrations on tolerability.(6) 
Therefore, the aim of the study was to firstly elicit the pharmacokinetics of APAS, GPAS and 
parent PAS (see chemical structures in Figure 4.1) in plasma samples, using the above 
described instrumentation. Secondly, the study investigates the influence of metabolite plasma 
concentrations on the tolerability of GSR-PAS administered orally in an 8g once-daily dose 
and 4g twice-daily dose.  
Figure 4.1: Chemical structures of the investigated compounds, glycine-PAS (GPAS, p-aminosalicyluric acid), 
acetyl-PAS (APAS, N-acetyl-p-aminosalicylic acid) and parent drug PAS (PAS, p-aminosalicylic acid). 
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4.2. Experimental methods  
4.2.1 Chemicals and Reagents 
 
All reference standards including PAS, APAS, the internal standard thiacetazone (THIA) and 
formic acid were purchased from Sigma-Aldrich (St Louis, MO, USA). Analytical grade 
methanol, and acetonitrile were purchased from ROMIL Ltd (Cambridge, England). Water was 
purified through a Milli-Q water purification system (Millipore, Milford, USA). Drug-free 
human plasma was obtained from Tygerberg Hospital Blood Bank (Western Cape, South 
Africa), and heparinized prior to use.  
The second metabolite derivative, GPAS was synthesized from the parent PAS. Briefly, the 
synthesis involved a double protection followed by the acid coupling and global deprotection. 
The identity of GPAS was confirmed by the Waters Synapt G2 high resolution LC-MS/MS 
and NMR, included in the supplementary material. The purity of GPAS was found to be more 
than 99% by HPLC. 
 
4.2.2 Preparation of calibration standards and quality control samples 
 
Stock solutions of PAS, APAS, and GPAS were prepared separately by dissolving 10 mg of 
each pure powder in 10 mL methanol to achieve a primary concentration of 1 mg/mL. The 
internal standard, THIA (1 mg/mL) was also prepared in methanol. A working solution of 
THIA was then prepared in methanol to achieve a final concentration of 2.0 μg/mL. All the 
stock solutions were kept in volumetric glass flasks and stored at 4 °C.  
 
The plasma standards for calibration curves were prepared by diluting appropriate volumes of 
PAS, APAS and GPAS standard stock solutions with blank plasma. A series of standards were 
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prepared to yield final concentrations of 0.52 μg/mL – 167 μg/mL. Quality control samples 
(QCs) were prepared at 1 μg/mL (limit of low quality control, LLOQ), 4.2 μg/mL (low quality 
control, LOQ), 17.0 μg/mL (medium quality control, MCQ), and 100.0 μg/mL (high quality 
control, HQC).  
4.2.3 Sample extraction 
The frozen plasma samples were thawed at room temperature before the analysis. Aliquots of 
250 μL for each plasma sample were dispensed into 2mL microcentrifuge tubes. A volume of 
750 μL of internal standard working solution (2.0 μg/mL) was added to each sample, for protein 
precipitation. The mixture was vortexed for 1min, and centrifuged at 11 000 rpm for 3 min. 
Eight hundred micro litres (800 μL) of supernatant was transferred to a suitable auto sampler 
vial and sealed cap, before storage in a refrigerator at 4 ˚C prior to analysis within 1 day. The 
plasma standard samples were prepared similarly prior to LC-MS/MS analysis.  
4.2.4 LC-MS/MS instrumentation and conditions 
Liquid chromatography was performed using a Waters Xevo TQS triple quadrupole mass 
spectrometer connected to a Waters Acquity UPHLC system equipped with a temperature 
controlled sample organiser. Electrospray ionisation was performed in the positive mode at a 
desolvation temperature of 350°C, desolvation gas was nitrogen at a flow rate of 800L/h, 
capillary voltage of 3.8kV and the multiple reaction monitoring (MRM) settings are 
summarised in Table 4.1. Separation was achieved using a reverse-phase Waters HSS T3 
column (1.8μm particle size, 2.1 x 50 mm), which was purchased from Waters Corporation 
(Milford, MA, USA).  The method followed a binary gradient mobile phase A containing water 
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and 0.1% formic acid while mobile phase B contained 0.1% formic acid in acetonitrile. The 
flow rate was kept at 0.5 mL/min, the gradient started at 95% of A and followed a linear curve 
to 70% of A over 3 minutes, followed by a wash step for half a minute at 100% of B and re-
equilibration to initial conditions to yield a total run time of 4.5 minutes. 
Table 4.1: Multiple reaction monitoring (MRM) conditions of each analyte and internal 
standard. 
Analyte M+H 
Retention 
Time 
(minutes) 
Cone Voltage 
(V) 
Quantifier product ion 
(Collision energy) 
Quantifier product ion 
(Collision energy) 
PAS 154 1.44 15 91 (25) 136 (10) 
APAS 196 1.97 15 80 (25) 136 (15) 
IS 237 2.17 20 120 (20) 161 (15) 
GPAS 211 1.38 15 80 (25) 136 (10) 
4.2.5 Method validation 
The sample preparation method used in the study, is a protein precipitation extraction protocol 
that has been developed and validation by Liwa et al.(7) For this reason a partial validation of 
only the newly developed UPHLC-MS/MS method was done and is described below. The 
freeze and thaw stability of PAS and its metabolite APAS has been assessed and published by 
Hong et al.(8), and adapted to the assay.  
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4.2.5.1. Selectivity and Specificity 
 
Specificity was studied by testing for lack of interference and the absence of co-eluting peaks 
in the same MRM channel. Chromatographs of samples from various matrices (blank plasma 
from three different lots, methanol containing and samples spiked with all analytes) were 
compared.  
 
4.2.5.2. Accuracy and Precision 
 
The accuracy of the method was determined by 6x injection of QCs at four different 
concentrations (LLOQ, LOQ, MQC, HQC) within a batch for intra-day accuracy. A QC and 
blank was included after every 20 injections.  The inter-day batch accuracy of the assay was 
evaluated at the same QC concentrations on three different days. A percentage recovery was 
recorded as the difference between the mean measured values and experimental value. 
Precision was recorded as a percentage of relative standard deviation (RSD), and included 
acceptance criteria for intra and inter-batch as no more than 20% for LLOQ and 15% at higher 
concentrations.  
 
4.2.5.3. Linearity and LLOQ 
 
Calibration standards were prepared by dilution of PAS, APAS and GPAS stock solution with 
blank plasma, proceeded with IS. The entire concentration range (0.52 μg/mL – 167 μg/mL) 
included the LOD. The curve was constructed by plotting the peak area ratio (y-axis) of 
analytes PAS, APAS and GPAS to the internal standard, versus, the corresponding 
concentrations (x-axis). 
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4.2.5.4. Stability  
The post preparation stability of PAS, APAS and GPAS in plasma was maintained by storage 
in a refrigerator at 4º C prior to LCMS analysis within 24 hours.(8) The long term storage 
stability (-80º C) of the clinical samples was determined by comparing the concentrations of 
PAS in the original study(9) with those achieved in the presented study. The percentage recovery 
of PAS was determined and an RSD of 15% was acceptable.  
4.2.6 Clinical application 
As part of an on-going project, the study protocol was approved by the Health Research Ethics 
Committee at Stellenbosch University (S17/05/107), and followed the guidelines of the 
Helsinki Declaration of 1975 and its amendments.  
4.2.6.1 Study subjects and design 
The two-week crossover study was conducted in 29 adult MDR and XDR-TB patients 
hospitalised at the Brooklyn Chest Hospital, Cape Town. All subjects participated in the PK 
study, which involved one week (Day 1 – 8) of 8 g once-daily PAS dosing followed by one 
week (Day 9 – 16) of 4 g twice-daily dosing. Blood samples were collected in EDTA-
containing tubes at 1, 2, 3, 4, 6, 8, 12 and 24 hours (post-dose) on days 8 and 16, with a 10-
minute deviation time. The specimens were collected on ice, centrifuged for 10 minutes at 3500 
rpm, where after the plasma was harvested and stored at -80˚ C until analysis. The plasma 
samples were spiked with the internal standard and treated as per the extraction procedure 
described above. Dual analysis of the clinical samples and QC samples was performed.  
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4.2.6.2 Pharmacokinetic analysis 
The PK parameters of PAS, APAS and GPAS, were determined by non-compartmental 
analysis (NCA) using Winnonlin (Princeton, NJ, USA) version 8.0. Cmax and time to Cmax 
(Tmax) were determined from the plasma concentration time data. The software default linear 
trapezoidal method was used to assess the area under the curve from zero up to 24 hour 
concentration (AUC0-24).  
4.2.6.3 Tolerability and safety 
Tolerance of PAS was determined using a visual analogue scale (VAS) rating gastrointestinal  
(GI) adverse effects (AEs) including nausea, vomiting, abdominal pain and cramps, diarrhoea, 
and bloating. The form contained 10 vertical demarcations, separated by 1 cm each, with the 
most left indicating no symptoms and the most right indicating severe symptoms. The subjects 
were asked to complete an evaluation on a daily basis after dosing, by circling the mark that 
most closely fitted their perception of the symptom.  
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4.2.6.4 Statistical analysis  
 
Frequency and percentage were determined for subject demographic characteristics (gender, 
race, TB diagnosis, HIV status). The median as well as interquartile range (IQR) value which 
is reported as the 75th and 25th percentile, were calculated for all measured data including 
subject characteristics (age, height, body weight and body mass index), PK parameters of each 
compound (Cmax, Cmin, AUC0-24, and Tmax), and gastrointestinal AEs (nausea, vomiting, 
bloating, diarrhoea, and abdominal pain and cramps), using STATA statistical software (Texas, 
USA) version 15.1.  
All measured data were evaluated for normality using the Shapiro-Wilk test. Data not normally 
distributed were evaluated using non-parametric tests.  
PK parameters of each compound were compared for any differences using a non-parametric 
Wilcoxon signed-rank test (STATA), on the two dosing regimens. The same was done for the 
VAS scores of each adverse effect between the two doses.  
 
Correlation analysis (STATA) was performed to measure the association between each adverse 
effect and the median Cmax (PK parameter) of PAS, APAS and GPAS using a non-parametric 
Spearman’s rank correlation coefficient (Spearman’s Rho). Statistical significance was set at a 
P value less than 0.05. 
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4.3. Results 
4.3.1 MS/MS detection optimization 
Optimization of the mass spectrometry conditions was performed to achieve the maximum 
stable response of the precursor ions and corresponding product ions of the analytes in question. 
The tuning of MS parameters was performed in positive and negative ionization modes for 
PAS, APAS, GPAS and internal standard THIA. Both positive and negative modes showed 
signal for all analytes. The positive mode displayed a higher response and was therefore 
selected. The Q1 MS full scan mass spectra of PAS, APAS and GPAS was dominated by 
protonated precursor ions [M+H]+ at m/z 154, 196 and 211 respectively. These precursor ions 
were used to obtain the Q3 product ion spectra. Hereby, the mass transition ion pair was 
selected as m/z 154>91; 154>119; 154>136 for PAS, and m/z 196>80; 196>136; 196>178 for 
APAS, and m/z 211>80; 211>108; 211>136 for GPAS, due to the high similarity in structure 
between the analytes. The inherent selectivity of MS/MS detection was expected to be 
beneficial in developing a selective and sensitive method. The MRM parameters such as cone 
voltage and collision energy were optimized to obtain a constant and suitable intensity for all 
analytes. 
4.3.2 LC separation optimization 
The composition of the mobile phase and column was optimized to achieve adequate 
chromatographic resolution and symmetrical peak shape within a short run time. Various 
combinations of solvents such as methanol and acetonitrile along with altered ratios of formic 
acid were evaluated on Waters BEH C18, Xbridge C18, Agilent Zorbax C18 and Waters HSS 
T3 C18 columns. The mobile phase consisting of 0.1 % formic acid in acetonitrile(7,10) mixture 
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(minute, % mobile phase B): 0.30, 5; 3.00, 30; 3.10, 100; 3.60, 100; 3.80, 5 delivered on the 
Waters HSS T3 C18 column (1.8 µm, 2.1 x 50 mm)(1,3) at a flow rate of 0.5 mL/min was found 
to be most suitable for faster elution, better reproducibility and peak shape for all targeted 
analytes. 
4.3.3 Selection of internal standard 
A number of compounds were evaluated to find an appropriate internal standard. Based on the 
compound’s chromatographic behaviour and extraction efficiency, thiacetazone was found to 
be the most appropriate IS comparable with the targeted analytes. 
4.3.4 Selectivity and specificity 
The representative chromatographs obtained from various matrices, including blank plasma 
spiked with LLOQ 0.5 standard of each analyte and IS are presented in Figure 4.2. The 
chromatographs expressed no significant endogenous interferences observed in the respective 
MRM channel at the retention time of PAS (1.44 min), APAS (1.97 min), GPAS (1.38 min) 
and THIA (2.17 min). The short run time of 4.5 min, showed the method to be suitable for 
routine analysis.  
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4.3.5 Accuracy and precision 
 
Intra- and inter-day accuracy and precision are presented in Table 4.2 for each PAS, APAS 
and GPAS. The inter-batch precision (%RSD) at LLOQ, LQC, MQC and HQC levels varied 
from 4.7% to 8.3% for PAS, 2.23% to 10.2% for APAS and 3.1% to 13.0% for GPAS. The 
intra-batch varied from 2.9% to 9.2% for PAS, 0.9% to 7.9% for APAS and 1.8% to 4.8% for 
GPAS.  
 
 
Figure 4.2: Ion chromatograms for (A) internal standard THIA, (B) PAS, (C) APAS, and (D) GPAS, achieved by 
blank plasma spiked with 0.500 μg/mL of each standard. The retention times of IS, PAS, APAS and GPAS are 
2.17 min, 1.44 min, 1.97 min, and 1.38 min respectively.  
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4.3.6 Linearity and detection range  
 
The nine-point calibration curve was linear over the concentration range of 0.52 – 167 µg/mL 
for all targeted analytes, with correlation coefficient in the range of 0.996 ≤ r2 ≤ 0.999 for all 
calibration curves on all 4 days of analysis. Table 4.3 summarizes the calibration curve results 
for each analyte. The accuracy results varied from 96.50% to 114.00% while the precision 
(%RSD) results varied from 0.20% to 6.40% amongst all analytes. Due to the very high 
concentrations that the analytes are present in the plasma, the limit of quantification was taken 
as 120% above the reading of the blank injected after the highest plasma standard. 
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Table 4.2: Intra- and inter-batch precision and accuracy of PAS, APAS and GPAS (mean 
µg/mL, RSD %, accuracy %).  
Analyte 
Theoretical 
Concentration 
(µg/mL) 
Intra-day (n=5) Inter-day (n=6) 
Mean 
(µg/mL) 
RSD 
(%) 
Accuracy 
(%) 
Mean 
(µg/mL) 
RSD 
(%) 
Accuracy 
(%) 
PAS 
LLOQ 1 1.01 9.2 103.3 1.05 7.9 105.3 
LQC 4.2 4.19 2.9 99.8 4.05 8.3 96.5 
MQC 17 16.78 3.6 98.7 17.41 7.2 102.4 
HQC 100 100.14 4.8 100.1 97.44 4.7 97.4 
APAS 
LLOQ 1 1.11 6.0 111.0 1.11 5.9 110.9 
LQC 4.2 4.18 1.4 99.6 4.23 2.3 100.7 
MQC 17 16.90 0.9 99.4 16.85 5.8 99.14 
HQC 100 105.71 7.9 105.7 106.34 10.2 106.3 
GPAS 
LLOQ 1 1.09 3.7 109.2 1.14 13 114 
LQC 4.2 4.19 1.8 99.8 4.13 3.1 98.4 
MQC 17 17.24 2.6 101.4 17.21 3.2 101.2 
HQC 100 94.63 4.8 94.6 96.13 4.4 96.1 
LLOQ = lower limit of quantification; LQC = low quality control; MQC = medium quality control; HQC = high 
quality control.  
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Table 4.3: Linearity of calibration standards (mean µg/mL, RSD %, accuracy %). 
µg/mL 
PAS (n=6) APAS (n=6) GPAS (n=6) 
Mean 
(µg/mL) 
RSD 
(%) 
Accuracy 
(%) 
Mean 
(µg/mL) 
RSD 
(%) 
Accuracy 
(%) 
Mean 
(µg/mL) 
RSD 
(%) 
Accuracy 
(%) 
0.52 0.59 6.4 114.0 0.51 9.2 97.9 0.56 4.1 108.5 
1.5 1.53 1.8 101.9 1.51 1.4 100.9 1.51 3.3 100.5 
2.1 2.10 4.3 99.9 2.33 4.2 110.7 2.19 3.7 104.1 
4.2 4.21 1.8 100.3 4.22 1.4 100.6 4.21 1.3 100.3 
8.3 8.78 1.3 105.8 8.59 4.1 103.5 8.48 1.3 102.2 
17 17.09 0.8 100.5 17.37 4.2 102.2 17.05 2.2 100.3 
33 33.65 0.6 100.8 33.13 1.2 99.2 33.16 2.2 99.3 
66 65.06 1.2 98.6 65.25 0.2 98.9 63.72 7.3 96.5 
167 167.10 1.0 100.1 166.41 1.0 99.6 166.44 1.2 99.7 
 
4.3.7 Study subjects  
 
Subjects’ characteristics and concomitant medications administered are summarized in Tables 
4.4, 4.5 and 4.6. Twenty-five (n=25) subjects completed both dosing regimens while four (n=4) 
subjects had PK data for either the once-daily dosing (n=2) or the twice-daily dosing regimen 
(n=2), but not for both. Statistical analysis was performed on all 29 subjects in the study. 
 
Twenty-five subjects (86%) were Coloured (mixed racial decent), four subjects (14%) African 
Blacks, and there were no White or Asian study participants. Seventeen subjects (59%) were 
male. Five males (17%) were HIV positive, while 6 (21%) males had XDR-TB. The mean age 
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in males was 35 years. Twelve subjects (41%) were female. Three females (10%) were HIV 
positive, and one (3%) had XDR-TB. The mean age among females was 38 years.  
 
Subjects showed no difference between the two dosing regimen periods based on body weight 
and body mass index (BMI).  
 
Table 4.4: Demographic characteristics of subjects crossed over in the study.  
Characteristic  Subjects (n=29)  
Gender (%)  
Male 
Female  
 
17 (59%) 
12 (41%) 
Race (%) 
Coloured  
Black  
 
25 (86%) 
4 (14%) 
TB diagnosis (%)  
MDR  
XDR  
 
22 (76%) 
7 (24%) 
HIV Status (frequency, %)  
Negative 
Positive  
  
21 (72%)  
8 (28%)  
Age (years) 
Median (IQR)  
 
34 (29 – 44) 
Height (m)  
Median (IQR) 
 
1.7 (1.6 – 1.7)  
IQR = interquartile range; Coloured = is the term applied to racially distinct group of individuals with mixed 
ancestry, residing in South Africa.(11)  
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Table 4.5: A comparison of body weight and BMI as recorded at the start of each regimen 
throughout the cross over.  
Characteristic 
Dosing regimens of PAS 
8 g once-daily 4 g twice-
daily 
P-value
Body weight (kg) 
Median 
IQR  
56.5 
50 – 62.3  
58.5 
50 – 62.0  
0.2065 
Body Mass Index  (kg/m2) 
Median 
Range 
20.1 
15.1 – 25.2 
20.3 
16.0 – 34.7 
0.0728 
IQR = interquartile range. 
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Table 4.6: Summary of all concomitant medication administered with PAS. 
Drug category 
Subjects (n) 
Frequency (%) 
Anti-tuberculosis  
Capreomycin 
Moxifloxacin 
Ethambutol 
Ethionamide 
Isoniazid 
Kanamycin 
Teridizone 
Pyrazinamide 
Clarithromycin 
Clofazimine 
 
24 (83%)  
27 (93%)  
25 (86%) 
24 (82%)  
12 (41%) 
2 (7%) 
26 (90%) 
26 (90%) 
1 (3%)  
9 (31%) 
Antiretroviral  
Efavirenz 
Stavudine 
Lamivudine  
 
6 (21%) 
5 (17%) 
6 (21%)  
Gastrointestinal medicines  
Metoclopromide 
Ranitidine  
 
6 (21%) 
4 (14%)  
Vitamins 
Pyridoxine  
Vitamin B Complex  
 
27 (93%) 
11 (38%)  
Antidepressants and Psychotics   
Amitriptyline 
 
5 (17%)  
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4.3.8 Pharmacokinetics of PAS and metabolites 
Data was available for 27 patients on the once-daily regimen and 25 patients on the twice- daily 
regimen, respectively, Table 4.7. Tmax of APAS was statistically significantly different between 
the two regimens (p=0.0144). This was the same for Cmax (p=0.0006), AUC0-24 (p=0.0009), and 
Tmax (p=0.0189) in parent drug PAS.  
Table 4.7: Summary of the pharmacokinetic parameters of PAS, APAS and GPAS at both 
dosing regimens.  
PK Parameter 
Dosing regimen 
P-value8 g once-daily 
(n=27) 
4 g twice-daily 
(n=25) 
PAS (median, IQR) 
Cmax (mg/L)  
AUC0-24 (mg.h/L)  
Tmax (h)  
82.69 (62.43 – 102.41) 
950.93 (610.84 – 1274.97) 
8 (4 – 8)  
53.63 (40.42 – 68.55)  
609.55 (367.07 – 821.40)  
6 (3 – 8)  
0.0006* 
0.0009* 
0.0189* 
APAS (median, IQR) 
Cmax (mg/L)  
AUC0-24 (mg.h/L)  
Tmax (h) 
16.36 (11.31 – 20.30)  
239.08 (185.36 – 376.07)  
8 (6 - 8)  
14.59 (10.00 – 22.36) 
235.28 (177.61 – 326.00) 
6 (4 - 8)  
0.6500 
0.3065 
0.0144* 
GPAS (median, IQR) 
Cmax (mg/L)  
AUC0-24 (mg.h/L)  
Tmax (h) 
6.08 (4.56 – 9.45) 
74.66 (41.38 – 106.47) 
8 (4 – 8)  
5.02 (3.90 – 8.02)  
63.45 (44.95 – 83.31) 
4 (3 – 8)  
0.2130 
0.0575 
0.5233 
IQR = interquartile range; * = indicates statistical significant P value < 0.05 
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The plasma concentration time profile for each compound (PAS, APAS and GPAS) is 
presented at each dosing regimen (4 g twice-daily and 8 g once-daily at steady state conditions) 
in Figure 4.3. The 8 g once-daily regimen parent PAS and its metabolites APAS and GPAS 
had a higher peak concentration (Cmax) compared to the 4 g twice-daily regimen whilst the peak 
concentrations were reached earlier in the 4 g twice-daily regimen (Table 4.7).  
Figure 4.3: Plasma concentrations (mg/L) for PAS (orange), APAS (yellow) and GPAS (purple) in subjects 
receiving 8 g once-daily regimen (A) and 4 g twice-daily dosing regimen (B), over 24 hours. Each time point 
presents the median concentration and vertical lines represent the interquartile range around the point.   
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4.3.9 Tolerability and safety 
VAS score data was available for all subjects. Table 4.8 summarises the median score for each 
AE and for both regimens. The Wilcoxon sign-rank test reported statistically significant more 
abdominal pain and cramps in the twice-daily regimen compared with once-daily (p=0.018) 
regimen, while there was no statistically significant difference noted in any other category of 
GI adverse effects. 
Table 4.8: Summary of gastrointestinal adverse effects (nausea, vomiting, bloating, diarrhoea, 
abdominal pain and cramps) at both dosing regimens. 
Adverse Effect 
Dosing regimen of PAS 
P-value8 g once-daily 
(Median; IQR) 
4 g twice-daily 
(Median; IQR) 
Nausea 0.37 (0.05 – 1.66) 0.44 (0.03 – 1.39) 0.899 
Vomiting 0 (0 – 0.13) 0 (0 – 0.25) 0.541 
Bloating 0 (0 – 0.65) 0.15 (0 – 0.62) 0.311 
Diarrhoea 0.44 (0 – 2.01) 0.31 (0 – 1.59) 0.119 
Abdominal pain and 
cramps  
0 (0 – 0.08) 0.14 (0 – 0.59) 0.018* 
* = significant P-value < 0.05
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4.3.10 Relationship between peak concentrations and gastrointestinal 
AE’s 
Displayed in Tables 4.9, 4.10 and 4.11 is the Spearman’s correlation coefficient and its 
corresponding p-value, which measured the association between each adverse effect and the 
median Cmax of PAS, APAS, and GPAS, respectively. Statistically significant correlations were 
observed for APAS concentration in terms of bloating (p= 0.025) and diarrhoea (p=0.044), 
respectively. Similarly, GPAS concentration showed a significant correlation with diarrhoea 
(p= 0.041). Although significant correlations are seen, the strength of the associations as 
described by the Spearman’s rho are all below 0.05 and thus represents a very low correlation 
as seen in Figure 4.4 and 4.5. The negative rho values indicate that with increasing 
concentrations of APAS and GPAS, less bloating and diarrhoea is observed.  
Table 4.9: Correlation between the median AE score and median plasma concentrations of 
parent compound PAS, at each dosing regimen.  
Adverse effect 
8 g once-daily 
Spearman’s Rho (P-value) 
4 g twice-daily 
Spearman’s Rho (P-
value) 
Nausea 0.151 (0.461) 0.089 (0.673) 
Vomiting 0.048 (0.817) 0.099 (0.640) 
Bloating 0.204 (0.318) 0.123 (0.558) 
Diarrhoea 0.024 (0.908) -0.384 (0.058)
Abdominal pain and 
cramps 
0.027 (0.897) -0.153 (0.466)
* = significant; P-value < 0.05
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Table 4.10: Correlation between the median AE score and median plasma concentrations of 
metabolite APAS, at each dosing regimen.  
Adverse effect 
8 g once-daily 
Spearman’s Rho (P-value) 
4 g twice-daily 
Spearman’s Rho (P-
value) 
Nausea -0.189 (0.355)  -0.189 (0.365) 
Vomiting 0.079 (0.698)  0.062 (0.769)  
Bloating -0.074 (0.719) -0.448 (0.025)* 
Diarrhoea -0.337 (0.092)  -0.407 (0.044)*   
Abdominal pain and 
cramps 
-0.042 (0.839) -0.327 (0.111) 
* = significant; P-value < 0.05  
 
 
Table 4.11: Correlation between the median AE score and median plasma concentrations of 
metabolite GPAS, at each dosing regimen.  
Adverse effect 
8 g once-daily 
Spearman’s Rho (P-value) 
4 g twice-daily 
Spearman’s Rho (P-
value) 
Nausea 0.140 (0.496)  -0.378 (0.062)  
Vomiting 0.016 (0.937) -0.177 (0.398) 
Bloating  0.195 (0.3398) 0.023 (0.912) 
Diarrhoea -0.319 (0.112) -0.412 (0.041)*   
Abdominal pain and 
cramps 
0.053 (0.798) -0.108 (0.609)  
* = significant; P-value < 0.05  
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Figure 4.4: Scatter plot of the median plasma maximum concentration of APAS versus the VAS score for adverse 
effects, on each dosing regimen. Significant correlations were observed for APAS and bloating on 4g twice-daily 
regimen, p= 0.025; rho= -0.448 (C) and APAS and diarrhoea, p = 0.044; rho= -0.407 (A). 
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Figure 4.5: Scatter plot of the median plasma maximum concentration of GPAS versus the VAS score for adverse 
effects, on each dosing regimen. One significant correlation was observed for GPAS and diarrhoea on 4g twice-
daily regimen, p = 0.041; rho= -0.412 (A).  
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Figure 4.6: Scatter plot of the median plasma maximum concentration of PAS versus the VAS score for adverse 
effects, on each dosing regimen. No significant correlations were observed between these two variables.  
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Chapter Five 
Discussion, conclusion, limitations and future 
work  
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5.1. Discussion 
There has only been one previously reported study, which analysed PAS and its major 
metabolites in blood and urine, using a paper chromatography method(1) and there has to our 
knowledge not been any published report on the simultaneous determination of PAS, APAS 
and GPAS in plasma matrix by UHPLC-MS/MS. The development of such a method was thus 
aimed at extending the quantification accuracy for these compounds while also generating 
pharmacokinetic data for the anti-TB agent PAS and its metabolites APAS and GPAS. We 
achieved this by optimizing the chromatographic and mass spectrometric conditions suitable to 
these three compounds by using a simple and efficient one step protein precipitation extraction 
procedure. The present study showed a large inter-individual variability between parent drug 
PAS and its metabolites with regards to concentration time curves, with Cmax ranging from 
40.42 to 102.41 mg/L for PAS. Metabolites ranged between 10.00 to 22.36 mg/L, and 3.90 to 
9.45 mg/L for APAS and for GPAS, respectively necessitating a wide linear concentration 
range of the calibration curve (0.50 – 160.0 mg/L).  
PAS is currently used in the treatment of drug-resistant tuberculosis. Since its discovery it has 
shown substantial efficacy and the ability to prevent acquired resistant in its companion 
drugs.(2–4) PAS has also displayed the potential to have early bactericidal activity, a result 
observed when it was administered as a single 15g daily dose(5) and its efficacy was measured 
by the fall in the CFU of M. tuberculosis in sputum samples. Over the first two days, a fall of 
0.259 log10 CFU/mL sputum was recorded indicating that although PAS is mainly valued for 
preventing drug resistance in companion drugs, it also has the ability of bactericidal activity 
similar to that of first-line drugs, rifampicin and isoniazid.(6,7) At present, PAS is used with 
reluctance, due to its notoriously gastrointestinal intolerance. Among a large number of studies 
conducted by the British Medical Research Council(3,4,8) it was concluded that PAS intolerance 
was undoubtedly affected by the dose.(9–11) Investigations comparing divided daily dosing with 
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single daily dosing found that intolerance was experienced similarly and probably somewhat 
better with a single dose than with divided dosing.(9–14) Sy and colleagues(14) reported that 
neither Cmax nor AUC0-12 were associated with intolerance. However, in terms of other 
pharmacokinetic parameters, a higher degree of abdominal pain and discomfort and diarrhoea 
was associated with lower minimum concentration (Cmin) of PAS.(14) At minimum PAS 
concentrations, it is expected that concentrations of metabolites, APAS and GPAS are high, due 
to biotransformation processes. This suggestion has set the premise for the presented work.(14) 
 
In the present study the slow release formulation of PAS was well tolerated, with even 
distribution of AEs scored across the two dosing regimens. Three subjects (n=3) experienced 
no gastrointestinal AEs. The remaining 26 had evidence of gastrointestinal AEs, however, the 
majority of the scores were clustered around zero. The most frequently reported AEs were 
nausea and diarrhoea, consistently recorded at both dosing regimens. It was noted that 
abdominal pain and cramps (APC) were statistically more frequent in the 4g twice-daily than 
the 8g once-daily dose [0.14(0 – 0.59) versus 0(0 – 0.08); median (IQR); p= 0.018], and GI 
AEs were also not worse than with the higher 8g dose. This finding is in keeping with previously 
reported studies, by Riska(9–11) and Yue (12), and would suggest that the twice-daily dosing 
strategy of PAS should be discontinued and replaced by a once-daily higher dose.  
 
In addition the present study looked specifically at the role that the metabolites APAS and 
GPAS might play in GI adverse events. The Spearman’s correlation test was utilised to assess 
the relationship between AE scores and maximum plasma concentrations (Cmax) of each 
metabolite, APAS and GPAS, after oral administration of PAS. There were statistically 
significant inverse associations between APAS concentrations and bloating (rho= -0.448; p= 
0.025) and diarrhoea (rho= -0.407; p= 0.044), respectively, for the twice-daily dose. The same 
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was found for GPAS concentrations and diarrhoea occurrences (rho= -0.412; p= 0.041). 
Although this was statistically significant the strength of the correlations, which is described by 
the rho value (Table 4.9), - suggested a relatively low association, and therefore a low linear 
relationship between metabolite median Cmax and AEs. Interestingly, the association was an 
inverse correlation, indicating that as the metabolites APAS and GPAS concentrations 
increased in the 4 g twice-daily regimen, the occurrence of bloating and diarrhoea decreased 
(Figure 4.4 and 4.5). A possible explanation for this type of relationship is that the main factor 
of PAS intolerance is its presence in the GIT. Therefore, the presence of high concentrations of 
metabolites APAS and GPAS would indicate the removal of PAS from the GIT, allowing less 
intolerance to be experienced. Amongst the correlations, which were not statistically 
significant, positive relationships between AEs and concentrations of APAS and GPAS were 
noted.  
Our study describes the pharmacokinetics of APAS and GPAS following administration of 
GSR-PAS and the pharmacokinetic parameter estimates (Cmax, Tmax, and AUC0-24) of APAS 
and GPAS were very similar in both dosing regimens. Importantly we noted that the PAS 
concentrations remained higher than the conjugates at both doses (4g and 8g), over the 24 hour 
study period. In earlier reports, Lehmann(1) recounted that in plasma, GPAS concentrations 
followed the trend of the PAS curve, but in lower quantities. By contrast, APAS conjugation 
showed to dominate at low doses, such as 4g PAS and then diminish when the dose was 
increased to 8g PAS. These trends in the concentration time curve were reported after single 
and repeated oral doses of PAS tablets (4g, 8g, and 12g). Lehmann(1) reported this in plasma as 
well, whereas Peloquin et al.(15) displayed mean serum APAS concentrations exceeding PAS, 
in healthy volunteers after a single 4g granular PAS dose. In the present study, APAS and GPAS 
concentrations remained 3-8 fold and 5-10 fold lower that the PAS concentration suggesting 
that PAS, administered as granular slow release formulation is not so rapidly metabolized due 
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to the substantially prolonged release and absorption of the granular slow release 
formulation.(15) Typically, approximately 80% of absorbed PAS is excreted renally, while the 
remaining 20% is metabolized mainly to APAS and GPAS among other inactive 
compounds.(16,17) Interestingly, both acetylation and glycine conjugation are saturable 
processes.(18) It is hypothesized that these processes compete for available acetyl-CoA, a known 
common substrate.(1,18,19) Very little is known about the enzymes responsible for conjugation 
of PAS with glycine to form p-aminosalicyluric acid (GPAS), while the acetylating enzyme 
system has been widely studied. Arylamine N-acetyltransferases are most importantly involved 
in the metabolism of PAS, producing APAS which is modulated by N-acetyltransferase 1 
(NAT1) and to a lesser degree NAT2.(7,20)  
 
Regarding the pharmacokinetics of PAS, comparison of the median Cmax, AUC0-24 and Tmax 
parameters between the 4g twice-daily and 8g once-daily PAS displayed linearity relative to 
the dosage. This current study noted that PAS was present in similar concentrations, although 
slightly higher than previously reported.(15,21,22) This may be due to subject variability in our 
study, as the coefficient of variation for Cmax in PAS (Table 4.7) varied by 34.9% and 39.4% 
in the 8g dose and 4g dose respectively. Factors such as low body weight, TB disease state, co-
infection with HIV or the effects of other concomitant medications may also contribute to these 
outcomes. Additionally, this particular formulation of PAS provides a slower release while in 
the stomach and therefore inhibits the rapid acetylation via first pass metabolism, in turn 
allowing PAS concentrations to be higher.  
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5.2. Conclusions 
The study’s research aim and objectives have been addressed in Chapter 3. The findings of the 
presented work has shown that it is possible to assay PAS and its two major metabolites, APAS 
and GPAS, in plasma by UHPLC-MS/MS using a single protein precipitation extraction 
method. This method proves to be simple and effective in routine clinical drug monitoring of 
patients treated with PAS. 
Additionally, our study provides data on the pharmacokinetics of PAS and its metabolites 
APAS and GPAS, in a population of adult patients with MDR- and/or XDR-TB. A large amount 
of inter-individual variation was found in the population for the Cmax of the metabolites and 
parent drug. The granular slow release PAS formulation administered, and the disease state of 
the population may be contributing factors to this variance. Our data shows that PAS was not 
as rapidly metabolized as previously reported. This is consistent with the slow release 
formulation used, which prolonged the absorption and allowed the metabolites to be present in 
concentrations lower than PAS, over the course of the study period.  
By characterizing the PK profiles of PAS and its metabolites we were able to use this data to 
make inferences regarding the toxic effects of the drug. Opinions may differ to the use of PAS 
in the treatment of TB. This is often due to the low tolerance of the drug. However, the 
experimental and clinical findings presented suggest that maximum PAS concentrations 
achieved from a single 8g daily dose does not pose a higher risk of GIT intolerance. In contrast, 
more occasions of AE’s were experienced in the fractionated regimen. Therefore, a higher 
single daily dose of PAS is recommended for use in TB regimens as this may be advantageous 
in preventing acquired resistance in companion drugs as well as improved clinical efficacy of 
PAS.  
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5.3. Limitations 
The study is limited by the low number of patients studied. This consequently limits the impact 
of our conclusions, including the statistically significant differences found in the 
pharmacokinetic parameters described and the type of relationship seen between the metabolite 
concentrations and occurrence of GIT intolerance. Therefore, a further study of PAS and its 
metabolites and their influence on toxicity  
Although the use of the VAS is a validated method of determining tolerability, this method can 
become subjective. Therefore, a reviewed method of the VAS tool should be considered in 
future work.  
5.4. Future work 
One of the covariates in determining the tolerability of PAS was the use of other concomitant 
medications. It would therefore we worthwhile investigating a control group receiving second-
line agents without PAS, to clarify the extent of intolerance attributed to PAS administration, 
and to eliminate other second-line agents such as capreomycin and ethionamide, which are 
known to have similar toxic effects.   
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Appendix 1: Individual pharmacokinetic parameters of study subjects.  
Individual pharmacokinetic parameters for PAS in patients on the 8g once-daily GSR-PAS and 
4g twice-daily GSR-PAS dosing regimens.  
Subject 
PK parameter 
8g once-daily 4g twice daily 
Cmax (mg/L) 
AUC0-24 
(hr*mg/L) 
Tmax (hr) Cmax (mg/L) 
AUC0-24 
(hr*mg/L) 
Tmax (hr) 
1 70.64 721.32 4 29.62 265.79 4 
2 52.52 610.84 12 45.48 370.72 3 
3 98.74 1185.98 8 53.63 817.56 6 
4 46.34 450.02 4 39.42 322.41 4 
5 69.08 724.23 3 40.42 703.42 12 
6 102.41 1295.97 8 54.57 663.94 3 
7 38.29 487.92 24 72.39 1219.75 8 
8 91.58 950.93 3 49.31 311.76 2 
9 62.43 813.84 8 76.31 766.35 8 
10 85.1 1274.97 12 51.13 656.19 2 
11 66.69 827.75 8 31.77 363.42 3 
12 131.49 1580.68 8 89.17 1245.94 2 
13 89.9 1105.4 4 68.55 487.7 3 
14 107.94 1144.05 8 53.82 825.23 8 
15 82.69 987.96 4 41.48 609.55 4 
17 66.11 804.99 8 26.15 432.61 8 
18 150.94 1922.41 8 92.06 1337.02 8 
19 72.89 479.85 8 21.76 260.83 12 
20 135.99 1702.59 6 113.01 1459.56 6 
21 124.6 1435.82 8 63.7 578.58 6 
22 85.61 851.19 6 65.04 934.95 6 
23 94 1271.98 8 56.9 614.55 6 
24 46.04 247.94 8 missing missing missing 
25 77.05 1098.23 8 missing missing missing 
26 missing missing Missing 72.02 595.29 2 
27 52.25 424.15 4 missing missing missing 
28 51.64 587.26 12 missing missing missing 
29 missing missing Missing 50.85 527.41 3 
30 missing missing missing 35.37 283.19 6 
31 142.62 1962.72 6 missing missing missing 
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Individual pharmacokinetic parameters for APAS in patients on the 8g once-daily GSR-PAS 
and 4g twice-daily GSR-PAS dosing regimens.  
Subject 
PK parameter 
8g once-daily 4g twice daily 
Cmax (mg/L) AUC0-24 
(hr*mg/L) 
Tmax (hr) Cmax (mg/L) AUC0-24 
(hr*mg/L) 
Tmax (hr) 
1 25.87 443.59 6 22.97 341 6 
2 17.46 227.53 6 14.89 196.96 4 
3 11.92 197.05 12 14.59 268.44 4 
4 9.78 163.68 8 7.59 135.03 3 
5 11.31 199.33 12 14.61 262.78 6 
6 7.97 128.06 8 8.96 176.65 2 
7 19.75 387.05 4 20.67 407.65 6 
8 24.37 441.46 6 34.54 294.92 8 
9 20.3 320.5 6 14.02 268.19 3 
10 40.93 845.02 8 28.05 540.43 8 
11 10.69 173.2 6 11.8 165.83 6 
12 14 239.08 4 9.81 186.68 4 
13 11.57 217.28 8 11.29 186.85 4 
14 27.01 393.76 8 25.38 418.91 8 
15 13.38 271.09 12 12.89 235.28 8 
17 14.19 216.98 8 15.03 234.08 4 
18 18.43 291.64 8 22.51 383.76 6 
19 9.04 122.59 8 10.14 178.57 6 
20 31.83 507.2 6 29.6 517.59 6 
21 16.36 212.25 6 7.94 157.97 8 
22 19.87 255.91 8 15.57 250.33 6 
23 20.96 317.76 6 22.2 146.76 8 
24 14.1 77.36 8 missing missing missing 
25 10.93 185.36 6 missing missing missing 
26 missing missing missing 8.95 146.76 2 
27 10.72 156.88 12 missing missing missing 
28 16.74 248.87 8 missing missing missing 
29 missing missing missing 12.15 312.99 8 
30 missing missing missing 4.99 214.41 6 
31 19.23 376.07 24 missing missing missing 
122
Stellenbosch University  https://scholar.sun.ac.za
Individual pharmacokinetic parameters for GPAS in patients on the 8g once-daily GSR-PAS 
and 4g twice-daily GSR-PAS dosing regimens.  
Subject 
PK parameter 
8g once-daily 4g twice daily 
Cmax (mg/L) AUC0-24 
(hr*mg/L) 
Tmax (hr) Cmax (mg/L) AUC0-24 
(hr*mg/L) 
Tmax (hr) 
1 9.1 75.41 4 3.82 32.28 4 
2 2.77 33.14 12 2.07 23.65 3 
3 6.4 72.94 3 3.89 64.95 24 
4 7.62 74.23 6 6.65 52.05 4 
5 3.8 45.65 3 3.01 50.6 24 
6 6.08 77.1 8 5.06 60.93 3 
7 10.7 106.47 24 14.06 269.31 8 
8 29.11 248.58 3 9.95 56.64 2 
9 9.45 89.91 4 4.47 63.45 6 
10 17.16 261.33 12 17.39 171.56 24 
11 4.56 52.95 8 5.02 65.65 3 
12 5.73 89.69 8 6.79 69.02 2 
13 20.51 236.51 6 16.8 143.12 4 
14 6.14 74.66 3 4.87 71.29 24 
15 11.98 151.46 4 7.31 99.62 4 
17 3.29 39.73 8 2.43 34.97 2 
18 5.76 78.6 8 5.72 86.15 8 
19 3.01 24.96 8 1.08 19.47 12 
20 8.65 118.1 6 8.54 130.9 6 
21 5.89 67.88 8 8.07 80.46 4 
22 5.29 41.38 3 4.39 60.01 3 
23 3.6 54.1 12 2.93 29.96 3 
24 5.18 11.62 8 missing missing missing 
25 6.84 99.7 8 missing missing missing 
26 missing missing missing 7.96 76.49 3 
27 5.17 31.83 4 missing missing .missing 
28 2.34 27.14 12 missing missing missing 
29 missing missing missing 4.37 41.93 3 
30 missing missing missing 4.99 47.96 6 
31 14.55 228.05 8 missing missing missing 
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Addendum A 
Quantification of esomeprazole and its three major 
metabolites in human plasma by UHPLC-MS/MS 
using a simple sample extraction method 
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6.1 Introduction 
Esomeprazole is chemically (S)-5-methoxy-2-[(4-methoxy-3-5-dimethylpyridin-2-yl) 
methylsulfinyl)]-3-H-benzoimidazole (Figure 4.1), and one of the optical isomers of its 
counterpart omeprazole.(1–3) Esomeprazole is part of a class of drugs classified as proton 
pump inhibitors (PPI’s), which reduce gastric acid secretion by inhibiting the 
hydrogen/potassium adenosinetriphosphate enzyme (H+, K+ -ATPase).(4,5) and has shown to 
be clinically effective and safe in the treatment of gastric acid-related diseases such as 
gastroesophageal reflux disease (GERD), non-steroidal anti-inflammatory drugs (NSAID’s) 
induced gastric intestinal symptoms, Helicobacter pylori infection, peptic ulcers and 
Zollinger-Ellison syndrome.(1,6–8) 
Similar to other PPI’s, esomeprazole is a prodrug that is converted to its active inhibitor 
sulphonamide, in the acidic compartment of the parietal cells.(9) For this reason it is 
formulated as a delayed-release capsule to prevent the rapid dissolution in the acidic gastric 
cavity, during absorption.(6,10) The pharmacokinetic profile of esomeprazole is widely 
described.(3,9,11,12) It is highly bound to plasma proteins (97%) and metabolised by two 
cytochrome P450 (CYP) isoenzymes namely, CYP3A4 and CYP2C19, through sulfoxidation 
and hydroxylation, respectively. The major metabolites present in plasma are 5-hydroxy 
esomeprazole, omeprazole sulfone and a minor metabolite 5-O-desmethyl esomeprazole 
(Figure 6.1). According to clinical studies, the overall metabolism relies more on the activity 
of CYP2C19 than that of CYP3A4.(2,13) 
The rate of metabolism of esomeprazole is known to be lower and less variable than its 
optical enantiomer, (R)-omeprazole and its racemate.(12) This is supported by in vivo studies 
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of healthy individuals, where the plasma concentrations of esomeprazole were higher than 
those of omeprazole.(4) Furthermore, a higher area under the concentration time curve (AUC) 
of almost two fold than that of omeprazole was observed in patients with GERD.(8) As a 
result of this pharmacokinetic profile for esomeprazole, it is considered to be a better choice 
in the treatment of acid related diseases.(3,5) 
 
A number of methods have been developed to assay esomeprazole in biological samples, 
using liquid chromatography tandem mass spectrometry (LC-MS/MS).(1,14–16) Methods 
proposed by Hultman et al.(14) for quantification of esomeprazole including two metabolites 
(5-hydroxyesomeprazole, omeprazole sulfone) in human, rat and dog plasma and Mogili et 
al.(15) for determination of esomeprazole in human plasma required lengthy chromatography 
run times, and lacked sensitivity. Gopanith et al.(16) developed a more sensitive method for 
determination of esomeprazole in human plasma applying an expensive sample preparation 
technique using solid phase extraction (SPE). The method published by Chunduri et al.(1) 
quantified esomeprazole and another PPI using the superior ultra-high performance liquid 
chromatography-tandem mass spectrometry (UHPLC-MS/MS) system, which offered several 
advantages over previously discussed techniques including the use of a liquid-liquid 
extraction (LLE) sample preparation method.  
 
To the best of our knowledge, no UPLC-MS/MS method has been developed to assay 
esomeprazole and its three metabolites simultaneously in human plasma. The current study 
describes a rapid and sensitive method, which employed a protein precipitation (PPT) 
technique for sample extraction. Ultra performance liquid chromatography with electrospray 
ionization (ESI) and tandem mass spectrometry is applied to quantify esomeprazole and its 
main metabolites, 5-hydroxyesomeprazole, omeprazole sulfone and 5-O-desmethyl 
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omeprazole simultaneously in a short run time (4 minutes), wide linearity range, and a simple 
reproducible extraction method that is cost effective.  
 
The aim of the study was to develop and validate the presented method according to bio-
analytical guidelines set out by the Food and Drug Administration.(17) Application of the 
assay included a clinical pharmacokinetic study following oral administration of 40mg of 
esomeprazole to pregnant women diagnosed with pre-eclampsia as described by Cluver et 
al.(18) in the American Journal of Obstetrics and Gynecology. The latter study was conducted 
to determine whether esomeprazole prolonged gestation in pregnancies with pre-eclampsia 
and if it could decrease circulating soluble fms-like tyrosine kinase 1 (sFlt-1)(19) which is 
released by placental tissue and considered to be responsible for causing widespread maternal 
endothelial dysfunction and organ injury associated with pre-eclampsia.(19)  
 
 
Figure 6.1: Chemical structures of (S)-enantiomer esomeprazole and the three metabolites 5-hydroxy 
omeprazole, omeprazole sulfone, and 5-O-desmethyl omeprazole. Adapted from Abelo et al.(12) 
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6.2 Experimental methods 
6.2.1 Chemicals and Reagents 
All reference standards including esomeprazole magnesium hydrate, 5-hydroxy omeprazole, 
omeprazole sulfone, 5-O-desmethyl omeprazole, and a deuterated internal standard d3-
esomeprazole were purchased from Sigma Aldrich (St Louis, MO, USA). Analytical grade 
acetonitrile and methanol were from ROMIL Ltd (Cambridge, England). Water was purified 
through a Milli-Q water purification system (Milford, MA, USA) and used throughout the 
study. Drug-free human plasma was obtained from Tygerberg Hospital Blood Bank (Western 
Cape, South Africa), and heparinized prior to use.  
6.2.2 Preparation of calibration standards and quality control samples 
Stock solutions of esomeprazole, 5-hydroxy omeprazole, omeprazole sulfone, 5-O-desmethyl 
omeprazole, and d3-esomeprazole were prepared separately by dissolving requisite amounts 
in acetonitrile:water (70:30 v/v) in volumetric flasks to achieve a primary concentration of 
200 µg/mL respectively. These analytes were then combined, excluding the internal standard, 
by serial dilution with blank plasma to generate calibration standards in the concentration 
range of 0.001 – 2.5 µg/mL. Quality control (QC) samples were prepared similarly at 
concentrations of 3.7 µg/mL (high quality control, HQC), 0.37 µg/mL (medium quality 
control, MQC), 0.106 µg/mL (low quality control, LOQ), and 0.014 µg/mL (lower limit of 
quality control, LLOQ).  
Working solution (0.2 µg/mL) of the internal standard was prepared by diluting the stock 
solution (200 µg/mL) in acetonitrile.  
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 6.2.3 Sample preparation 
 
A simple protein precipitation method was developed for the extraction of the analytes and 
internal standard from human plasma. Prior to analysis, all frozen calibration standards and 
subject samples were thawed at room temperature. Aliquots of 100 µL of each subject 
samples, standards, QC’s and blank plasma were dispensed into 2 mL microcentrifuge tubes. 
Then, a volume of 900 µL extraction solvent containing internal standard (0.1 µg/mL) in 
acetonitrile:2 mM ammonium formate buffer (50:50 v/v) at pH 5.5, was added to the sample 
tube for protein precipitation. The mixture was vortexed for 10 min, and centrifuged at 11000 
rotations per minute (rpm) for 3 minutes. Eight hundred micro litres (800 µL) of supernatant 
was transferred to a suitable auto sampler vial and sealed cap, before storage in a refrigerator 
at 4 ºC prior to analysis within 1 day.  
 
6.2.4 LC-MS/MS instrumentation and conditions  
 
Liquid chromatography was performed using a Waters Xevo TQS triple quadrupole mass 
spectrometer connected to a Waters Acquity Ultra performance liquid chromatograph 
(UPLC) system (Waters Corporation, Milford, MA, USA) equipped with a binary solvent 
pump and temperature controlled sample organizer. Quantification of the analytes and IS 
were achieved by operating the mass spectrometer in positive ion electrospray ionization 
(ESI) at a desolvation temperate of 400 ºC, desolvation gas as nitrogen at a flow rate of 800 
L/h and capillary voltage of 3.5 kV. Multiple reaction monitoring mode (MRM), summarized 
in Table 6.1, was used for data acquisition. Separation was achieved using a Waters HSS T3 
column (1.7 μm particle size, 2.1 x 50 mm), maintained at column temperature of 40°C and 
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flow rate of 0.5 mL/min with a binary gradient method. Mobile phase A contained 0.1% 
formic acid in water while mobile phase B had 0.1% formic acid in acetonitrile. The gradient 
started with 0.3 minutes of 95% mobile phase A followed by a linear gradient over 1.7 
minutes of 62% mobile phase A and a wash step of 0.5 minutes with 100% mobile phase B.  
 
Table 6.1: Multiple reaction monitoring (MRM) conditions of each analyte and internal 
standard.  
Analyte M+H 
Retention 
Time 
(minutes) 
Cone voltage 
(V) 
Quantifier product ion 
(Collision energy) 
Qualifier product ion 
(Collision Energy) 
Esomeprazole 346.2 1.9 20 136.1 (25) 151.2 (20) 
5-Hydroxy 
Omeprazole 
362 1.7 15 152 (25) 167 (20) 
Omeprazole 
Sulfone 
362 2.2 15 150 (25) 168 (20) 
5-O-Desmethyl 
Omeprazole 
332 1.5 10 151 (15) 198 (10) 
d3-Esomeprazole 349 1.9 15 151 (20) 198 (15) 
 
6.2.5 Method validation 
 
All validation procedures were performed according to U.S. Food and Drug Administration 
(FDA)(17) industry guidance for the validation of bio-analytical methods. 
 
6.2.5.1 Selectivity and Specificity  
 
Selectivity of the method is accepted as lack of interference by endogenous plasma 
components and/or absence of co-eluting peaks in the same MRM channel. This was 
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evaluated by comparing the chromatograms of numerous placebo samples included in the 
trial, which were spiked with all analytes.  
6.2.5.2 Accuracy and Precision 
 
The method was evaluated for accuracy and precision by 6x injection of quality control (QC) 
samples at four different concentrations (LLOQ, LOQ, MQC, HQC) within a batch for intra-
day accuracy. A QC and blank sample was included after every 20 injections. Inter-day batch 
accuracy and precision was determined at the same QC concentrations on three different 
days. Acceptance criteria included percentage recovery as the difference between the mean 
measured values and experimental value within ± 15% deviation at higher concentrations and 
± 20% at the LLOQ. Precision was recorded as a percentage of relative standard deviation 
(%RSD), with the same criteria.  
 
6.2.5.3 Linearity and LLOQ 
 
Calibration standards were prepared by dilution of analyte stock solutions with blank plasma 
proceeded with IS, in a concentrations range of 0.001 – 2.5 µg/mL which included the 
LLOQ. The curves were constructed by plotting the peak area ratio (y-axis) of each analyte to 
the internal standard, versus, the corresponding concentrations (x-axis). Acceptance criteria 
for each back calculated standard concentration was ± 15% deviation from the nominal value, 
and ± 20% at the LLOQ value.  
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The lowest standard on the curve where the analyte peak should be identifiable, discrete and 
reproducible was considered as the LLOQ. Accepted criterion included precision of 20% and 
an accuracy of 80-120% at this value.  
 
6.3 Results and Discussion 
 
In an effort to simultaneously determine the pharmacokinetics of esomeprazole and its 
metabolites, we developed a sensitive and high throughput assay using UPLC-MS/MS. To 
address this objective, parameters attaining to chromatography, mass spectrometry and 
sample extraction conditions were evaluated and are reported below.  
 
6.3.1 Optimization of chromatographic conditions  
 
Mass spectrometry conditions were optimization to achieve the maximum stable signal of the 
precursor ions and corresponding product ions of the analytes in question. Using an 
electrospray ionization source, tuning of the MS parameters was performed in positive and 
negative ionization for each analyte and IS. Better intensity was observed in the positive 
mode, with Q1 MS scan dominated by protonated precursor ions m/z 364.2, 362, 362, 332 
and 349 for esomeprazole, 5-hydroxy omeprazole, omeprazole sulfone, 5-O-desmethyl 
omeprazole and IS, d3-esomeprazole respectively. These precursor ions were used to obtain 
the Q3 product ion spectra, summarized in Table 6.1. Hereby, the mass transition ion pair 
was selected as m/z 346.2>136.1; 346.2>151.2 for esomeprazole, m/z 362>152; 362>167 for 
5-hydroxy omeprazole, m/z 362>150; 362>168 for omeprazole sulfone, m/z 332>151; 
332>198 for 5-O-desmethyl omeprazole, and m/z 349>151; 349>198 for IS, d3-esomeprazole 
(Figure 6.2). The characteristic selectivity of using MS/MS detection was expected to be 
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advantageous in developing a selective and sensitive method. Collision energy and cone 
voltage were optimized to get the highest intensity signal for these precursor and product 
ions.  
 
 
Figure 6.2: Product ion mass spectra of (a) esomeprazole, (b) 5-hydroxy omeprazole, (c) omeprazole sulfone, 
and (d) 5-O-desmethyl omeprazole. 
 
Composition and nature of the mobile phase together with different columns were optimized 
in order to achieve good chromatographic resolution and symmetrical peak shapes within a 
short run time. The viability of several solvents including acetonitrile and methanol with 
different buffers including ammonium acetate, and ammonium formate were evaluated on C18 
columns through many experiments, to determine the best resolution of all analytes and IS 
from any interfering biological components. Good separation and elution were achieved with 
a gradient mobile phase system consisting of 0.1% formic acid solution (A) to  acetonitrile 
containing 0.1% formic acid (B) solution, for a total run time of 3.5 minutes carried out on a  
Waters HSS T3 (1.7 µm, 2.1 x 50 mm) column. The chromatography time included diversion 
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of flow from the LC to waste for the first minute of the run. The retention times are 
summarized in Table 6.1, for each analyte including the IS.  
 
6.3.2 Selectivity  
 
The placebo samples were spiked with LLOQ working solutions, which included internal 
standard in order to confirm the lack of interference at the analyte’s specific retention times 
and the absence of lot-to-lot variation, as shown by Figure 6.3. 
 
 
Figure 6.3: Typical chromatogram of analytes (a) esomeprazole, (b) omeprazole sulfone, (c) 5-hydroxy 
omeprazole, (d) 5-O-desmethyl omeprazole, and (e) IS, d3-esomeprazole in human blank plasma spiked with 
LLOQ standard.  
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6.3.3 Accuracy and Precision 
The intra- and inter-day precision and accuracy values were within the acceptance limit for 
all the analytes and are summarized in Table 6.2.  The intra-day accuracy ranged between 
83% and 104.5% with a precision of 1.7% - 10.5%, while the inter-day accuracy was between 
80.0% and 113% with a precision of 5.3% - 20%.  
Adequate sensitivity was observed for the LLOQ control samples for all analytes. The intra-
day precision ranged from 2.6% to 10.5%, while the accuracy was between 80% and 111%.  
6.3.4 Linearity and LLOQ 
The nine-point calibration curve was found to be linear over the concentration range of 0.001 
– 2.5 µg/mL for all four analytes, as summarized in Table 6.3. The accuracy values ranged
from 97.5% to 104.5% for esomeprazole, 98.3% to 110% for 5-hydroxy omeprazole, 77.9% 
to 110% for omeprazole sulfone, and 73.6% to 108% for 5-O-desmethyl omeprazole. 
Precision (%RSD) values vary from 1.3% to 12% for esomeprazole, while more variation 
was observed for the metabolites ranging from 1.3% to 20%.  
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Table 6.2: Intra- and inter-batch precision and accuracy of all analytes (mean µg/mL, RSD 
%, accuracy %). 
Analyte 
Theoretical 
Concentration (µg/mL) 
Intra-day (n=6) Inter-day (n=6) 
Mean 
(µg/mL) 
RSD 
(%) 
Accuracy 
(%) 
Mean 
(µg/mL) 
RSD 
(%) 
Accuracy 
(%) 
Esomeprazole 
LLOQ 0.014 0.014 2.6 103.4 0.011 11.8 94 
LQC 0.106 0.107 2.4 97.5 0.120 12.9 112 
MQC 0.37 0.37 1.7 99.3 0.371 10.4 100.2 
HQC 3.7 3.7 2.0 100.6 3.7 5.5 98.8 
5-Hydroxy Omeprazole
LLOQ 0.014 0.014 5.6 99.8 0.012 15 85 
LQC 0.106 0.109 9.1 99 0.121 11.8 113 
MQC 0.37 0.38 2.3 104.5 0.35 9.9 95.8 
HQC 3.7 3.5 9.4 93.6 3.5 8.7 94.3 
Omeprazole Sulfone 
LLOQ 0.014 0.014 2.6 103.4 0.011 11 80 
LQC 0.106 0.107 2.4 97.5 0.103 10.4 96 
MQC 0.37 0.37 1.7 99.3 0.38 10.2 104 
HQC 3.7 3.3 3.4 96.3 3.8 6.2 102.6 
5-O-Desmethyl Omeprazole
LLOQ 0.014 0.011 10.5 83 0.015 20 111 
LQC 0.106 0.109 5.5 99.2 0.120 14 112 
MQC 0.37 0.38 2.4 102.1 0.36 10 100.3 
HQC 3.7 3.8 1.7 101.8 3.7 5.3 99.7 
LLOQ = lower limit of quantification; LQC = low quality control; MQC = medium quality control; HQC = 
high quality control.  
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Table 6.3: Linearity of calibration standards (mean µg/mL, RSD %, accuracy %). 
(µg/mL) 
Esomeprazole 
(n=6) 
5-Hydroxy Omeprazole
(n=6) 
Omeprazole Sulfone 
(n=6) 
5-O-Desmethyl Omeprazole
(n=6) 
Mean 
(µg/mL) 
RSD 
(%) 
Accuracy 
(%) 
Mean 
(µg/mL) 
RSD 
(%) 
Accuracy 
(%) 
Mean 
(µg/mL) 
RSD 
(%) 
Accuracy 
(%) 
Mean 
(µg/mL) 
RSD 
(%) 
Accuracy 
(%) 
0.001 0.002 12.0 102.5 0.002 9.0 106.0 0.001 12.0 77.9 0.001 20 73.6 
0.027 0.027 1.8 99.2 0.028 8.5 101.6 0.027 1.8 99.2 0.028 8 103.5 
0.055 0.054 1.8 98.0 0.054 9.0 98.3 0.054 1.8 98.0 0.055 4.6 100.7 
0.165 0.134 1.3 98.7 0.169 6.3 102.7 0.162 1.3 98.7 0.164 8.5 99.5 
0.246 0.243 2.1 98.9 0.259 6.4 105.4 0.243 2.1 98.9 0.253 4.5 103.1 
0.555 0.565 1.6 101.8 0.557 5.8 105 0.565 1.6 101.8 0.568 4.4 102.4 
0.833 0.852 1.9 102.3 0.920 2.3 110 0.852 2.5 102.3 0.892 3.9 107 
1.25 1.31 2.5 104.5 1.29 9.4 103.8 1.31 2.5 105 1.35 5.3 108 
2.5 2.4 3.1 97.5 2.7 7.7 106 2.4 3.1 97.5 2.4 3.4 96 
6.3.5 Sample extraction 
A crucial part of the study was to develop a simple, reliable and cost effective extraction 
method to analyse esomeprazole and its metabolites in human plasma. Therefore, the 
extraction procedure was investigated as the first priority. Protein precipitation (PPT) 
experiments using ammonium formate-acetonitrile (50:50 v/v) and ammonium formate-
acetonitrile (70:30 v/v) were compared over a period of 3 days. A concentration of 2 mM 
ammonium formate showed to stabilize the compounds better than the previously reported 
use of 5 mM ammonium formate.(15) The area response for esomeprazole was similar 
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between the two ratios, but the 70:30 ratio was not optimal for the metabolites. For this 
reason the final optimized extraction solvent was 2 mM ammonium formate-acetonitrile 
(50:50 v/v). It was noted that once extracted, the samples needed to be cooled down before 
centrifugation and LCMS analysis. PPE showed to be suitable in recovery percentage and 
reproducibility. This type of extraction protocol is useful in saving costs on solvents and 
extraction time necessary for clinical sample analysis.  
 
6.3.6 Stability  
 
The stability of esomeprazole is pH dependent, as it rapidly degrades in acidic environments. 
It has acceptable stability under alkaline conditions. At pH of 6.8, the half-life is 
approximately 19 hours and 8 hours at 25ºC and 37 ºC respectively.(20) 
 
6.3.7 Robustness  
 
To evaluate robustness of the method, analysis was performed by two separate analysts, sites, 
machines and chromatographic conditions. The results were comparable within the 
acceptance range of 15% in accuracy and precision.  
 
6.3.8 Application of method in pharmacokinetic study 
 
The presented UPLC-MS/MS method was successfully used to quantify esomeprazole and its 
three metabolites in human plasma collected from pregnant volunteers administered 
esomeprazole (n=10) or placebo (n=9) and umbilical cord blood collected at birth (n=82). 
Pharmacokinetic analysis was conducted on maternal samples only, collected at 15, 30, and 
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45 minutes (pre-dose) and at 1, 1.5, 2, 4, 8, 24 hours (post-dose). With such a large number of 
samples, it was necessary for the assay to be rapid. All clinical samples were quantifiable 
using the described precipitation extraction protocol and LC-ESI-MS/MS system. The area 
under plasma concentration time curves (AUC0-24) investigated for esomeprazole and each of 
its metabolites are presented in Cluver et al.(18) Esomeprazole exposure levels were in the 
same range as previously reported.(1) Metabolites 5-hydroxy and 5-O-desmethyl were present 
in low concentrations, and much lower than the parent drug. Overall, omeprazole sulfone 
displayed higher levels among the metabolites.  
6.4 Summary and Conclusion 
The method development is reliable for determination of esomeprazole and metabolites 5-
hydroxy, sulfone, and 5-O-desmethyl, within a single run. This method can be applied for the 
rapid clinical monitoring of esomeprazole in human plasma, under 4 minutes per run. It 
makes use of a simple and efficient sample clean up using protein precipitation and sample 
volume of 100 µL plasma. Method validation performed on this method supports its high 
precision and accuracy, at the LLOQ of 0.001 µg/mL, and a wide linear range. All 
performance characteristics evaluated proved to be within the accepted criteria as per the 
FDA bioanalytical guidelines. Less precision and accuracy was observed for the metabolites 
when compared with esomeprazole, as a result of the low concentrations these metabolites 
are present. Additionally, this method showed to be sufficient for use in bioequivalence and 
other pharmacokinetic studies following oral administration of esomeprazole in human 
subjects.  
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BACKGROUND: Preterm preeclampsia has a high rate of fetal death or was 29þ4 weeks gestation. There were no between-group differences in
disability. There is no treatment to slow the disease, except delivery. Pre-
clinical studies have identified proton pump inhibitors as a possible treatment.
OBJECTIVE: The purpose of this study was to examine whether eso-
meprazole could prolong pregnancy in women who have received a
diagnosis of preterm preeclampsia.
STUDYDESIGN:We performed a double-blind, randomized controlled
trial at Tygerberg Hospital in South Africa. Women with preterm pre-
eclampsia (gestational age 26 weeksþ0 days to 31 weeksþ6 days) were
assigned randomly to 40-mg daily esomeprazole or placebo. The primary
outcome was a prolongation of gestation of 5 days. Secondary outcomes
were maternal and neonatal outcomes. We compared circulating markers
of endothelial dysfunction that was associated with preeclampsia and
performed pharmacokinetic studies.
RESULTS: Between January 2016 and April 2017, we recruited 120
participants. One participant was excluded because of incorrect
randomization, which left 59 participants in the esomeprazole and 60
participants in the placebo group. Median gestational age at enrolmentCite this article as: Cluver CA, Hannan NJ, van
Papendorp E, et al. Esomeprazole to treat women with
preterm preeclampsia: a randomized placebo controlled
trial. Am J Obstet Gynecol 2018;219:388.e1-17.
0002-9378/$36.00
ª 2018 Elsevier Inc. All rights reserved.
https://doi.org/10.1016/j.ajog.2018.07.019
388.e1 American Journal of Obstetrics& Gynecology OCTOBER 2018median time from randomization to delivery: 11.4 days (interquartile
range, 3.6e19.7 days) in the esomeprazole group and 8.3 days (inter-
quartile range, 3.8e19.6 days) in the placebo group (3 days longer in the
esomeprazole arm; 95% confidence interval, e2.9e8.8; P¼.31). There
were no placental abruptions in the esomeprazole group and 6 (10%) in
the placebo group (P¼.01, P¼.14 adjusted). There were no differences in
other maternal or neonatal outcomes or markers of endothelial dysfunc-
tion. Esomeprazole and its metabolites were detected in maternal blood
among those treated with esomeprazole, but only trace amounts in the
umbilical cord blood.
CONCLUSION: Daily esomeprazole (40 mg) did not prolong gestation
in pregnancies with preterm preeclampsia or decrease circulating soluble
fms-like tyrosine kinase 1 concentrations. Higher levels in the maternal
circulation may be needed for clinical effect.
Key words: esomeprazole, trial, preterm preeclampsia, sFlt1,
pharmacokineticsreeclampsia is one of the mostP serious complications of preg-
nancy. It affects 3e8 % of pregnancies
and is a leading cause of maternal, fetal,
and neonatal morbidity.1,2 There is no
treatment that can slow disease pro-
gression, and the only treatment option
is to deliver the pregnancy. For pre-
eclampsia that occurs at preterm gesta-
tions, clinicians are often required to
deliver the fetus early, which results in
iatrogenic prematurity with a risk of
major disability that includes cerebral
palsy, intracerebral bleeding, retinopathy
of prematurity, chronic lung disease, and
death. The risks of these complications
are higher if pregnancies are delivered at
earlier gestations.3 If a treatment wereavailable that temporizes disease pro-
gression, it could be used to safely delay
delivery to gain gestation, thereby
decreasing the degree of prematurity and
improving perinatal outcomes.
The preeclamptic placenta releases
elevated levels of soluble fms-like tyro-
sine kinase 1 (sFlt1) and soluble endo-
glin into thematernal circulation.4 These
antiangiogenic factors cause maternal
endothelial dysfunction, hypertension,
and multiorgan injury.5 Esomeprazole is
a proton pump inhibitor (PPI) that is
prescribed widely in pregnancy to relieve
symptomatic gastric reﬂux. Members of
our team have performed preclinical
laboratory studies that have shown that
PPIs such as esomeprazole are a candi-
date therapeutic for preeclampsia.6
Esomeprazole, in particular, has been
shown to have diverse biologic actions.
Firstly esomeprazole decreases sFlt1 and
soluble endoglin production and release
from primary trophoblast cells and
placental tissue explants and primary
endothelial cells/tissues in both normaland preeclamptic pregnancies. Secondly
esomeprazole was able to dilate whole
human vessels from both normal preg-
nancies treated with a constrictor and
vessels that were obtained from women
with preeclampsia. Thirdly, preclinical
studies also showed that esomeprazole
decreased endothelial dysfunction by
mitigating tumor necrosis aeinduced
endothelial injury, as demonstrated by
reducing expression of endothelial
vascular cell adhesion molecule-1 and
reduced leucocyte adhesion to the
endothelium. Lastly important animal
studies clearly show that esomeprazole
reduces blood pressure in a transgenic
mouse model of preeclampsia in which
human sFlt1 is overexpressed in the
placenta and released in excess into the
maternal blood, as seen in women with
preeclampsia.6 Others have subsequently
found decreased circulating sFlt1 and
soluble endoglin levels in an existing
cohort of bloods of women with sus-
pected or conﬁrmed preeclampsia that
were coincidentally taking PPIs.7145
AJOG at a Glance
Why was this study conducted?
Preeclampsia has high rates of fetal death or disability. There is no treatment to
slow the disease, except delivery. Preclinical studies have identiﬁed proton pump
inhibitors as a possible treatment.
Key ﬁndings
Daily oral esomeprazole (40 mg) did not prolong gestation in pregnancies with
preterm preeclampsia or decrease circulating soluble fms-like tyrosine kinase 1
concentrations.
What does this add to what is known?
This is the ﬁrst trial for preterm preeclampsia that has integrated clinical out-
comes, mechanistic studies, and pharmacokinetics. Oral esomeprazole (40 mg)
may be too low a dose to treat preterm preeclampsia; higher doses may still be
effective. This may be the fastest completed randomized clinical trial of a treat-
ment for preterm preeclampsia. It is possible to complete clinical trials for pre-
term preeclampsia in a reasonable timeframe by running the trials in settings in
which the incidence of disease is high.
ajog.org OBSTETRICS Original Research
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suggest that esomeprazole is a potential
candidate treatment; we therefore set out
to examine whether oral esomeprazole
may be an effective treatment for pre-
term preeclampsia.
Methods
Trial design
In this single-site phase II double-blind,
randomized, placebo-controlled clinical
trial, we compared oral esomeprazole
with placebo. A 40 mg daily dose was
selected based on pharmacokinetic data
that showed effective suppression of
gastrointestinal symptoms in nonpreg-
nant patients and on reassuring data that
showed no adverse effects if taken during
pregnancy.8-11 The trial site was Tyger-
berg Hospital, Cape Town, South Africa,
which is a large academic referral center
that is situated in a regionwith high rates
of preeclampsia. We have published the
protocol,12 and the trial was registered
with the Pan African Clinical Trials
Registry (PACTR201 504000771349).
Pregnant women with singleton preg-
nancies were invited to participate if they
had been diagnosed with preterm pre-
eclampsia between 26þ0 and 31þ6 weeks
gestation. The gestation at enrolment
was determined by either menstrual
dates (if the women was certain of her
last menstrual period) or by an early
or mid-trimester pregnancy ultrasoundexamination. Both the managing perina-
tologist and neonatologist had to agree
that expectant management could beneﬁt
the fetus.
Women were not eligible if they had an
indication for immediate delivery because
they could not be treated expectantly to
gain further fetal maturity. Exclusion
criteria therefore included established
maternal or fetal compromise that
necessitated delivery, the current use or
contraindications to the use of PPIs, and
the use of medications that could interact
with PPIs (which included warfarin, ke-
toconazole, voriconazole, atazanavir, nel-
ﬁnavir, saquinavir, digoxin, St John’s
Wort, rifampin, cilostazol, diazepam,
tacrolimus, erlotinib, methotrexate, and
clopidogrel). Speciﬁc clinical exclusion
criteria included eclampsia, severe hyper-
tension not be controlled within 48 hours
of admission, a cerebrovascular event,
posterior reversible encephalopathy syn-
drome, severe renal impairment with a
creatinine >125 mmol/L, pulmonary
edema, disseminated intravascular coag-
ulation, hemolysis, elevated liver enzymes
and low platelets (HELLP) syndrome,
liver hematoma or rupture, severe ascites
on ultrasound examination. We excluded
pregnancies with a suspicion of a major
fetal anomaly or malformation. Expectant
management involved hospital admission
with close maternal and fetal surveillance.
Maternal surveillance involved 4 hourlyOCTOBER 2018 Ameriblood pressure measurement, twice daily
clinical assessments, daily urinalysis, and
twice weekly biochemical testing. Fetal
surveillance involved 6 hourly car-
diotocography and ultrasound assess-
ments every 2 weeks ormore frequently, if
indicated. To enhance fetal lung maturity,
all participants received 2 doses of beta-
methasone that were given 24 hours apart,
followed by a single repeat dose 1 week
later if not delivered, as per local proto-
col.13 Expectant management ended at 34
weeks gestation; women who reached this
gestation were delivered. Delivery at <34
weeks gestation was a clinical decision
made by the patient’s treating team.
The study participants provided
written informed consent. The study had
Health Research Ethics Committee
(HREC) approval, was approved by the
South African Medicines Control
Council. Study data were collected and
managed with the use of REDCap elec-
tronic data capture tools.14
Randomization and masking
Randomization was performed in a 1:1
ratio with the use of an online, web-
based sequence generator. Because
gestation at randomization could
possibly impact the length of pregnancy
prolongation, randomization was strati-
ﬁed (strata 1 was 28þ6 weeks; strata 2
was 29þ0 until 31þ6 weeks gestation).
Randomization was done within blocks
of random size within 4e6. The tablets
and treatment packs weremanufactured,
packed, and labelled by the Institute of
Drug Technology Limited (en.idtaus.-
com.au) in Victoria, Australia, and were
identical with respect to variables such as
size, thickness, physical properties, and
appearance. The investigators had no
access to the randomization list, and
allocation concealment was maintained
throughout the trial.
Placental and blood collection to
measure angiogenic markers of
preeclampsia and endothelial
dysfunction and to perform
pharmacokinetics
Plasma samples to measure circulating
preeclampsia and angiogenic biomarkers
were collected at randomization and twice
weekly until delivery. Placental tissuecan Journal of Obstetrics& Gynecology 388.e2146
FIGURE 1
Flowchart of screening, randomization, and follow up
The flowchart summarizes the screening, randomization, allocation to esomeprazole or placebo, exclusion after randomization, complications and follow
up of the study.
SLE, systemic lupus erythematosus.
Cluver et al. Esomeprazole to treat preterm preeclampsia. Am J Obstet Gynecol 2018.
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were collected at delivery when possible.
After recruitment was completed, circu-
lating concentrations and placental
expression of molecules that are markers
of preeclampsia and endothelial dysfunc-
tion were measured.
Pharmacokinetics was performed in a
subgroup of patients who had been
administered esomeprazole. Plasma
samples were drawn from a catheter in a388.e3 American Journal of Obstetrics& Gynecolforearm vein at the following dosing in-
terval: predose, at 15, 30, and 45minutes;
postdose, at 1, 1.5, 2, 4, 8, and 24 hours.
Levels were measured in batch after the
trial was completed (the Supplemental
Material provides further details on how
the esomeprazole was measured).
Outcome measures
The primary outcome was prolongation
of pregnancy, and the study was poweredogy OCTOBER 2018to show a prolongation of 5 days. Sec-
ondary outcomes included composite
and individual maternal, fetal, and
neonatal outcomes, maternal bio-
markers, pharmacokinetics, and
placental samples.
After completion of the trial, we
measured the plasma circulating con-
centrations of the following markers of
preeclampsia: sFlt1, soluble endoglin,
placental growth factor (PlGF) with the147
TABLE 1
Characteristics of trial participants at enrolment
Characteristics Esomeprazole (n¼59) Placebo (n¼60)
Gestation at randomization, wkþd
Median [interquartile range] 29þ4 [27þ6e30þ6] 29þ5 [28þ1e30þ5]
Mean (standard deviation) 29.4 (1.65) 29.4 (1.66)
Gestation <29 weeks at randomization, n (%)a 20 (33.9) 20 (33.3)
Maternal age (y), median [interquartile range] 24 [21e31] 30 [25e34]
Body mass index (kg/m2), median [interquartile range] 29.4 [24.8e33.3] 29.0 [24.0e35.2]
Race or ethnicity, n (%)
Black 34 (57.6) 33 (55)
Colored (multiracial ethnic group native to Southern Africa) 25 (42.4) 27 (45.0)
Smoking, n (%) 8 (13.6) 4 (6.7)
Aspirin use, n (%) 1 (1.7) 0
Calcium use, n (%) 1 (1.7) 0
HIV positive, n (%) 8 (13.6) 12 (20.0)
Chronic hypertension, n (%) 13 (22.0) 21 (35.0)
Nulliparous, n (%) 26 (44.1) 12 (20)
Multiparous, n (%)
Without hypertension in a previous pregnancy 25 (42.4) 27 (45)
With hypertension in a previous pregnancy 8 (13.6) 21 (34.9)
New paternity in current pregnancy, n (%) 11/37 (29.7) 17/48 (35.4)
Highest systolic blood pressure before randomization
(mm Hg), mean (standard deviation)
166 (17.5) 168 (16.4)
Highest diastolic blood pressure before randomization
(mm Hg), mean (standard deviation)
103 (13.4) 103 (11.4)
24-Hour protein creatinine ratio at enrolment (g/24 hr),
median [interquartile range]
1.46 [0.62-3.16] 1.06 [0.57-16.86]
Hemoglobin (g/dL), mean (standard deviation) 12.3 (1.5) 11.6 (1.4)
Platelet count (109/L), mean (standard deviation) 207 (59.9) 222 (67.2)
Urea (mmol/L), mean (standard deviation) 4.0 (1.64) 3.7 (1.4)
Creatinine (mg/dL), mean (standard deviation) 0.05 (0.015) 0.05 (0.013)
Estimated fetal weight (g), mean (standard deviation) 1153 (300.4) 1153 (217.7)
Fetal weight percentile, median [interquartile range] 6.0 [2.1-24.8] 9.5 [1.7-22.5]
Absent blood flow on umbilical artery Doppler, n (%) 2 (3.4) 4 (6.7)
a Percentage of each group.
Cluver et al. Esomeprazole to treat preterm preeclampsia. Am J Obstet Gynecol 2018.
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linked immunosorbent assays. We also
measured markers of endothelial
dysfunction: endothelin-1, vascular
endothelial cell adhesion molecule-1
(VCAM-1).
Total RNA was extracted from the
placental biopsy specimens that were
collected at delivery; the expression ofsFlt1, PlGF, vascular endothelial growth
factor-1, and the anti-oxidant molecule
heme oxygenase-1 was measured by
polymerase chain reaction
(Supplemental Material).
Adherence and adverse events
Medication adherence was checked
daily. After delivery, the treatment packsOCTOBER 2018 Ameriwere collected, and the remaining tablets
were counted. The trial midwife
reviewed participants daily for adverse
events. Serious adverse events were re-
ported to the Data Monitoring and
Safety Committee and Health Research
Ethics Committee and were handled in
accordance with Good Clinical Practice
guidelines.can Journal of Obstetrics& Gynecology 388.e4148
FIGURE 2
Survival curve
Survival curve shows the proportion of trial participants who remained undelivered, graphed against the number of days of gestation after randomization.
Blue indicates the women who were treated with esomeprazole; red indicates the women who were treated with placebo.
Cluver et al. Esomeprazole to treat preterm preeclampsia. Am J Obstet Gynecol 2018.
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The sample size was based on data on the
duration of expectant management at
TygerbergHospital.15 To identify a gain in
gestation of 5 days, we needed to recruit
86 women (90% power, 2-sided alpha
0.05). This sample size was multiplied by
1.15 to statistically correct for non-
normality. An additional 10 per armwere
added to account for anticipated drop-
outs. Thus, a total of 120 participants
(60 per arm) had to be recruited.
Statistical analyses were performed on
an intention-to-treat principle. A 2-sided
P-value <.05 was considered to indicate
statistical signiﬁcance. The primary
outcome was tested with the use of
quantile regression analysis with the388.e5 American Journal of Obstetrics& Gynecoltreatment group and gestational strata as
covariates. Results are presented as me-
dian group difference with 95% conﬁ-
dence interval (95%CI). Survival analyses
were done with Cox proportional hazards
regression and graphed with Kaplan-
Meier survivorship curves. Continuous
variables were compared with either t-test
(normally distributed variables) orMann-
Whitney U (nonnormally distributed
data). Categoric values were compared
with the use of the Fisher’s exact test.
For circulating biomarker studies,
between-group comparisons of circulating
analyte concentrations were performed by
amarginalmeanmodel thatwas estimated
with the use of generalized estimating
equations to allow for both within patientogy OCTOBER 2018correlation and missing samples. Graphic
presentation used median, 25th, and 75th
percentiles that were calculated from
samples that were available at each day
after random assignment. A smoothed
scatterplot of these quantiles was con-
structed with the use of kernel-weighted
local polynomial regression over a pre-
speciﬁed number of time units each side of
the time of interest. The analysis used an
Epanechnikov kernel function, automatic
optimization of the degree of polynomials,
and a bandwidth of 4 days.
Results
Trial participants
Participants were recruited from
January 2016 until April 2017149
TABLE 2
Outcomes according to trial group
Outcome Esomeprazole (n¼59) Placebo (n¼60) P value
Primary
Prolongation of gestation, d
Median [interquartile range] 11.4 [3.6e19.7] 8.3 [3.8e19.6] .31
Mean (standard deviation) 12.9 (10.8) 13.1(12.2)
Gestation at delivery (wkþd), median [interquartile range] 31þ2 [29þ3e33þ3] 31þ3 [29þ3e33þ4] .93
Secondary
Composite maternal outcome, n (%)a 1 (1.7) 4 (6.7) .36
Individual maternal outcomes
Eclampsia, n (%) 0 3 (5.0) .24
Pulmonary edema, n (%) 1 (1.7) 1 (1.7) .99
Admission to high care unit or intensive care unit, n (%) 3 (5.1) 6 (10.0) .49
Proteinuria 3g/24h, n (%) 22 (37.3) 24 (40) .85
Systolic blood pressure >160 mm Hg, n (%) 29 (49.2) 24 (40.0) .36
Diastolic blood pressure >110 mm Hg, n (%) 13 (22.0) 8 (13.3) .24
Highest systolic blood pressure during trial (mm Hg), mean
(standard deviation)
160 (11.9) 160 (12.3) .91
Highest diastolic blood pressure during trial (mm Hg), mean
(standard deviation)
102 (10.6) 101 (8.7) .57
Platelet count <50109, n (%) 0 1 (1.7) .99
HELLP (hemolysis, elevated liver enzymes, and low platelet count)
syndrome, n (%)
5 (8.5) 3 (5.0) .49
Aspartate aminotransferase (level) >60 m/L, n (%) 3 (5.1) 1 (1.7) .30
Hemolysis (lactate dehydrogenase >600 m/L) or hemolysis on
peripheral blood smear or decreased haptoglobin, n (%)
2 (3.4) 3 (5.0) .99
Placental abruption, n (%) 0 6 (10.0) .03
Major postpartum hemorrhage, n (%) 0 3 (5.0) .24
Thromboembolic disease, n (%) 1 (1.7) 0 .99
Moderate-to-severe ascites, n (%) 7 (11.9) 4 (6.7) .36
Composite fetal outcome, n (%)b 49 (83.1) 45 (75) .37
Individual fetal outcomes
Persistent absent flow in umbilical artery Doppler, n (%) 4 (6.8) 7 (11.7) .53
Redistribution in the middle cerebral artery, n (%) 28 (47.5) 27 (45) .85
Growth restriction (estimated fetal weight <10th percentile), n (%) 38 (64.4) 30 (50) .14
Significant changes in fetal heart rate pattern necessitating delivery,
n (%)
28 (47.5) 26 (43.3) .74
Intrauterine death, n (%) 1 (1.7) 1 (1.7) .99
Neonatal composite outcome, n (%)c 10 (16.9) 11 (18.3) .88
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admitted with preterm preeclampsia
who were considered eligible, 4 women
declined to participate (96.7% recruit-
ment rate). One participant in theesomeprazole group was excluded after
randomization because it was later
discovered that she did not meet the
trial criteria for a diagnosis of pre-
eclampsia because she did not haveOCTOBER 2018 Amerisigniﬁcant hypertension and protein-
uria. This left 59 women in the eso-
meprazole group. Two participants in
this group were given the incorrect
treatment pack and received placebo.can Journal of Obstetrics& Gynecology 388.e6150
TABLE 2
Outcomes according to trial group (continued)
Outcome Esomeprazole (n¼59) Placebo (n¼60) P value
Individual neonatal outcomes
Neonatal death within 6 weeks after the due date, n (%) 7 (11.9) 9 (15.0) .67
Grade III or IV intraventricular hemorrhage, n (%) 2 (3.4) 0 .24
Necrotizing enterocolitis, n (%) 4 (6.8) 3 (5.0) .72
Bronchopulmonary dysplasia, n (%) 1 (1.7) 0 .50
Apgar score <7 at 5 minutes, n (%) 1 (1.7) 7 (11.7) .06
Umbilical artery pH <7.05, n (%) 1/35 (2.9) 2/34 (5.9) .61
Surfactant use, n (%) 14 (23.7) 9 (15.0) .25
Neonatal intensive care unit admission, n (%) 8 (13.6) 4 (6.7) .24
High care unit admission, n (%) 53 (89.8) 45 (75.0) .05
Intubation and mechanical ventilation, n (%) 6 (10.2) 6 (10.0) .99
Continuous positive airway pressure support, n (%) 46 (78.0) 39 (65.0) .16
Grade III or IV hyaline membrane disease, n (%) 7 (11.9) 9 (15.0) .79
Retinopathy of prematurity, n (%) 2 (3.4) 0 .24
Neonatal sepsis, n (%) 9 (15.3) 5 (8.3) .27
Birthweight (g), mean (standard deviation) 1343 (466.5) 1379 (441.3) .54
Discharge time (d), median [interquartile range] 3 (3e5) 3 (3e4) .24
NOTE: No participant had any of the following outcomes: maternal death, severe renal impairment, cerebral vascular event, liver hematoma or rupture, posterior reversible encephalopathy syndrome,
left ventricular failure, serum creatinine >125 mmol, disseminated intravascular coagulation, home oxygen support, persistent reversed flow in the umbilical artery Doppler.
a Included the occurrence of any of the following serious maternal outcomes: maternal death, eclampsia, pulmonary edema (oxygen saturation90%, with clinical signs and symptoms that required
treatment), severe renal impairment or the need for dialysis, a cerebral vascular event, and liver hematoma or rupture; b Reversed a-wave in the ductus venosus, significant changes in fetal heart
rate pattern that necessitated delivery, intrauterine fetal death, fetal growth restriction, persistent reversed flow in the umbilical artery, redistribution in the middle cerebral artery Doppler, reversed
a-wave in the ductus venosus Doppler; c Neonatal death within 6 weeks after the expected due date, grade III or IV intraventricular hemorrhage, necrotizing enterocolitis; and bronchopulmonary
dysplasia.
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hospital treatment 1 week after
randomization, left the hospital, and
returned with a stillbirth. Sixty women
were allocated to placebo, and all were
included in the analysis. One partici-
pant delivered before taking her trial
medication, and 1 participant was
diagnosed with systemic lupus erythe-
matosus after randomization. One
participant in this group stopped taking
her medication a few days before de-
livery. The maternal characteristics and
obstetrics history of the cohort are
shown in Table 1.
The median gestational age at
randomizationwas 29 weeks 4 days in the
esomeprazole group and 29 weeks 5 days
in the placebo group. The placebo group
had a higher median maternal age at
enrolment. There were also more multi-
parous women, women with underlying388.e7 American Journal of Obstetrics& Gynecolhypertension, and women who had a
previous pregnancy complicated by hy-
pertension in the placebo group.
Primary outcome
The median time from randomization to
deliverywas 11.4 days (mean, 12.9 days) in
the esomeprazole group vs 8.3 days (mean,
13.1 days) in the placebo group. There was
no signiﬁcant difference in median pro-
longation between treatment groups
either unadjusted (median difference, 3.0;
95% CI, 2.9 to 8.8; P¼.31) or adjusted
for gestational age strata (median differ-
ence, 0.81; 95% CI, 5.1 to 6.7; P¼.79).
Therewas also no difference in themedian
prolongation between strata when
adjusted for treatment group (median
difference, 3.0; 95% CI, 3.2 to 9.2;
P¼.34) days.
There was no difference in the
instantaneous hazard of delivery, at anyogy OCTOBER 2018time, between the 2 treatment arms for
either stratum (Figure 2). The estimated
hazard ratio was 1.13 (95% CI,
0.70e2.17; P¼.70) for <29 weeks and
1.07 (95% CI, 0.68e1.68; P¼.78) for
29 weeks.
Secondary outcomes
There were no signiﬁcant differences
between treatment groups for any of the
maternal, fetal, and neonatal composite
or individual outcomes (Table 2), except
for placental abruption. There were no
placental abruptions (0/59) in the eso-
meprazole group and 10% (6/60) in the
placebo group (P¼.01), which was not
signiﬁcant when we adjusted for the fact
that we performed multiple compari-
sons for other secondary outcomes
(P¼.14).
SFlt1 and soluble endoglin are anti-
angiogenic factors that are increased151
FIGURE 3
Circulating plasma levels of antiangiogenic factors in women who were treated with either placebo or esomeprazole
A,Median circulating plasma soluble fms-like tyrosine kinase 1 concentrations (solid lines) and 25th and 75th percentiles (dotted lines) among participants
administered placebo (red) or esomeprazole (blue). There were no differences in circulating soluble fms-like tyrosine kinase 1 levels between groups.
B, Median circulating plasma soluble endoglin concentrations (solid line), and 25th and 75th percentiles (dotted line) among participants administered
placebo (red) or esomeprazole (blue). There were no differences in circulating soluble endoglin levels between groups. Numbers that were still undelivered at
each 5-day time point and that could have contributed to the data for soluble fms-like tyrosine kinase 1 or soluble endoglin are shown in A.
sENG, soluble endoglin; sFlt1, soluble fms-like tyrosine kinase 1.
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FIGURE 4
Circulating plasma levels of antiangiogenic factors in women who were treated with either placebo or esomeprazole
The graphs show analyte concentrations among the subcohorts of women who were either under (A and B) or over (C and D) 29 weeks gestation at
recruitment. All graphs depict median circulating plasma concentrations (solid lines) of analytes and the 25th and 75th percentiles (dotted lines). None of
the comparisons between esomeprazole (blue) and placebo (red) were significant. Numbers that were still undelivered at each 5-day time point and that
could have contributed to the data are shown in A and C for soluble fms-like tyrosine kinase 1. The numbers that were left undelivered for soluble endoglin
for B are the same as that shown in A for soluble fms-like tyrosine kinase 1; and the numbers that were left undelivered for D are the same as that shown
in C for soluble fms-like tyrosine kinase 1.
sENG, soluble endoglin; sFlt1, soluble fms-like tyrosine kinase 1.
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FIGURE 5
Circulating plasma levels of placental growth factor in women who were treated with either placebo or esomeprazole
The graphs show analyte for A, the entire cohort or the entire cohort split according to whether women were B, under or C, over 29 weeks gestation at
recruitment. All graphs depict median circulating plasma concentrations (solid lines) of analytes and the 25th and 75th percentiles (dotted lines). None of
the comparisons between esomeprazole (blue) and placebo (red) were significant. Numbers that were still undelivered at each 5-day time point and could
have contributed to the data are shown below each graph.
PlGF, placental growth factor.
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FIGURE 6
Circulating plasma levels of endothelin1 and soluble vascular cell adhesion molecule-1 in women who were treated
with either placebo or esomeprazole
The graphs show analyte concentrations among A and B, the entire cohort or the entire cohort split according to whether women were C and D, under or E
and F, over 29 weeks gestation at recruitment. All graphs depict median circulating plasma concentrations (solid lines) of analytes, and the 25th and 75th
centiles (dotted lines). None of the comparisons between esomeprazole (blue) and placebo (red) were significant. Numbers that were still undelivered at
each 5-day time point and that could have contributed to the data for A and B are shown below graph A; numbers that were still undelivered at each 5-day
time point and that could have contributed to the data for C and D are shown below graph C; numbers that were still undelivered at each 5-day time point
and that could have contributed to the data for E and F are shown below graph E.
ET-1, endothelin -1; sVCAM1, soluble vascular cell adhesion molecule-1.
Cluver et al. Esomeprazole to treat preterm preeclampsia. Am J Obstet Gynecol 2018.
Original Research OBSTETRICS ajog.org
388.e11 American Journal of Obstetrics& Gynecology OCTOBER 2018 155
Stellenbosch University  https://scholar.sun.ac.za
FIGURE 7
Placental messenger RNA expression
A, Soluble fms-like tyrosine kinase 1, B, placental growth factor, C, vascular endothelial growth factor, and D, heme oxygenase -1 in placental tissues
that were collected from women who received placebo (n¼32) or esomeprazole (n¼33). None of the comparisons were significant. Data are mean fold
changestandard error of the mean.
HO-1, heme oxygenase-1; mRNA, messenger RNA; PlGF, placental growth factor; sFlt1, soluble fms-like tyrosine kinase 1; VEGF, vascular endothelial growth factor.
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nant women with preeclampsia and may
have a role in the pathophysiology of the
disease. Circulating sFlt1 and solubleendoglin concentrations were extremely
high among trial participants, and there
were no signiﬁcant differences in con-
centrations on serial samples (whichOCTOBER 2018 Americwere obtained from those who were still
undelivered at each time point) between
the groups (Figure 3; Figure 4 shows
analyte concentrations split into the 2an Journal of Obstetrics& Gynecology 388.e12156
FIGURE 8
Pharmacokinetic analysis
Pharmacokinetic analysis showed that esomeprazole was detectable in the maternal circulation, with levels peaking soon after administration and a
decline in concentration by 500 minutes after administration. Metabolites of esomeprazole (5-hydroxy, 5-O-desmethyl and omeprazole sulphone) were
also detectable at lower levels soon after administration with overall higher levels of the metabolite omeprazole sulphone and a steady decrease across
the first 1400 minutes.
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both rapidly declined after delivery, as
expected. There were also no differences
in circulating levels of PlGF (a proan-
giogenic factor that is decreased in pre-
eclampsia; Figure 5), endothelin 1
(endogenous vasoconstriction factor
that is increased in preeclampsia), or
vascular cell adhesion molecule-1
(associated with endothelial dysfunc-
tion; Figure 6). Analysis of placental
messenger RNA expression of sFlt1,
PlGF, vascular endothelial growth factor
(proangiogenic factor) and heme
oxygenaes-1 (endogenous antioxidant
molecule) showed no differences388.e13 American Journal of Obstetrics& Gynecbetween the esomeprazole and placebo
arms (Figure 7).
Esomeprazole pharmacokinetics
Esomeprazole and its metabolites were
measured in 10 participants who were
assigned randomly to esomeprazole;
exposure was similar to that of healthy
nonpregnant volunteers with area under
the curve geometric means of 5.88
mmol,h/L (95% CI, 2.96e11.68
mmol,h/L; Figure 8).16 In contrast, eso-
meprazole and these metabolites were all
undetectable in 9 participants who were
administered placebo. Concentrations of
esomeprazole and the metabolites wereology OCTOBER 2018extremely low in the umbilical cord
blood taken at birth.
Adverse events and adherence
Adherence was excellent. Only 1 partic-
ipant in the placebo group stopped tak-
ing the trial medication. There were no
signiﬁcant differences in the incidences
of serious adverse events between the 2
groups (Table 3).
Comment
In our trial, a daily dose of 40 mg of oral
esomeprazole did not prolong gestation
statistically further than expectant
management alone. Additionally, there157
TABLE 3
Severe adverse events
Adverse event
Esomeprazole
(n¼59), n (%)
Placebo
(n¼60), n (%) P value
Maternal
Eclampsia 0 3 (5) .24
Pulmonary edema 1 (1.7) 1 (1.7) .99
Blood loss of >1000 mL 0 3 (5) .24
Fetal/neonatal
Intrauterine death 1 (1.7) 1 (1.7) .99
Neonatal death 7 (11.9) 9 (15.0) .67
Necrotizing enterocolitis 4 (6.8) 3 (5) .68
Neonatal sepsis 9 (15.3) 5 (8.3) .24
Intracranial hemorrhage 2 (3.4) 0 .15
NOTE: No participant had any of the following serious adverse events: maternal death, severe renal impairment, cerebral
vascular event, liver or rupture, posterior reversible encephalopathy syndrome, left ventricular failure, disseminated intra-
vascular coagulation, fetal or neonatal congenital anomaly.
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biomarker outcomes or secondary
maternal, fetal, and neonatal outcomes,
except for placental abruption. However,
this is a secondary outcome and did not
remain signiﬁcant on an adjusted
analysis.
Ours is only one of very few
completed randomized trials to explore
treatments for preterm preeclampsia.
We have completed perhaps the fastest
recruitment for a randomized trial of a
drug treatment for preterm preeclamp-
sia, and we achieved this at 1 site by
undertaking our study in an area with a
very high incidence of disease. It is also
the ﬁrst completed randomized treat-
ment trial of preterm preeclampsia in
which blood biomarkers of preeclampsia
or endothelial dysfunction were
measured, as well as placental messenger
RNA expression of genes that are rele-
vant to the pathophysiology of
preeclampsia.
There was a nonsigniﬁcant trend in
median prolongation in the esomepra-
zole group of 3 days; however, to show
that such a difference is signiﬁcant, we
would have needed 402 participants in
each arm (alpha error, 5% for 90% po-
wer; a post hoc analysis that was calcu-
lated from the actual length of gestation
observed in the current trial). Despite
this, there were no trends in the meanprolongation or the instantaneous haz-
ard of delivery to support this. There was
a decrease in the incidence of placental
abruption, but this difference was no
longer signiﬁcant after we adjusted for
the fact that we performed multiple
comparisons for all the different sec-
ondary outcomes. Therefore, the signif-
icance of this ﬁnding, if any, is uncertain.
Esomeprazole is 97% bound to pro-
tein and 80% renally excreted. We
were concerned that the signiﬁcant
proteinuria that often is associated with
preterm preeclampsia may alter esome-
prazole pharmacokinetics. Those who
received esomeprazole had exposure
levels similar to healthy nonpregnant
volunteers that had been reported pre-
viously.17 The esomeprazole concentra-
tions that were observed in our
participants were around the lower
range of concentrations that were used in
our preclinical in vitro studies.6 Thus,
although 40 mg may be an optimal dose
that is effective in decreasing gastric
pH,18 it is possible that a higher dose or
an intravenous dose, which has a higher
exposure over time and peak concen-
tration,16 may be effective in treating
preeclampsia.
There is now strong (though circum-
stantial) evidence that placental secre-
tion of sFlt1 (which causes endothelial
dysfunction) may be a signiﬁcant driverOCTOBER 2018 Americof the disease.5,19 We and others have
pegged decreasing sFlt1 secretion as a
strategy to treat preeclampsia.6,20-24 We
did not ﬁnd changes in any of these
markers, which provides biologic evi-
dence to support our clinical ﬁndings
that 40mg of oral esomeprazole does not
seem to arrest the disease course of
preeclampsia once it is diagnosed.
We note that rescuing a pregnancy
with advanced preterm disease with se-
vere placental involvement may be a
difﬁcult proposition. It has been re-
ported recently that proton inhibitor
use, to combat reﬂux, was associated
with decreased sFlt1, soluble endoglin,
and endothelin-1 levels.7 We believe it
remains possible that a 40-mg dose may
still have merit as a preventative treat-
ment for preeclampsia and may be more
realistic.Whether this is the case will also
require clinical trials.
Esomeprazole is prescribed widely
during pregnancy, and levels in the
umbilical cord have not been reported
previously. It was reassuring therefore
that there was very little, or no, esome-
prazole detected in umbilical cord blood
that was sampled at birth among those
who received the drug. It provides
further reassurance that there is likely to
be minimal fetal exposure and is
consistent with epidemiologic data that
show no adverse effects of PPIs on fetal
development.9-11
There have not been many completed
phase II clinical trials that have tested
candidate treatments for preterm pre-
eclampsia. Previous trials have met
problems with recruitment. One of the
main difﬁculties is that the incidence of
disease is low in the developing world.
Sildenaﬁl was assessed in a single-site,
double-blind randomized controlled
trial in Brazil.25 Over a 28-month period,
100 women were recruited. There was a
signiﬁcant prolongation of gestation in
the sildenaﬁl group of 4 days; however,
given that sildenaﬁl is a vasodilator, it is
possible that this prolongation in gesta-
tion may have occurred because the drug
decreased blood pressure and mitigated
a clinical reason to deliver, rather than
temporize disease progression. Anti-
thrombin was assessed to treat preterm
preeclampsia in the PRESERVE-1 trialan Journal of Obstetrics& Gynecology 388.e14158
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tiary hospitals in the United States over
28 months (ISRCTN23410175).26 There
was no difference in prolongation of
pregnancy or composite neonatal out-
comes.27 Trials that have assessed ser-
elaxin (NCT01566630), pravastatin,
high doses of antithrombin,28 and cele-
coxib (NCT00442676) have been
attempted, but all were terminated,
perhaps because of poor recruitment.
A potential limitation of our trial is
that we were powered to detect a 5-day
prolongation of pregnancy and there-
fore cannot exclude the possibility that
40 mg of esomeprazole may be effective
in prolonging pregnancy by 3 days (there
was a nonsigniﬁcant median difference
of 3 days). However, given the ﬁndings of
pharmacokinetic and biomarker studies,
we are inclined to pursue further trials
with higher doses rather than to repeat
this same trial with a larger number of
participants.
Our trial has several strengths. As
noted, we performed an integrated trial
in which we not only obtained data on
clinical outcomes but also derived
important insights by undertaking
biomarker studies and pharmacokinetics
that will inform our next trial. Further-
more, it was run at 1 center, which
allowed us to obtain a high recruitment
rate, to closely monitor compliance, and
to collect uniform high-quality data.
Importantly, by basing this trial at an
academic center that is embedded within
a population with a high incidence of
preterm preeclampsia, we overcame the
problem faced by previous trials of low
recruitment.
In conclusion, in women with a
diagnosis of preterm preeclampsia at
26e32 weeks gestation, a daily oral dose
of 40 mg of esomeprazole did not pro-
long pregnancies. Circulating levels of
sFlt1 and other antiangiogenic markers
were extremely high among the cohort
and were not lowered by esomeprazole.
The drug appears safe and is well toler-
ated. In pharmacokinetic studies, we
found that esomeprazole was present in
the maternal circulation, but concen-
trations were relatively low compared
with those required to elicit tissue/cell
responses in our previous laboratory388.e15 American Journal of Obstetrics& Gynecstudies. This raises the possibility that
higher doses may be effective. Reassur-
ingly, levels of esomeprazole in the um-
bilical cord blood were very low, or not
detectable, which provides further reas-
surance that very little reaches the fetal
compartment.
Furthermore, we have developed and
successfully completed a new protocol
to evaluate drugs to treat preterm pre-
eclampsia that embeds mechanistic in-
sights and pharmacokinetics with
clinical endpoints. We also completed
recruitment in a reasonable timeframe
by performing this trial in an area
where the incidence of preterm pre-
eclampsia is very high. We propose this
may be an optimal approach when
designing clinical trials for preterm
preeclampsia. n
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Measuring plasma concentrations
of esomeprazole and its
metabolites
Plasma concentrations of esomeprazole
and its metabolites (5-hydroxy omepra-
zole, omeprazole sulphone, and 5-
O-desmethyl omeprazole) were
determinedwith the use of a validated ultra-
performance liquid chromatographye
tandem mass spectrometry method. A
Waters Acquity ultra-performance liquid
chromatograph (Waters Corporation,
Milford, MA) with a Waters HSS T3
column was linked to a Xevo TQ-S mass
spectrometer (Waters Corporation). A
gradient of 0.1% formic acid to aceto-
nitrile was used, with d3-esomeprazole
as the internal standard. In brief, the
drugs were extracted with a buffered (2
mmol/L ammonium formate; pH 5.5)
acetonitrile 60% solution, and the
precipitated plasma proteins were sepa-
rated by centrifugation (12 000g). The
intra- and interday accuracy of the
quality control samples was >90% and
85%, respectively; the intra- and interday
precision was <11% and <15%, except
for 5-O-desmethyl omeprazole that was
20% at the lower limit of quantiﬁcation.
The limit of quantitation was 1 ng/mL
for all analytes. Phoenix WinNonlin
software (version 9.0; Certara, Prince-
ton, NJ) was used to characterize the
pharmacokinetic parameters of esome-
prazole with the use of non-
compartmental analyses. The area under
the plasma concentration-time curve
was calculated for the 24-hr dosing in-
terval with the log-linear trapezoidal388.e17 American Journal of Obstetrics& Gynecmethod. Pharmacokinetic data were
summarized as geometric mean values
with 95% conﬁdence intervals.
Preparation of placental tissue for
analysis
Placental tissue was dissected from the
whole placenta. Four pieces were dissected
from distant sites; the tissue pieces were
thenwashed in sterile phosphate-buffered
saline solution, and smaller pieces were
then dissected (to allow appropriate
penetration of RNA preservation buffer
[RNAlater]). Each piece was immersed in
RNAlater according to manufacturer’s
instruction. Tissue samples were then
blotted dry, snap frozen, and stored at
e80C until subsequent analysis.
Measuring analytes in the plasma
by enzyme-linked immunosorbent
assay
Patient plasma was assessed with the use
of enzyme-linked immunosorbent assay
for the presence of the following soluble
factors: soluble Flt-1 (DuoSet VEGF R1/
Flt-1 kit; R&D Systems by Bioscience,
Waterloo, Australia), soluble endoglin
(DuoSet Human Endoglin CD/105;
R&D Systems), placental growth factor
(P DuoSet PlGF; R&D Systems),
endothelin-1 (Quantikine endothelin-1;
R&D Systems), and soluble vascular
cell adhesion molecule-1 (human
VCAM-1/CD106 DuoSet; R&D Sys-
tems). Optical density for enzyme-
linked immunosorbent assays was
determined with a BioRad X-Mark
microplate spectrophotometer (BioRad
Laboratories, Inc, Hercules, CA). Pro-ology OCTOBER 2018tein levels were determined with BioRad
Microplate Manager software (version 6;
BioRad Laboratories, Inc).
Measuring expression of genes in
placental tissue
Total RNA was extracted from placental
tissue (from placebo [n¼32] and esome-
prazole [n¼33] treated women) with the
use of the RNeasy mini kit (Qiagen,
Valencia, CA) and was quantiﬁed with a
Nanodrop ND 1000 spectrophotometer
(NanoDrop Technologies Inc, Wilming-
ton, DE). RNA (0.2 mg) was converted to
complementary DNA with the use of a
high-capacity complementary DNA
reverse transcriptase kit (Applied Bio-
systems Life Technologies Corporation,
Carlsbad, CA), according to manufacturer
guidelines.
Quantitative polymerase chain reac-
tion was performed with the use of
Taqman gene expression assays for the
following genes: sFlt1, HO-1, PlGF and
VEGFA. Polymerase chain reaction was
performed on the CFX 384 (BioRad
Laboratories, Inc) using FAM-labeled
Taqman universal polymerase chain
reaction mastermix (Applied Bio-
systems) with the following run condi-
tions: 50C for 2 minutes, 95C for 10
minutes, 95C for 15 seconds, 60C for
1 minute (40 cycles). All data were
normalized to the housekeeping genes
TOP1 and CYC1 as an internal control
and calibrated against the average cycle
threshold of the control samples. The
results were expressed as fold-change
relative to control subjects. All samples
were run in triplicate.161
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1. PROTOCOL SYNOPSIS
1.1. Title 
Pharmacokinetic study of metabolites acetyl-PAS and glycine-PAS and the correlation between 
the rate of metabolism and the development of toxicity in MDR and XDR-TB patients treated 
with PAS. 
1.2.  Introduction 
Para-aminosalicylic acid (PAS), is a bacteriostatic chemotherapeutic agent used in the therapy 
of all forms of tuberculosis (TB). It is readily absorbed in the gastrointestinal (GI) tract and 
primarily metabolised in the liver to, N-acetyl-para-aminosalicylic acid (APAS) and p-
aminosalicyluric acid (GPAS). Since its clinical introduction in the late 1940’s, PAS was part 
of the standard first-line TB treatment for over 20 years. Along with isoniazid (INH) and 
streptomycin, PAS showed substantial efficacy and prevention of drug resistance in companion 
drugs. However, it was notorious for gastrointestinal intolerance, causing nausea, vomiting and 
abdominal discomfort. Hereby, PAS was replaced with other efficacious drugs that showed 
better tolerance.  
Fuelled by the HIV pandemic, increasing rates of multidrug-resistance (MDR) and also 
extensively drug-resistance (XDR) to first-line TB agents, the use of available drugs needs to 
be revised. Because of the relative lack of use of PAS over the past three decades, most strains 
of Mycobacterium tuberculosis remain susceptible to it. This has urged the resurgence of PAS 
in the management of patients with MDR-TB.   
When PAS was introduced in anti-TB management, it was administered in divided daily doses. 
Several groups later turned to once daily dosing and found favourable results. Lehmann, later 
also advocated a single daily dose, emphasising the greater PAS exposure brought about 
allowed greater drug penetration into tuberculosis tissue (Lehmann 1969). The results of the 
single study of PAS in a once daily 15 g dose suggest that, although usually thought 
bacteriostatic, PAS might have bactericidal activity if high enough concentrations are reached 
(Jindani et al. 1980).  
In a study by Sy et al. (2015), the safety and tolerability of two dosing regimens (8 g once-daily 
vs 4 g twice-daily) was investigated. No distinctive difference in the extent of the side effects 
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could be found between the two regimens. The results indicated that PAS adverse 
gastrointestinal (GI) effects were not necessarily attributed to higher PAS concentrations seen 
with the once-daily regimen. It was rather found that once-daily dosing was associated with 
less intolerance versus the twice daily dosing. These findings are in agreement with earlier 
studies by the British Medical Council (1952). Sy et al. did however observe the influence of 
other characteristics of pharmacokinetics such as Cmin (minimum drug plasma concentration), 
which correlated with abdominal pain, discomfort and diarrhoea.  
These findings have led to the speculation that factors such as absorption and metabolism may 
well be related to the GI effects observed in treatment with PAS. The current study therefore 
hypothesises, that more rapid absorption of PAS and its biotransformation to APAS may be the 
causative of increased GI adverse effects, as opposed to the notion of high serum PAS 
concentrations.   
1.3. Aims and Objectives 
The current study aims to establish a practical method for the simultaneous clinical monitoring 
of PAS and its metabolites APAS and GPAS in human plasma. 
⇒ By developing and validating an analytical method using ultra-performance liquid
chromatography (UPLC) in tandem with triple quadrupole mass spectrometer (MS).
It aims to study the in vivo pharmacokinetics (PK) of metabolites APAS and GPAS in MDR 
and XDR TB adult patients. 
⇒ By measuring the levels of APAS and GPAS in plasma, using the developed LC-
MS/MS method.
It aims to evaluate the possible cause of adverse reactions experienced in patients treated with 
PAS. 
⇒ By determining if a correlation exists between high or low levels of APAS and GPAS
and reported events of gastrointestinal intolerance (nausea, bloating, diarrhoea,
abdominal pain). This data was previously collected (M12/01/006). The events were
rated using a 10-point visual analogue scale (VAS).
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1.4. Study Design 
 
As part of an ongoing study (HREC #: M12/01/006), the same PAS samples will be analysed 
for determination of its metabolites. Therefore, this two-period, cross over study will be 
conducted in a population with high prevalence of drug resistant TB and on a TB regimen which 
includes PAS. Forty one (41) adults at Brooklyn Hospital for Chest and Diseases, Cape Town, 
will be enrolled in the study. They will be divided into two groups with the following PAS 
dosing regimen: 4 g twice-daily and 8 g once-daily, for a period of 8 days (Days 1-8). 
Thereafter, the regimens will be crossed over and followed for another 8 days (Days 9-16).  
 
Blood samples will be collected over a 24 hour period on Day 8 and Day 16, and dosing 
regimen, dosing time, blood sampling times and demographic characterises will be recorded 
for each patient. Three millilitre (3 mL) blood specimens will be collected at time 0, 1, 2, 3, 4, 
6, 8, 12 (pre-dose) and 24 hours after dosing.  
 
1.5. Sample Stability 
 
The stability of the samples (stored at - 80˚C) will be evaluated by comparing the PAS levels 
achieved previously by de Kock et al. (2013) to those quantified in the current study. Internal 
standard drug for PAS, APAS and GPAS will be included in the analytical analysis as control 
standards.  
 
1.6. Methodology  
 
A method will be established and validated according to bio-analytical method validation 
guidance by U.S Food and Drug Administration (FDA), under the supervision of Dr Marietjie 
Stander (Director of LCMS unit, Central Analytical Facilities, Stellenbosch University).  
 
The samples will be analysed for APAS, GPAS and parent PAS, at t0, 1, 2, 3, 4, 6, 8, 12 (pre-
dose) and 24 hours post dose. The MS/MS assay will be determined using a Waters Xevo TQ 
triple quadrupole mass spectrometer (MS) connected to a Waters Acquity Ultra performance 
liquid chromatograph (UPLC) system equipped with an appropriate analytical column.  
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1.7. Ethical Considerations  
 
The data and information of each patient will remain concealed by use of a unique subject code, 
previously allocated. The patient confidentiality will be maintained at all times allowing only 
researcher and authorized official’s access to personal information.  
 
No additional consent is required from the patients as no specific limit on the period of analysis 
of the stored specimen was disclosed.   
 
2. LITERATURE REVIEW  
 
Tuberculosis is a chronic infectious disease cause by the acid-fast bacillus Mycobacterium 
tuberculosis  (Kvasnovsky et al. 2011). According to the 2015 global TB report the epidemic 
accounts for 10.4 million cases and 1.4 million deaths worldwide (Global Tuberculosis Report: 
WHO report 2015). The World Health Organization (WHO) has classified TB endemic in the 
developing world, with 80% of all cases occurring in high burdened countries, including South 
Africa.  
 
Multidrug-resistance tuberculosis (MDR-TB) caused by strains of M. tuberculosis resistant to 
first-line TB drugs, rifampicin and isoniazid (INH), has emerged as an increasing threat in TB 
management (Wells et al. 2007, Iseman 2002). Additionally, extensively drug-resistant 
tuberculosis (XDR-TB) drugs, are required in isolates resistant to second-line drugs such as 
fluoroquinolones and injectable drugs kanamycin and capreomycin (Kvasnovsky et al. 2011).  
 
Fuelled by the HIV pandemic and increasing rates of resistance to established anti-TB drugs, 
several new drugs have now completed clinical trials in patients with drug-resistant TB. 
However, even if these drugs are successful in shortening treatment duration, the need for 
protection from the emergence of resistance needs to be maintained. Due to these 
circumstances, the use of available drugs needs to be revised. This has urged the re-introduction 
of para-aminosalicylic acid (PAS), one of the earliest efficacious anti-TB chemotherapeutic 
agents used.  
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2.1. PAS 
 
Since its clinical introduction in the late 1940’s, PAS has formed part of the standard treatment 
of TB for decades. PAS is classified as a bacteriostatic agent and has shown to inhibit growth 
of M. tuberculosis at a concentration of 1-2 µg/mL2, in vitro (Peloquin et al. 1994, Annabel 
2017). In a study conducted in healthy individuals, a mean maximum concentration (Cmax) of 
20 µg/mL with a mean peak time of 6 hours was achieved after a single 4 g PAS dose, in a 
granular slow release formulation (Lehmann 1969, PASER 1996, Cynamon 2001).  
 
2.2. Pharmacokinetics of PAS  
 
PAS is readily and completely absorbed from the gastrointestinal (GI) tract, 50-73% bound to 
plasma proteins and well distributed systemically (Momekov et al. 2015). It is then metabolised 
beginning in the gut wall and primarily in the liver. The main pathway of PAS metabolism 
comprises conjugating processes (Figure 1), of three different active groups in the benzene ring. 
The two major metabolites are formed by conjugation of the amino group (-NH2) in position 4 
and the carboxyl group (-COOH) in position 1 (Lehmann 1969, Momekov et al. 2015).  
 
Following an oral dose, PAS has a half-life of approximately 1 hour. Concentrations in the 
plasma are negligible within 4-5 hours post dose (Berning and Peloquin 1998). Within 24 hours, 
more than 80% of the dose is excreted in the urine. Apart from glomerular filtration the half of 
the dose and its metabolites are eliminated by tubular secretion (Otten et al. 1975).  
 
  
Figure 1: Schematic of the alternative conjugations of PAS. Adapted from Lehmann 1969.  
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 2.3. Biotransformation of PAS  
 
The 3 functional groups in the benzene ring of PAS are crucial for the anti-tuberculosis 
activity of PAS (Lehmann 1969). The conjugation of the two main metabolites occurs as 
follows:  
⇒ N-Acetylation 
The amino group (-NH2) at position 4 is conjugated with acetyl Co-enzyme A (Co-A) 
to form acetyl-PAS (APAS). APAS is the primary metabolite of PAS, and is known to 
be devoid of bacteriostatic activity against M. tuberculosis (Momekov et al. 2015).   The 
rate of this reaction is modulated by N-acetyltransferase 1 (NAT1) which is encoded by 
the gene NAT1 (Figure 2).  
 
 
Figure 2: Schematic adapted from Wang et al. 2016.  
Isoniazid (INH) metabolism is catalysed by N-acetyltransferase 2 (NAT2), the 
isoenzyme of NAT1 (Butcher et al. 2002). Shortly after introduction of INH in anti-
tuberculosis treatment,, substantial differences in its N-acetylation activity was found 
to be due to a polymorphic NAT2 (Sim et al. 2008).  
The biotransformation of PAS was thought to be unimodal, but after the sequencing of 
NAT1, several polymorphisms affecting NAT1 activity were identified thus PAS N-
acetylation is considered polymorphic like that of INH (Blum et al. 1990).  
 
⇒ Glycine-conjugation  
Glycine N-acyltransferase (GLYAT), is the enzyme responsible for glycine conjugation 
of several xenobiotic organic acids (Badenhorst et al. 2013). However, due to a small 
number of pharmaceutical drugs conjugated to glycine, the pathway has not yet been 
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characterized in detail. The following pathway was adapted from that of salicylic acid 
(aspirin). First PAS is ligated to Co-A to form a high energy salicyl-CoA thioester. 
Thereafter, salicyl-CoA is conjugated to a glycine amino acid by GLYAT to form 
aminosalicyluric acid, and releasing Co-A (Figure 3) (Knights et al. 2007). Glycine-
PAS has shown anti-tuberculosis activity that varies between 50% and 75% that of PAS, 
depending on the dosage of PAS (Lehmann 1969). Single nucleotide polymorphisms 
(SNPs) have been observed in human GLYAT, but the influence on the enzyme activity 
is not clear.  
 
 
 
Figure 3: Schematic adapted from Badenhorst et al. 2013.  
 
In studies by Lipman (1945) and Chantrenne (1951), acetylation was least when glycine 
conjugation is at its maximum. Lehmann (1969), observed the same shift in processes. When 
glycine conjugation declines, acetylation continues long after. This phenomenon was explained 
by the competition for a common substrate, presumably CoA. At a low dose, PAS absorption 
is accompanied by first-pass rapid acetylation beginning in the gut wall, therefore APAS may 
be detected in the blood before PAS itself (Peloquin et al. 1994). However, at high doses 
acetylation is saturated due to scarcity of available Co-A, inhibiting the enzyme function. This 
allows PAS and GPAS concentrations to rise expressively higher while APAS is relatively low 
(Dubovsky and Lehmann 1991, Lehmann 1946). In the same way, INH acetylation will be 
repressed during PAS therapy, allowing its concentrations to be higher when INH and PAS are 
administered together (Lauener and Favez 1959, Johnson and Corte 1956, Morse et al. 1956). 
These findings have emphasis the substantial effect of PAS dosage. 
 
2.4. PAS tolerance and safety  
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Shortly after the introduction of PAS, intolerance was noted with common adverse effects 
manifested in nausea, vomiting, diarrhoea, anorexia, abdominal pain and cramping (Lehmann 
1949). During the MRC studies done on PAS, it was evident that PAS dose affected intolerance. 
12%, 15%, and 52% of patients receiving 5 g, 10 g and 20 g daily, reported GI intolerance 
respectively (MRC 1952). In another investigation by Marsden (1954), 119 (30%) of 399 
patients reported GI intolerance when administered divided PAS doses, but only in 44 (12%) 
of 383 patients when given a once-daily dose. Similar findings were reported by Riska from 
1954-1962, as better or equivalent tolerance with PAS given once-daily compared with the 
same dose in divided doses.  
In an attempt to improve intolerance, a granular slow release PAS formulation (GSR-PAS) was 
introduced in the USA, and made available for treatment of drug resistant TB, in South Africa 
(Donald and Schaaf 2007). GSR-PAS seemed to be better tolerated with fewer patients 
reporting moderate nausea, vomiting, bloating and diarrhoea (Peloquin 1994, 1999). A similar 
investigation by Sy et al. (2015), compared GSR-PAS 4 g twice-daily vs 8 g once-daily. Little 
difference in tolerance was observed, a result similar to other studies. However, the influence 
of other pharmacokinetic characteristics such as the Cmin (minimum observed plasma 
concentration) of PAS, correlated with abdominal pain, discomfort and diarrhoea.  
2.5. PAS optimal dosing regimen 
When PAS was first introduced in anti-TB management, it was administered in divided daily 
doses. Several groups later turned to once daily dosing, a change supported by Lehmann (1969) 
who stated that the greater PAS exposure brought about the greater the drug penetration into 
tuberculosis tissue. In a study by Jindani et al. 1980 which investigated the early bactericidal 
activity of PAS in a once daily 15 g dose, reported that although PAS is thought to be 
bacteriostatic, it may have bactericidal activity if high enough concentrations are reached. The 
prevention of resistance in companion drugs is often related to bactericidal activity. This may 
explain the improved activity of a higher individual dose of PAS for preventing resistance 
shown in earlier trials by the British MRC in the absence of INH (MRC 1952, Daniels and Hill 
1952).  
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3. RATIONALE OF STUDY 
 
As part of an ongoing study (#M12/01/006) to report the pharmacokinetics of PAS which lacks 
available data, the current study aims to determine the pharmacokinetics of the major 
metabolites of PAS. Due to the potential bactericidal characteristics of PAS at a higher dose 
regimen, there is an urgent need to shed light on the factors that contribute to gastrointestinal 
intolerance associated with PAS treatment. This study aims to suggest a regimen that uses PAS 
dosing optimally for better management of DR-TB cases co-infected with HIV. If we were able 
to elicit the correlation between the serum concentration of PAS metabolites and GI effects, it 
could add to our understanding of the individual pharmacokinetic profile of PAS which may be 
greatly affected by the enzymes responsible for the rate of its biotransformation.  
  
4. AIMS  
 
⇒ The main aim of this research project is to study the in vivo pharmacokinetics (PK) of 
metabolites N-acetyl-para-aminosalicylic acid (acetyl-PAS, APAS) and p-
aminosalicyluric acid (glycine-PAS, GPAS) in adults. The study aims to establish 
whether high plasma concentrations of these metabolites are associated with 
gastrointestinal intolerance?  
 
⇒ The second aim of this study for a MSc degree is to develop a sensitive and high 
throughput LC-MS/MS method for the simultaneous quantification of para-
aminosalicylic acid (PAS) and its major metabolites (APAS) and (GPAS), in human 
plasma. The analytical method will be developed on an ultra-performance liquid 
chromatography system (UPLC) in tandem with triple quadrupole mass spectrometer 
(MS). Such a system is a proven analytical tool that offers very low limits of 
quantification, together with high throughput and excellent specificity. 
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5. OBJECTIVES 
 
⇒ The primary objective is to measure the levels of APAS and GPAS in plasma, using the 
developed and validated LC-MS/MS analytical method. This assay will indicate the 
pharmacokinetic profile of subjects under two dosing regimens (8 g once-daily vs 4 g 
twice-daily).  
⇒ The secondary objective is to determine if high or low levels of APAS and GPAS 
contribute to toxicity. This will be done by comparing the measured levels to a 10-point 
visual analogue scale (VAS) which rates adverse effects including abdominal pain, 
nausea, diarrhoea and bloating. 
 
6. STUDY METHODOLOGY  
 
As part on an ongoing study (HREC #: M12/01/006) by de Kock et al. (2013), a selection of 
the same PAS samples will be analysed to assay the major metabolites of the parent drug. 
Therefore, the current study is a randomized two period cross over study which will report the 
pharmacokinetics of metabolites APAS and GPAS under two dosing regimens: 4 g twice-daily 
and 8 g once-daily in adult patients. The study will be conducted in a population based on 
inclusion criteria of high prevalence of drug resistant (DR) TB, HIV positive or negative status 
and a treatment regimen which includes PAS.  
 
6.1. Sample size  
 
Adult patients, from the Brooklyn Hospital for Chest and Diseases in Cape Town, who are 
routinely screened for DR-TB and treated with PAS, will be enrolled in this study. All patients 
in the larger study will be included (41) minus 11 patients due to the loss of specimen during 
the previous study analysis.  
 
6.2. Sample collection   
 
The blood samples will be collected for pharmacokinetic analysis over a 24 hour period on Day 
8, after which the regimens will be crossed over. The patients who received 2x 4 g GSR-PAS 
will then receive 1x 8g GSR-PAS (PASER® granules) and vice versa. These regimens will be 
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followed for another 8 days (Day 9-16). The blood samples will be collected on Day 16. Three 
millilitres (3mL) of blood specimen will be collected through a catheter inserted into a forearm 
vein over 24 hours as follows: t0, 1, 2, 3, 4, 6, 8, 12 (pre-dose) and 24 hours after post dose.  
 
6.3. Sample criteria  
 
o Male and female patients aged ≥ 18 years  
o Race and gender data will be collected  
o Known HIV status has to be advised or obtained before enrolment  
o It is required of the patient to be on a clinically stable and unchanged regimen which 
includes PAS as part of their treatment for at least 14 days 
o The following data will be collected at enrolment: TB disease status, disease spectrum, 
mycobacterial culture and drug susceptibility test pattern, concurrent illness, concomitant 
medication, age, Body Mass Index (BMI), blood pressure, liver and renal function  
o And physical examination will take place before commencement of the study  
 
6.4. Informed Consent  
 
De Kock et al. set up two consent forms for research involving genetic analysis (DNA 
extraction from plasma sample) and pharmacokinetic analysis using the same sample. In the 
form for genetic studies the storage time is worded ambiguously, but as said in the last sentence, 
the sample will be stored for a minimum of 2 years. We acknowledge that this was not written 
very well and apologise sincerely. In terms of the pharmacokinetic analysis, de Kock did not 
specify a limit on the period that the sample may be stored or analysed. This is due to the fact 
that there was a lack of funding and LC-MS equipment available at the time for more extensive 
PK analysis. 
 
Therefore, with the support of NRF funding from Prof Peter Donald and a new LC-MS system 
at Clinical Pharmacology we can now look at not only the parent PAS but also its metabolites, 
as we would have hoped to do with the initial study. No additional consent is thus required from 
the patients as we are doing the exact same pharmacokinetic analysis of the samples, using 
more advanced analytical procedures. No DNA or protein analysis will be performed on these 
samples.  
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7. SAMPLE STABILITY
The stability of the samples (stored at - 80˚C) will be determined by comparing the PAS levels 
achieved previously by de Kock et al. (2013) to those quantified in the current study. Internal 
standard drug for PAS and acetyl-PAS will be purchased while glycine-PAS will be synthesised 
by Laboratory of Organic Chemistry (Stellenbosch University) and used in the LC-MS/MS 
analysis as a control standard. These control standards will also be tested for purity prior to 
analysis. Stability will also be assessed by dual analysis at Central Analytical Facilities (CAF, 
Stellenbosch University) and the Clinical Pharmacology Bioanalytical Laboratory (Tygerberg 
Medical Campus, Stellenbosch University).  
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8. METHOD DEVELOPMENT  
 
The purpose of this section of the study is to develop a sensitive and high throughput LC-
MS/MS method for the simultaneous quantification of para-aminosalicylic acid (PAS) and its 
major metabolites (APAS) and (GPAS), in human plasma. The analytical method will be 
developed on an ultra-performance liquid chromatography system (UPLC) in tandem with 
triple quadrupole mass spectrometer (MS). Such a system is a proven analytical tool that offers 
very low limits of quantification, together with high throughput and excellent specificity. 
 
With this type of system, small sample volumes can be used and relatively shorter run times 
established therefore it offers a practical method for the clinical monitoring of the therapeutic 
agent PAS and its metabolites in TB patients.  
For the successful development of a method, the following prerequisites will be met, selection 
of a qualified and calibrated instrument, purchasing of reliable reference standards and the 
selection and integrity of the sample.  The common steps that we will follow in the method 
development are as follows:  
 
1) Standard analyte characterization  
2) Method requirements  
3) Literature search  
4) Selecting the method based on a suitable solvent  
5) Instrumental (LC and MS) setup and preliminary studies 
6) Optimization of parameters on the instrument  
7) Documentation of analytical figure which may include chromatographs 
8) Evaluation of the method development with the sample specimen (plasma) 
9) Determination of percent recovery of the sample using analytical performance 
characteristics including specificity, accuracy, linearity, limit of detection (LOD), 
quantification limits (LOQ), range, and precision.  
10)  Demonstration of quantitative sample analysis 
 
The method performance will be assessed according to the Guidance for Industry Bioanalytical 
Method Validation criteria (published by Food and Drug Administration – FDA). The method 
will also be governed for quality standards by Good Laboratory Practice (GLP) regulations.  
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9. PHARMACOKINETIC ANALYSIS
A pharmacokinetic profile for APAS, GPAS and PAS will be generated under each dose 
regimen in order to visually determine any differences between the two occasions. Assays at 
sample collection times t0, 1, 2, 3, 4, 6, 8, 12 and 24 taken on Day 8 and Day 16 will be used 
to determine the following pharmacokinetic parameters. 
⇒ Area under the concentration-time curve (AUC0-24) post dose on Day 8 and Day 16
⇒ Maximum observed concentration (Cmax) from time 0 to 12 hours post dose
⇒ Time to reach the maximum observed concentration (tmax)
⇒ Minimum observed concentration (Cmin) from time 0 to 12 hours post dose
10. STATISTICAL ANALYSIS
10.1. Sample size 
The sample size remains the same as the initial study, minus 11 patients due to specimen loss. 
Sample size therefore requires no power analysis as only 30 patients are available for the 
proposed study.  
10.2. Data management 
The data will be captured using Microsoft excel 2016, which applies to all demographic data 
(gender, age, race, BMI, height, weight, concomitant medication, HIV status, and treatment 
regimen). A code will be allocated to all grouped data.  
Security access will be maintained on this data, using an access code. The data and information 
of each patient will remain concealed by use of a unique subject code, previously allocated. The 
patient confidentiality will be maintained at all times allowing only researcher and authorized 
official’s access to personal information. All the collected data will be backed up on external 
drives and iCloud.   
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10.3. Data analysis 
 
Microsoft excel will be used to capture demographic data (age, weight, height, BMI, 
concomitant medication), categorical data (gender, race, HIV status, concurrent illness). 
Descriptive statistics will be used to summarise the data, using STATA 14 (data analysis 
software system. Demographical data will be measured for normality and described by mean 
and standard deviation (SD) in the form of histograms or scatter plots. If the demographics are 
not normally skewed, it will be described by medians and IQR (25th and 75th percentile) using 
line graphs. Categorical data will be measured by quality data tests and presented in frequencies 
using bar graphs.  
The pharmacokinetic profile for APAS and GPAS generated from t0, 1, 2, 3, 4, 6, 8, 12 and 24 
hours will be used to determine AUC (area under the concentration-time curve), Cmax 
(maximum concentration), and Cmin (minimum concentration). The plasma concentrations will 
be captured in Microsoft excel and summarised by descriptive statistics (including number of 
subjects, mean, SD, percent co-efficient of variation (CV %), 25th and 75th median percentile, 
minimum and maximum), and the median on each time point will be calculated using STATA 
14.  
The safety and tolerability data, generated by a 10-point Visual Analogue Scale (VAS) will be 
summarised by descriptive statistics. The symptoms (abdominal pain, nausea, bloating and 
diarrhoea) will be summarised as a grouped under yes/no to determine GI effects. Therefore, if 
any of the symptoms were experienced that classifies as an adverse effect.  
 
11. TIME PLAN 
 
 
 
  
2017 Feb Mar Apr May Jun Jul Aug Sep Oct
Register
Ethical 
Approval Start study 
2018 Jan Feb Mar Apr May Jun Jul Aug Sep
Protocol write-up
Method development and 
validation 
PK and Data analysis Write-up 
Prepare for 
submission
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12. STRENGTHS AND LIMITATIONS
With use of an LC-MS system, a smaller plasma volume is required which allows for the 
possibility of repeat analysis when validating the results of the analytical method  
The current study sample size has been reduced from the initial study conducted in 2013 due 
to loss of sample during analysis procedures.  
13. ETHICAL CONSIDERATIONS
The project will be conducted accordingly to South African laws and regulations, including 
South African GCP and to the Declaration of Helsinki. 
The approval notice for the main study conducted by De Kock et al 2013 (M12/01/006) has 
been attached to the protocol. The data and information of each patient will remain concealed 
by use of a unique subject code, previously allocated. The patient confidentiality will be 
maintained at all times allowing only researcher and authorized official’s access to personal 
information.  
14. FUNDING AND BUDGET
Partial funding from the departmental funds have been made available. In addition, funding 
will be requested from grants provided to Prof PR Donald. Funding requests/applications will 
be submitted to the Wellcome Trust. A proposed budget has been set up as follows: 
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DESCRIPTION AMOUNT 
Consumables: 
Reagents 
Laboratory analysis: 
Development and validation 
LC-MS specimen analysis 
Glycine-PAS synthesis 
Courier service for samples 
TOTAL 
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